<?xml version="1.0" encoding="UTF-8"?><root><article><meta><jid>fbinf</jid><aid>fbinf-2023-1255159</aid><pit>discussion</pit><doi>10.3389/fbinf.2023.1255159</doi><vol>3</vol><subject>Bioinformatics</subject><subject>Opinion</subject><received day="8" month="7" year="2023"/><accept day="25" month="7" year="2023"/><conversion>nlm</conversion><customer>frontiers</customer></meta><head><lrh><query>LRH: <ins>Deschamps et al.</ins></query></lrh><rrh><query>RRH: <url url="https://doi.org/10.3389/fbinf.2023.1255159" title="https://doi.org/10.3389/fbinf.2023.1255159">10.3389/fbinf.2023.1255159</url><linenumber id="Line_as2tud_2"/></query></rrh><articletitle>Better <ins rule="ACEtool_articletitleShouldBeInSentenceCase">r</ins><del rule="ACEtool_articletitleShouldBeInSentenceCase">R</del>esearch <ins rule="ACEtool_articletitleShouldBeInSentenceCase">s</ins><del rule="ACEtool_articletitleShouldBeInSentenceCase">S</del>oftware <ins rule="ACEtool_articletitleShouldBeInSentenceCase">t</ins><del rule="ACEtool_articletitleShouldBeInSentenceCase">T</del>ools to <ins rule="ACEtool_articletitleShouldBeInSentenceCase">e</ins><del rule="ACEtool_articletitleShouldBeInSentenceCase">E</del>levate the ate of cientific <ins rule="ACEtool_articletitleShouldBeInSentenceCase">d</ins><del rule="ACEtool_articletitleShouldBeInSentenceCase">D</del>iscovery or why we need to
            invest in research software engineering<del rule="20052_single_actor"/><query>Q1:
            Confirm whether the article title is correct. </query></articletitle><aug><authors><query>Q2: If the following authors would like their LOOP profile to be linked to
                    the final published version, ensure that they with Frontiers at the provided
                    link, and provide us with the URLs to their profile(s). If just an email address
                    is provided, the profile link will not be added to the article. Non-registered
                    authors and authors with profiles set to "Private" will have the default profile
                    image displayed. Note that we will not be able to add profile links after
                    publication. Damian Dalle Nogare </query><query>Q3: The citation and surnames of all of the authors have been highlighted.
                    Check that they are correct and consistent with your previous publications, and
                    correct them if needed. Please note that this may affect the indexing of your
                    article in repositories such as PubMed. If adding/removing authors, or changing
                    the order of this list, please provide us with a signed , which should be
                    uploaded as a “Related Article” file type with your Author's Proof
                    Corrections. </query><au id="au1"><fnm>Joran</fnm><x/><snm>Deschamps</snm><xref id="corlowast" title="corlowast">*</xref><x><sup>,</sup></x><xref rid="authorid:https://loop.frontiersin.org/people/1478169/overview" title="authorid:https://loop.frontiersin.org/people/1478169/overview"><sup>AUTHORID</sup></xref></au><x>, </x><au id="au2"><fnm>Damian</fnm><snm>Dalle Nogare</snm></au><x> and </x><au id="au3"><fnm>Florian</fnm><snm>Jug</snm></au></authors><aff><text><affnorg>Fondazione Human Technopole</affnorg><affncity>Milan</affncity><query>Q4: Confirm that all author affiliations are correctly listed. Per our
                        style guidelines, affiliations are listed sequentially and follow author
                        order. Requests for non-sequential affiliation listing will not be
                        fulfilled. Note that affiliations should reflect those at the time during
                        which the work was undertaken. If adding new affiliations, specify if these
                        should be listed as a present address instead of a regular affiliation. </query><affncountry>Italy</affncountry></text></aff><cor id="corlowast"><label>*</label><text>Correspondence: Joran Deschamps, <e-address type="email">
                    joran.deschamps@fht.org</e-address>; Florian Jug, <e-address type="email">
                    florian.jug@fht.org</e-address><query>Q5: Confirm that the email address in your
                    correspondence section is accurate. Any changes to corresponding authors
                    requires individual confirmation from all original and added/removed
                    corresponding authors. </query></text></cor><fneditedby><b>Edited by:</b><url url="https://loop.frontiersin.org/people/100415/overview" title="https://loop.frontiersin.org/people/100415/overview">Daniel Sage</url>, <del>Biomedical
                Imaging Group (BIG) </del>Ecole Polytechnique Fédérale de Lausanne (EPFL),
                Switzerland</fneditedby><fneditedby><b>Reviewed by:</b><url url="https://loop.frontiersin.org/people/1445974/overview" title="https://loop.frontiersin.org/people/1445974/overview">Beth A. Cimini</url>,
                Broad Institute, United States</fneditedby></aug><keywordsdefault><query>Q6: Confirm that the keywords are correct, and keep them to a maximum of eight
                and a minimum of five. (Note: a keyword can be made up of one or more words.) </query><st>Keywords</st><x>: </x><kwd><ins rule="ACEtool_keywordsShouldBeInLowerCase">research software e</ins><del rule="ACEtool_keywordsShouldBeInLowerCase">Research Software E</del>ngineering</kwd><kwd><ins rule="ACEtool_keywordsShouldBeInLowerCase">i</ins><del rule="ACEtool_keywordsShouldBeInLowerCase">I</del>mage </kwd><ins><kwd>analysis</kwd></ins><del><kwd>analyis</kwd></del><kwd>mage analysis software</kwd><kwd>community support</kwd><kwd>opinion</kwd></keywordsdefault><authorcontribution><xref id="au1" title="#au1">Joran Deschamps</xref><con-role-group><con-concept>Conceptualization</con-concept><con-concept>Writing–original draft</con-concept><con-concept>Writing–review and editing</con-concept><x>. </x></con-role-group><xref id="au2" title="#au2">Damian Dalle Nogare</xref><xref id="au3" title="#au3">Florian Jug</xref><con-role-group><con-concept>Supervision</con-concept><x>.</x></con-role-group></authorcontribution></head><body><seca id="sec1"><sectitle><ins rule="ACEtool_rule_insert_sectiona">Introduction</ins><query>Q7: Confirm if the inclusion of the heading “Introduction” is
                    acceptable here. </query></sectitle><paragraph><query>Q8: Check if the section headers (i.e., section leveling) have been
                correctly captured. </query>In the past decade, enormous progress has been made in
                advancing the state-of-the-art in bioimage analysis<del>- </del><ins>—</ins>a
                young computational field that works in close collaboration with the life sciences
                on the quantitative analysis of scientific image data. In many cases, tremendous
                effort has been spent to package these new advances into us<ins rule="ACEtool_LE_SpellCheckBasedonDictionary_SmartSpell_metadata_specific_LE_group">
                e</ins>able software tools and, as a result, users can nowadays routinely apply
                cutting-edge methods to their analysis problems using software tools such as ilastik
                (<xref id="bib_berg_et_al_2019" title="bib_berg_et_al_2019">Berg et al., 2019</xref>),
                cellprofiler (<xref id="bib_mcquin_et_al_2018" title="bib_mcquin_et_al_2018">McQuin
                et al., 2018</xref>), Fiji/ImageJ2 (<xref id="bib_schindelin_et_al_2012" title="bib_schindelin_et_al_2012">Schindelin et al., 2012</xref>; <xref id="bib_rueden_et_al_2017" title="bib_rueden_et_al_2017">Rueden et al., 2017</xref>)
                and its many modern plugins that build on the BigDataViewer ecosystem (<xref id="bib_pietzsch_et_al_2015" title="bib_pietzsch_et_al_2015">Pietzsch et al.,
                2015</xref>), and many others. Such software tools have now become part of a
                critical infrastructure for science (<xref id="bib_hettrick_2018" title="bib_hettrick_2018">Hettrick, 2018</xref>).</paragraph><paragraph>Unfortunately, overshadowed by the few exceptions that have had long-lasting
                impact, many other potentially useful tools fail to find their way into the hands of
                users. While there are many reasons for this, we believe that at least some of the
                underlying problems, which we discuss in more detail below, can be mitigated. In
                this opinion piece, we specifically argue that embedding teams of research software
                engineers (RSEs) within imaging and image analysis core facilities would be a major
                step towards sustainable bioimage analysis software.</paragraph></seca><seca id="sec2"><sectitle>The maintenance problem and its technical and social causes</sectitle><paragraph>Two major determinants for the widespread adoption of a tool are its
                usability and its maintenance over time (<xref id="bib_carpenter_et_al_2012" title="bib_carpenter_et_al_2012">Carpenter et al., 2012</xref>; <xref id="bib_milewicz_and_rodeghero_2019" title="bib_milewicz_and_rodeghero_2019">Milewicz
                and Rodeghero, 2019</xref>). The first case is perhaps the more obvious: tools that
                are difficult to install or use are often neglected by the community of life
                scientists who could most benefit from them. The second case is perhaps more
                overlooked, although no less important. Modern bioimage analysis methods are
                complex, and even the simplest software implementations may depend on dozens of
                other pieces of scientific software (typically referred to as dependencies). This
                intricate web of interdependent software packages is, regrettably, extremely
                brittle, and changes in any one dependency can cause significant changes to be
                required for existing software tools to continue working properly. Over time, the
                probability that unmaintained tools are able to still function in up-to-date
                environments becomes quickly smaller and smaller. Even worse, the time and technical
                knowledge required to update bioimage analysis software tools is enormous (<xref id="bib_nowogrodzki_2019" title="bib_nowogrodzki_2019">Nowogrodzki, 2019</xref>),
                and few people have the know-how to do so.</paragraph><paragraph>In a perfect world, all software tools that find active users would be
                continuously maintained. Unfortunately, there are many reasons why even published
                software tools with an active user-base are not. Compared to publishing new methods
                and tools, the maintenance of existing tools typically does not provide much in
                terms of career advancement for the maintainer. At best, an existing publication
                might get cited more often, but the advantage of this pales in comparison with a new
                paper being published. Additionally, the person working on the maintenance of a
                software tool might not even be an author on the original publication, leaving this
                important work completely unrewarded by commonly used scientific performance
                indicators. Finally, maintaining software requires continuity of expertise, which is
                too easily lost when a main developer switches between labs or moves on to their
                next career stage. Incentive structures are therefore not aligned with the long-term
                commitment required to maintain open research software (<xref id="bib_anzt_et_al_2020" title="bib_anzt_et_al_2020">Anzt et al., 2020</xref>),
                leading to most tools being maintained only for a limited period of time (<xref id="bib_hasselbring_et_al_2020" title="bib_hasselbring_et_al_2020">Hasselbring
                et al., 2020</xref>).</paragraph><paragraph>Another difficulty in maintaining existing software tools is that funding for
                this kind of work is rare. While there exist both public and private funding
                mechanisms to support open source projects in general, a recent EU analysis (<xref id="bib_arora_2022" title="bib_arora_2022">Arora, 2022</xref>) found that the
                majority of this funding was dedicated to new projects, with comparatively little
                funding for long-term maintenance of existing ones. There are only a few notable
                exceptions we know of, where funding bodies have dedicated specific calls to
                software sustainability <del>(</del><ins>[</ins>e.g.<ins rule="ACEtool_LE_use period and comma after contractions and abbreviations">,</ins>
                the Chan-Zuckerberg Initiative (<xref id="bib_essential_open_source_sof_2019" title="bib_essential_open_source_sof_2019">Essential Open Source Software for
                science, 2019</xref>), the DFG (<xref id="bib_scientific_library_servic_2023" title="bib_scientific_library_servic_2023">Scientific Library Services and
                Information Systems LIS, 2023</xref>) and BMBF (de.NBI), the Virtual Institute of
                Scientific Software (<xref id="bib_matthews_2022" title="bib_matthews_2022">Matthews,
                2022</xref>), or the Software Sustainability Institute (<xref id="bib_crouch_et_al_2013" title="bib_crouch_et_al_2013">Crouch et al., 2013</xref><del>
                )). </del><ins>)]. </ins>Still, such funding is currently not available at the level
                required to build user friendly and better maintained software tools ().</paragraph><paragraph>Currently, not only are we unable to achieve these important goals, we
                struggle even to keep our best research software engineers employed and offer them a
                stable career or adequate income. It is therefore not surprising that many of the
                software engineering activities in academia are carried out by personnel in
                limited-term positions, such as PhD students, post-docs, or young RSEs on short term
                staff positions. Since experienced RSEs are highly qualified experts that are also
                in high demand outside academia, we regularly see talented people leave to work in
                industry. This makes the previously discussed software maintenance dilemma even more
                problematic: once such developers run out of time or funding, development is halted,
                maintenance is abandoned, and the expertise in which the hosting group and institute
                has invested is lost.</paragraph><paragraph>Could the existing academic technology transfer infrastructure be a solution
                for this problem? Instead of talented RSEs leaving to pursue a career in mainstream
                technology companies, they could be offered the chance to continue the development
                and maintenance of research software in the context of a newly incubated startup or
                spin-off company. There are successful examples, such as Cytomine (<xref id="bib_cytomine_2023" title="bib_cytomine_2023">Cytomine, 2023</xref>) or KNIME
                (<xref id="bib_berthold_et_al_2009" title="bib_berthold_et_al_2009">Berthold et al.,
                2009</xref>), where this has worked, but also many other instances where it has not.
                The idea of useful software receiving funding by selling licenses is obvious and
                clean, however it unfortunately often fails due to some combination of the following
                reasons: <del><i>(</i>i</del><ins>1</ins>) it is hard to find investors for open
                software, but closing the code base removes community engagement and slows
                development and interoperability, <del>ii</del><ins>2</ins>) the existing
                codebase is released under a license that makes it hard to commercialize it, <del><i>
                (</i>iii</del><ins>3</ins>) many users would rather switch to alternate software
                tools rather than pay money for licenses. The last point is critical: scientific
                analysis software is highly specialized and the number of users is, in absolute
                terms, limited. While some commercial software tools create value by enabling
                faster, more reproducible, more quantitative, and less biased academic research, the
                scientists and research groups in the user base may not have the money for software
                licenses. In addition, analyses performed in commercial software require other
                research groups to obtain similar licenses to replicate them, creating additional
                barriers to reproducibility and the dissemination of open science. We therefore
                believe that research software development should be supported by science funders
                and institutions.</paragraph><paragraph>Despite the undeniable importance of software tools in life science research,
                being a research software engineer has not yet become a common career path.
                Individuals that do choose to become RSEs are likely to suffer from job insecurity
                and will in many cases earn well below equally skilled colleagues working in
                industry.</paragraph><paragraph>But not all hope is lost. There are research groups and scientific institutes
                that are increasingly investing in their RSEs (a very incomplete set of examples are
                LOCI at the University of Wisconsin, the EMBL in Heidelberg or Hinxton, the MPI-CBG
                in Dresden, the Allen Institute in Seattle, or the Human Technopole in Italy).</paragraph></seca><seca id="sec3"><sectitle>Research software engineering in image analysis facilities</sectitle><paragraph>We believe that institutes and funding agencies have the power to elevate the
                usability and sustainability of bioimage analysis software by providing better
                career opportunities for RSEs. Such change would have a profound impact on the rate
                of scientific progress even beyond the field of bioimage analysis. More concretely,
                we postulate that image analysis facilities (or image analysis teams within imaging
                facilities) are an ideal place for RSEs to conduct their work and foster this
                potential.</paragraph><paragraph>Historically, bioimage analysis has often found fertile ground within imaging
                facilities, which have naturally been the first to see how important and tightly
                coupled adequate analysis methods and workflows are to the microscopy work conducted
                in those facilities. More recently this has led to increased hiring of skilled
                bioimage analysts in such facilities and even to the creation of dedicated core
                facilities focused on image analysis examples can be found,
                among other places, at Institut Pasteur (<xref id="bib_research_pasteur_frinstit_2017" title="bib_research_pasteur_frinstit_2017">Research pasteur frInstitut
                PasteurImage Analysis Hub, 2017</xref>), Institut Curie (<xref id="bib_cédric_2023" title="bib_cédric_2023">Cédric, 2023</xref>),
                EMBL Heidelberg (<xref id="bib_emblde_2023" title="bib_emblde_2023">Embl.de, 2023</xref>),
                Human Technopole (<xref id="bib_human_technopole_2020" title="bib_human_technopole_2020">Human Technopole, 2020</xref>), or the
                TU-Dresden (<xref id="bib_pol_2023" title="bib_pol_2023">PoL, 2023</xref><del>)).</del><ins rule="20052">)].</ins></paragraph><paragraph>Key performance indicators (KPI) of image analysis facilities or image
                analysis teams within imaging facilities are typically metrics like <ins>
                1</ins>) the number of interactions with users, ) the
                level of satisfaction those users report, <del>(iii</del>) the number of
                completed analysis projects, or <del>(iv</del><ins>4</ins>) the tally of
                co-authorships or other acknowledgements in resulting publications. The imperative
                to demonstrate usefulness using such KPIs can, however, leave little space for
                research software engineering activities. As a consequence, efforts spent on
                developing new methods and approaches remain circumscribed to the needs of the
                facility’s own users and too rarely impact users more globally. It is up to
                individual bioimage analysts to devote the extra time required to package an
                analysis pipeline into a useful tool and release it to the public. There exist
                examples of methods that were successfully translated into more generally available
                and popular software tools, such as Trackmate (<xref id="bib_tinevez_et_al_2017" title="bib_tinevez_et_al_2017">Tinevez et al., 2017</xref>; <xref id="bib_ershov_et_al_2022" title="bib_ershov_et_al_2022">Ershov et al., 2022</xref>),
                MoBIE (<xref id="bib_pape_et_al_2023" title="bib_pape_et_al_2023">Pape et al., 2023</xref>),
                Labkit (<xref id="bib_arzt_et_al_2022" title="bib_arzt_et_al_2022">Arzt et al., 2022</xref>),
                CellPose (<xref id="bib_pachitariu_and_stringer_2022" title="bib_pachitariu_and_stringer_2022">Pachitariu and Stringer, 2022</xref>),
                and others, which are broadly used in life-science research. Despite this success,
                these tools must now be maintained over time, bringing us right back to the above
                discussion: the difficulty in finding the time, money, and expertise to conduct
                software maintenance activities for analysis tools that others rely on.</paragraph></seca><seca id="sec4"><sectitle>Giving core facilities a new mission</sectitle><paragraph>A tremendous increase in the quality of open research software can be
                achieved ) by making the development of FAIR
                (Findability, Accessibility, Interoperability, and Reusability) (<xref id="bib_wilkinson_et_al_2016" title="bib_wilkinson_et_al_2016">Wilkinson et al.,
                2016</xref>; <xref id="bib_barker_et_al_2022" title="bib_barker_et_al_2022">Barker
                et al., 2022</xref>) and sustainable software a core mission of image analysis
                facilities (or analysis teams within imaging facilities) (<xref id="bib_soltwedel_and_haase_2023" title="bib_soltwedel_and_haase_2023">Soltwedel
                and Haase, 2023</xref>), ) by adding stable RSE
                positions to teams of bioimage analysts, and ) by
                facilitating networking activities between such teams across different facilities.
                We believe this would lead to more powerful and general-purpose core libraries that
                would be developed, maintained, and used by a larger group of research software
                engineers. As a consequence, users would have access to a set of software tools that
                have a higher degree of stability, interoperability and require less maintenance
                thanks to shared maintenance efforts, rather than duplicated ones. Additionally,
                this would mean that more RSEs would be involved in developing such core libraries,
                which would in turn increase those libraries bus-factor<sup><xref id="fn1" title="fn1">1</xref></sup><citation>fn1</citation>
                and thereby mitigate many of the software maintenance problems arising from single
                individuals leaving their jobs. All together, this would result in a more efficient
                translation from new methods to usable tools that can benefit bench scientists and therefore directly elevate
                the rate of scientific discovery.</paragraph><paragraph>Still, increased hiring of research software engineers alone is not a
                guarantee for success. It is also imperative to collaborate across team and
                institute boundaries and to broadly establish modern software development practices.
                At times, research software is hastily written and “just good enough”
                to demonstrate a working principle, but not of sufficient quality to easily reuse,
                share, or build other components stably on top of it. The more general purpose a
                library or software component is, the more important it is to invest in a good
                design that enables its reuse. This also means to invest in automated testing and
                good documentation. Such things take additional time at first, but pay back the
                investment many times over the lifetime of a software project. As coordinated
                exchange of best-practices and peer-teaching will become important, we believe that
                establishing specialized bioimage analysis RSE networks that review and give
                feedback on each other<ins rule="ACEtool_rule_change_apostrophes_to_straight_quotes-1_except_secionaAppsectiona" blackbox="true">’</ins><del rule="ACEtool_rule_change_apostrophes_to_straight_quotes-1_except_secionaAppsectiona" blackbox="true">'</del>s activities will be a key component to ensure that
                global RSE work is as efficient as it can be.</paragraph><paragraph>If our argument to include such a network of RSE teams within image analysis
                facilities is more broadly implemented, we believe that a number of benefits will
                naturally and directly emerge. In particular, we expect the following benefits to be
                a direct consequence<ins rule="ACEtool_toDeleteEndPunctuationAndInsertEndPeriod">.</ins><del rule="ACEtool_toDeleteEndPunctuationAndInsertEndPeriod">:</del></paragraph><secb id="sec4_1"><sectitle>User-driven requirement assessment</sectitle><paragraph>Bioimage analysts are the interface to bench scientists and microscopists
                    who generate raw image data that needs to be analyzed. As such, they observe
                    every day which analyses are well supported by user-friendly tools, and where
                    gaps exist in the tool landscape. This knowledge, shared with research software
                    engineers and method developers, is key to directing their attention to the most
                    important problems that need addressing.</paragraph></secb><secb id="sec4_2"><sectitle>Direct functionality and usability feedback throughout the software
                    development life-cycle</sectitle><paragraph>Bioimage analysts are often the first to use new analysis tools and
                    methods and they typically do so in the context of multiple analysis projects,
                    requiring a broader spectrum of features. Last but not least, bioimage analysts
                    not only use software tools but also help others use them on their own. The
                    feedback of bioimage analysts on existing pain points for users can therefore be
                    invaluable for research software engineers who seek to improve their tools. By
                    embedding RSEs within image analysis facilities, a constant feedback stream will
                    help to steer development efforts to where they are most needed and therefore
                    avoid wasting resources.</paragraph></secb><secb id="sec4_3"><sectitle>Long-term maintenance of software tools and components<del>: </del></sectitle><paragraph>Close collaboration between analysts and RSEs ensures that software tools
                    and the libraries they depend on stay well maintained and that
                    functionality-impeding bugs will be resolved quickly. Additionally, the
                    distribution of knowledge over multiple people will increase the above mentioned
                    bus-factor, enabling RSE teams to retain expertise even if some members leave.</paragraph></secb><secb id="sec4_4"><sectitle>Software interoperability and deduplication of effort</sectitle><paragraph>Bioimage analysis and imaging facilities are and need to remain well
                    networked. RSEs within such teams can use these networks to synchronize and
                    deduplicate efforts across teams and institutions. As a consequence, once common
                    libraries are developed and used, software tools will become interoperable, even
                    if not developed collaboratively. This will reduce the cost of research software
                    development, free up much needed RSE time, and most importantly, benefit users
                    who need interoperable software tools for their analyses (<xref id="bib_carpenter_et_al_2012" title="bib_carpenter_et_al_2012">Carpenter et
                    al., 2012</xref>; <xref id="bib_levet_et_al_2021" title="bib_levet_et_al_2021">Levet
                    et al., 2021</xref>).</paragraph></secb><secb id="sec4_5"><sectitle>Better software engineering and better career paths for RSEs</sectitle><paragraph>Finally, housing RSE teams within imaging or analysis facilities will
                    foster the dissemination of modern software engineering skills (<xref id="bib_johanson_and_hasselbring_2018" title="bib_johanson_and_hasselbring_2018">Johanson and Hasselbring, 2018</xref>
                    ; <xref id="bib_arvanitou_et_al_2021" title="bib_arvanitou_et_al_2021">Arvanitou
                    et al., 2021</xref>). Networked RSEs will naturally exchange best-practices. Not
                    only will RSEs themselves benefit from this accumulated knowledge, these skills
                    can also be shared with PhD students and post-docs who develop computational
                    methods and are therefore working at the interface with software tool
                    development. Additionally, more places employing RSEs will automatically create
                    an environment where RSEs can switch between jobs, without having to leave
                    academia, and will create new career opportunities for RSE-inclined students or
                    post-docs (<xref id="bib_cosden_et_al_2022" title="bib_cosden_et_al_2022">Cosden
                    et al., 2022</xref>).</paragraph><paragraph>If these statements are so obvious, why are many funders and institutions
                    not investing in such ideas? We believe that multiple factors come together.
                    Software development methods have improved tremendously over the past decades.
                    Dependency management, code versioning tools, test-driven development,
                    continuous integration, platforms such as Github, etc. all contribute to making
                    distributed software development possible. Hence, our ideas would have been much
                    harder to realize in the 1990s than they are now. Additionally, the return on
                    investment is not easily quantifiable, at least not until enough institutions
                    commit to the interconnected research software engineering and maintenance model
                    we propose. Still, we now benefit from the necessary infrastructure required to
                    collect useful KPIs regarding which software and libraries are successful and
                    widely used. For example: reporting the number of new software versions being
                    released each year, their usage through download statistics, the number of users
                    interacting with the developers through public platforms such as image.sc or
                    Github, the number of forks or stars project repositories receive, or more
                    classical indicators such as citations/mentions in the literature. Additional
                    KPIs can be collected based on teaching and consulting events and user feedback,
                    or by estimating the benefit of using certain software tools in projects
                    conducted within a facility (e.g.<ins rule="ACEtool_LE_use period and comma after contractions and abbreviations">
                    ,</ins> in terms of enabled projects or estimated overhead time if the analysis
                    was conducted without those tools).</paragraph><paragraph>While this strategy should hopefully find application in many places, we
                    are currently implementing such a structure at Human Technopole within NoBIAS,
                    the National Bioimage Analysis Service, which is part of the new National
                    Facility for Data Handling and Analysis. We firmly believe that a strong RSE
                    team is a key ingredient for a truly successful image analysis facility that
                    aims at serving many users in the context of heterogeneous life science
                    projects. As part of this commitment, we have built our facility around a model
                    which integrates an RSE team as a core part of the facility. This team has a
                    broad mandate to support the activities of the facility, including code review
                    and optimization for our analysis pipelines, casting new methods into
                    user-friendly tools that can then be used first by the analysis team and then
                    later also by the facility users and the scientific community. Another key part
                    of the NoBIAS RSEs mandate is the maintenance of previously developed tools and
                    contribution to open source projects created by others. We are aiming at
                    accelerating the rate of scientific discovery not only for our users on campus
                    and within our national user base, but also for life science research more
                    globally. In addition to enhancing the ability of our facility to serve our
                    users, we hope that such a model will function as a proof-of-concept for the
                    ideas outlined in this opinion piece, and as an example to other facilities of
                    the advantages of integrating RSEs into an image analysis facility.</paragraph></secb></seca><seca id="sec5"><sectitle>Author contributions <role>author_contribution</role></sectitle><paragraph><ins>JD: Conceptualization, Writing–original draft, Writing–review and
                    editing. DD: Conceptualization, Writing–original draft,
                    Writing–review and editing. FJ: Conceptualization, Supervision,
                    Writing–original draft, Writing–review and editing.</ins><del>All authors listed have made a substantial, direct, and intellectual
                    contribution to the work and approved it for publication.</del><query>Q9: Confirm that the details in the “Author Contributions”
                    section are correct. If any contributions need to be added /edited, choose the
                    appropriate CRedIT roles from the list available and indicate which one(s)
                    apply. </query></paragraph></seca><seca id="sec6"><sectitle>Funding <role>funding</role></sectitle><paragraph><query>Q10: Ensure all grant numbers and funding information are included and
                accurate (after publication it is not possible to change this information). All
                funders should be credited, and all grant numbers should be correctly included in
                this section. </query>This work was enabled by core funding of the group of F<ins rule="ACEtool_deleteAuthorDegAndRoleAbbreviateAuthorsNameInAckWithAlertForSameInitial">
                J</ins><del rule="ACEtool_deleteAuthorDegAndRoleAbbreviateAuthorsNameInAckWithAlertForSameInitial">lorian
                Jug</del> at Human Technopole, Italy.</paragraph></seca><seca id="sec7"><sectitle>Conflict of interest <role>conflictofinterest</role></sectitle><paragraph>The authors declare that the research was conducted in the absence of any
                commercial or financial relationships that could be construed as a potential
                conflict of interest.<query>Q11: Confirm if the text included in the Conflict of
                Interest statement is correct. Please do not suggest edits to the wording of the
                final sentence, as this is standard for Frontiers' journal style, per our . </query></paragraph></seca><seca id="sec8"><sectitle>Publisher’s note </sectitle><paragraph>All claims expressed in this article are solely those of the authors and do
                not necessarily represent those of their affiliated organizations, or those of the
                publisher, the editors and the reviewers. Any product that may be evaluated in this
                article, or claim that may be made by its manufacturer, is not guaranteed or
                endorsed by the publisher.</paragraph></seca></body><tail><ack><acknowledgements>We would like to thank Talley Lambert (Harvard Medical) and Eugenia
                Cammarota (Human Technopole) for valuable feedback on the manuscript.</acknowledgements></ack><bibreference><references>References</references><bibliography-sec><bib-reference id="bib_anzt_et_al_2020"><label>Anzt et al., 2020</label><journal><aus><au><snm>Anzt</snm><fnm>H.</fnm></au><au><snm>Bach</snm><fnm>F.</fnm></au><au><snm>Druskat</snm><fnm>S.</fnm></au><au><snm>Löffler</snm></au><au><snm>Loewe</snm><fnm>A.</fnm></au><au><snm>Renard</snm><fnm>B. Y.</fnm></au><au><et-al>et al.</et-al></au></aus><x> (</x><adate>2020</adate><x>). </x><atl>An environment for sustainable research software in Germany and beyond:
                            Current state, open challenges, and call for action</atl><stl>F1000Res</stl><vol>9</vol><first-page>295</first-page><doi>10.12688/f1000research.23224.1</doi></journal></bib-reference><bib-reference id="bib_arora_2022"><label>Arora, 2022</label><e-host><aus><au><snm>Arora</snm><fnm>S. S.</fnm></au></aus><adate>2022</adate><atl>Study: Public services need to nurture and sustain vulnerable small
                            projects Saranjit Singh ARORA [Internet]</atl><msc3>Available: </msc3><url url="https://joinup.ec.europa.eu/collection/fosseps/news/funding-sustainability" title="https://joinup.ec.europa.eu/collection/fosseps/news/funding-sustainability">
                            https://joinup.ec.europa.eu/collection/fosseps/news/funding-sustainability</url><msc>29 Apr 2022 [cited 5 Jul 2023]</msc></e-host></bib-reference><bib-reference id="bib_arvanitou_et_al_2021"><label>Arvanitou et al., 2021</label><journal><aus><au><snm>Arvanitou</snm><fnm>E-M.</fnm></au><au><snm>Ampatzoglou</snm></au><au><snm>Chatzigeorgiou</snm></au><x>, and </x><au><snm>Carver</snm><fnm>J. C.</fnm></au></aus><adate>2021</adate><atl>Software engineering practices for scientific software development: A
                            systematic mapping study</atl><stl>J. Syst. Softw.</stl><vol>172</vol><first-page>110848</first-page><doi>10.1016/j.jss.2020.110848</doi></journal></bib-reference><bib-reference id="bib_arzt_et_al_2022"><label>Arzt et al., 2022</label><journal><aus><au><snm>Arzt</snm><fnm>M.</fnm></au><au><fnm>J.</fnm></au><au><snm>Schmied</snm><fnm>C.</fnm></au><au><snm>Pietzsch</snm><fnm>T.</fnm></au><au><snm>Schmidt</snm><fnm>D.</fnm></au><au><snm>Tomancak</snm><fnm>P.</fnm></au></aus><atl>Labkit: Labeling and segmentation toolkit for big image data</atl><stl>Front. Comput. Sci.</stl><vol>4</vol><doi>10.3389/fcomp.2022.777728</doi></journal></bib-reference><bib-reference id="bib_barker_et_al_2022"><label>Barker et al., 2022</label><journal><aus><au><snm>Barker</snm></au><au><snm>Chue Hong</snm><fnm>N. P.</fnm></au><au><snm>Katz</snm><fnm>D. S.</fnm></au><au><snm>Lamprecht</snm><fnm>A-L.</fnm></au><au><snm>Martinez-Ortiz</snm></au><au><snm>Psomopoulos</snm></au></aus><atl>Introducing the FAIR Principles for research software</atl><stl>Sci. Data</stl><first-page>622</first-page><doi>10.1038/s41597-022-01710-x</doi></journal></bib-reference><bib-reference id="bib_berg_et_al_2019"><label>Berg et al., 2019</label><journal><aus><au><snm>Berg</snm></au><au><snm>Kutra</snm></au><au><snm>Kroeger</snm></au><au><snm>Straehle</snm><fnm>C. N.</fnm></au><au><snm>Kausler</snm><fnm>B. X.</fnm></au><au><snm>Haubold</snm></au></aus><adate>2019</adate><atl>ilastik: interactive machine learning for (bio)image analysis</atl><stl>Nat. Methods</stl><vol>16</vol><first-page>1226</first-page><x>–</x><last-page>1232</last-page><doi>10.1038/s41592-019-0582-9</doi></journal></bib-reference><bib-reference id="bib_berthold_et_al_2009"><label>Berthold et al., 2009</label><journal><aus><au><snm>Berthold</snm><fnm>M. R.</fnm></au><au><snm>Cebron</snm><fnm>N.</fnm></au><au><snm>Dill</snm></au><au><snm>Gabriel</snm><fnm>T. R.</fnm></au><au><snm>Kötter</snm></au><au><snm>Meinl</snm></au></aus><adate>2009</adate><atl>Knime - the Konstanz information miner</atl><stl>ACM SIGKDD Explor. Newsl.</stl><vol>11</vol><first-page>26</first-page><last-page>31</last-page><doi>10.1145/1656274.1656280</doi></journal></bib-reference><bib-reference id="bib_carpenter_et_al_2012"><label>Carpenter et al., 2012</label><journal><aus><au><snm>Carpenter</snm><fnm>A. E.</fnm></au><au><snm>Kamentsky</snm><fnm>L.</fnm></au><au><snm>Eliceiri</snm><fnm>K. W.</fnm></au></aus><adate>2012</adate><atl>A call for bioimaging software usability</atl><first-page>666</first-page><last-page>670</last-page><doi>10.1038/nmeth.2073</doi></journal></bib-reference><bib-reference id="bib_cédric_2023"><label>Cédric, 2023</label><e-host><aus><au><snm>Cédric</snm><fnm>Messaoudi</fnm></au></aus><atl>Images processing and analysing. In: Institut Curie [internet]</atl><url url="https://institut-curie.org/popin/images-processing-and-analysing" title="https://institut-curie.org/popin/images-processing-and-analysing">
                            https://institut-curie.org/popin/images-processing-and-analysing</url></e-host></bib-reference><bib-reference id="bib_cosden_et_al_2022"><label>Cosden et al., 2022</label><journal><aus><au><snm>Cosden</snm><fnm>I. A.</fnm></au><au><snm>McHenry</snm><fnm>K.</fnm></au></aus><atl>Research software engineers: Career entry points and training gaps</atl><stl>Comput. Sci. Eng.</stl><vol>24</vol><first-page>14</first-page><last-page>21</last-page><doi>10.1109/mcse.2023.3258630</doi></journal></bib-reference><bib-reference id="bib_crouch_et_al_2013"><label>Crouch et al., 2013</label><journal><aus><au><snm>Crouch</snm></au><au><snm>Hong</snm><fnm>N. C.</fnm></au><au><snm>Hettrick</snm></au><au><snm>Jackson</snm></au><au><snm>Pawlik</snm></au><au><snm>Sufi</snm></au></aus><adate>2013</adate><atl>The software sustainability institute: Changing research software
                            attitudes and practices</atl><vol>15</vol><first-page>74</first-page><last-page>80</last-page><doi>10.1109/mcse.2013.133</doi></journal></bib-reference><bib-reference id="bib_cytomine_2023"><label>Cytomine, 2023</label><e-host><aus><au><snm>Cytomine</snm></au></aus><x><query>Q12: Ref. Cytomine, 2023: Please provide the initial(s) for the
                            author.</query>(</x><adate>2023</adate><atl>An open-source rich internet application for collaborative analysis of
                            multi-gigapixel images</atl><url url="https://cytomine.be/" title="https://cytomine.be/">
                            https://cytomine.be/</url></e-host></bib-reference><bib-reference id="bib_emblde_2023"><label>Embl.de, 2023</label><e-host><aus><au><snm>Embl.de</snm></au></aus><atl>Centre for bioimage analysis</atl><url url="https://bio-it.embl.de/centres/cba/" title="https://bio-it.embl.de/centres/cba/">
                            https://bio-it.embl.de/centres/cba/</url></e-host></bib-reference><bib-reference id="bib_ershov_et_al_2022"><label>Ershov et al., 2022</label><journal><aus><au><snm>Ershov</snm></au><au><snm>Phan</snm><fnm>M-S.</fnm></au><au><snm>Pylvänäinen</snm><fnm>J. W.</fnm></au><au><snm>Rigaud</snm><fnm>S. U.</fnm></au><au><snm>Le Blanc</snm></au><au><snm>Charles-Orszag</snm></au></aus><atl>TrackMate 7: Integrating state-of-the-art segmentation algorithms into
                            tracking pipelines</atl><vol>19</vol><first-page>829</first-page><last-page>832</last-page><doi>10.1038/s41592-022-01507-1</doi></journal></bib-reference><bib-reference id="bib_essential_open_source_sof_2019"><label>Essential Open Source Software for science, 2019</label><e-host><aus><au><snm>Essential Open Source Software for science</snm></au></aus><atl>Chan zuckerberg initiative [internet]</atl><url url="https://chanzuckerberg.com/eoss/" title="https://chanzuckerberg.com/eoss/">
                            https://chanzuckerberg.com/eoss/</url><msc>14 Nov 2019 [cited 3 Jul 2023]</msc></e-host></bib-reference><bib-reference id="bib_hasselbring_et_al_2020"><label>Hasselbring et al., 2020</label><journal><aus><au><snm>Hasselbring</snm><fnm>W.</fnm></au><au><snm>Carr</snm></au><au><snm>Packer</snm></au><au><snm>Tiropanis</snm></au></aus><atl>Open source research software</atl><stl>Computer </stl><vol>53</vol><first-page>84</first-page><last-page>88</last-page><doi>10.1109/mc.2020.2998235</doi></journal></bib-reference><bib-reference id="bib_hettrick_2018"><label>Hettrick, 2018</label><book><aus/><adate>2018</adate><btl>softwaresaved/software_in_research_survey_2014: Software in research
                            survey</btl><doi>10.5281/zenodo.1183562</doi><query>Q13: Provide the city and publisher name for “Hettrick,
                            2018.”</query></book></bib-reference><bib-reference id="bib_human_technopole_2020"><label>Human Technopole, 2020</label><e-host><aus><au><snm>Human Technopole</snm></au></aus><query>Q14: Ref. Human Technopole, 2020: Please provide the initial(s) for
                            the author.</query><atl>National facility for data handling and analysis</atl><url url="https://humantechnopole.it/en/facilities/national-facility-for-data-handling-analysis/" title="https://humantechnopole.it/en/facilities/national-facility-for-data-handling-analysis/">
                            https://humantechnopole.it/en/facilities/national-facility-for-data-handling-analysis/</url><msc>Human Technopole [Internet] 16 Aug 2020 [cited 4 Jul 2023]</msc></e-host></bib-reference><bib-reference id="bib_johanson_and_hasselbring_2018"><label>Johanson and Hasselbring, 2018</label><journal><aus><au><snm>Johanson</snm></au></aus><atl>Software engineering for computational science: Past, present, future</atl><vol>20</vol><first-page>1</first-page><last-page>109</last-page><doi>10.1109/mcse.2018.108162940</doi></journal></bib-reference><bib-reference id="bib_levet_et_al_2021"><label>Levet et al., 2021</label><journal><aus><au><snm>Levet</snm></au><au><snm>Kreshuk</snm></au><au><snm>Bankhead</snm></au><au><snm>Haase</snm><fnm>R.</fnm></au></aus><atl>Developing open-source software for bioimage analysis: Opportunities
                            and challenges</atl><vol>10</vol><first-page>302</first-page><doi>10.12688/f1000research.52531.1</doi></journal></bib-reference><bib-reference id="bib_matthews_2022"><label>Matthews, 2022</label><journal><aus><au><snm>Matthews</snm></au></aus><atl>Ex-Google chief’s venture aims to save neglected science
                            software</atl><stl>Nature</stl><vol>607</vol><first-page>410</first-page><last-page>411</last-page><doi>10.1038/d41586-022-01901-x</doi></journal></bib-reference><bib-reference id="bib_mcquin_et_al_2018"><label>McQuin et al., 2018</label><journal><aus><au><snm>McQuin</snm></au><au><snm>Goodman</snm></au><au><snm>Chernyshev</snm><fnm>V.</fnm></au><au><snm>Cimini</snm><fnm>B. A.</fnm></au><au><snm>Karhohs</snm></au></aus><atl>CellProfiler 3.0: Next-generation image processing for biology</atl><stl>PLoS Biol.</stl><first-page>e2005970</first-page><doi>10.1371/journal.pbio.2005970</doi></journal></bib-reference><bib-reference id="bib_milewicz_and_rodeghero_2019"><label>Milewicz and Rodeghero, 2019</label><other-ref><aus><au><snm>Milewicz</snm></au><au><snm>Rodeghero</snm></au></aus><x> “</x><atl>Position paper: Towards usability as a first-class quality of HPC
                            scientific software</atl><x>,” in </x><conf-name>2019 IEEE/ACM 14th International Workshop on Software Engineering
                            for Science (SE4Science)</conf-name><conf-loc>Montreal, Canada</conf-loc><conf-date>May, 2019</conf-date><first-page>41</first-page><last-page>42</last-page><role>confproc</role></other-ref></bib-reference><bib-reference id="bib_nowogrodzki_2019"><label>Nowogrodzki, 2019</label><journal><aus><au><snm>Nowogrodzki</snm></au></aus><atl>How to support open-source software and stay sane</atl><vol>571</vol><first-page>133</first-page><last-page>134</last-page><doi>10.1038/d41586-019-02046-0</doi></journal></bib-reference><bib-reference id="bib_pachitariu_and_stringer_2022"><label>Pachitariu and Stringer, 2022</label><journal><aus><au><snm>Pachitariu</snm></au><au><snm>Stringer</snm></au></aus><atl>Cellpose 2.0: How to train your own model</atl><first-page>1634</first-page><last-page>1641</last-page><doi>10.1038/s41592-022-01663-4</doi></journal></bib-reference><bib-reference id="bib_pape_et_al_2023"><label>Pape et al., 2023</label><journal><aus><au><snm>Pape</snm></au><au><snm>Meechan</snm></au><au><snm>Moreva</snm><fnm>E.</fnm></au><au><snm>Schorb</snm></au><au><snm>Chiaruttini</snm></au><au><snm>Zinchenko</snm></au></aus><atl>MoBIE: A Fiji plugin for sharing and exploration of multi-modal
                            cloud-hosted big image data</atl><first-page>475</first-page><last-page>476</last-page><doi>10.1038/s41592-023-01776-4</doi></journal></bib-reference><bib-reference id="bib_pietzsch_et_al_2015"><label>Pietzsch et al., 2015</label><journal><aus><au><snm>Saalfeld</snm></au><au><snm>Preibisch</snm></au></aus><adate>2015</adate><atl>BigDataViewer: Visualization and processing for large image data sets</atl><vol>12</vol><first-page>481</first-page><last-page>483</last-page><doi>10.1038/nmeth.3392</doi></journal></bib-reference><bib-reference id="bib_pol_2023"><label>PoL, 2023</label><e-host><aus><au><snm>PoL</snm></au></aus><x><query>Q15: Ref. PoL: Please provide the initial(s) for the author.</query>
                            (</x><atl>Physics of life</atl><url url="https://physics-of-life.tu-dresden.de/research/core-groups/bio-image-analysis" title="https://physics-of-life.tu-dresden.de/research/core-groups/bio-image-analysis">
                            https://physics-of-life.tu-dresden.de/research/core-groups/bio-image-analysis</url></e-host></bib-reference><bib-reference id="bib_research_pasteur_frinstit_2017"><label>Research pasteur frInstitut PasteurImage Analysis Hub, 2017</label><e-host><aus><au><snm>Research pasteur fr</snm></au><x>,<query>Q16: Ref. Research pasteur frInstitut PasteurImage Analysis
                                Hub, 2017: Please provide the initial(s) for the 2nd and 3rd author.</query></x><au><snm>Institut Pasteur</snm></au><au><snm>Image Analysis Hub</snm></au></aus><adate>2017</adate><atl>Research [internet] Institut pasteur</atl><url url="https://research.pasteur.fr/en/team/image-analysis-hub/" title="https://research.pasteur.fr/en/team/image-analysis-hub/">
                            https://research.pasteur.fr/en/team/image-analysis-hub/</url><msc>15 Nov 2017 [cited 4 Jul 2023]</msc></e-host></bib-reference><bib-reference id="bib_rueden_et_al_2017"><label>Rueden et al., 2017</label><journal><aus><au><snm>Rueden</snm><fnm>C. T.</fnm></au><au><snm>Schindelin</snm></au><au><snm>Hiner</snm><fnm>M. C.</fnm></au><au><snm>DeZonia</snm><fnm>B. E.</fnm></au><au><snm>Walter</snm></au><au><snm>Arena</snm><fnm>E. T.</fnm></au></aus><atl>ImageJ2: ImageJ for the next generation of scientific image data</atl><stl>BMC Bioinforma.</stl><vol>18</vol><first-page>529</first-page><doi>10.1186/s12859-017-1934-z</doi></journal></bib-reference><bib-reference id="bib_schindelin_et_al_2012"><label>Schindelin et al., 2012</label><journal><aus><au><snm>Arganda-Carreras</snm><fnm>I.</fnm></au><au><snm>Frise</snm></au><au><snm>Kaynig</snm></au><au><snm>Longair</snm></au></aus><atl>Fiji: An open-source platform for biological-image analysis</atl><first-page>676</first-page><last-page>682</last-page><doi>10.1038/nmeth.2019</doi></journal></bib-reference><bib-reference id="bib_scientific_library_servic_2023"><label>Scientific Library Services and Information Systems (LIS), 2023</label><e-host><aus><au><snm>Scientific Library Services and Information Systems (Lis)</snm></au></aus><atl>Call for proposal research software sustainability</atl><url url="https://www.dfg.de/en/research_funding/programmes/infrastructure/lis/funding_opportunities/call_proposal_software/" title="https://www.dfg.de/en/research_funding/programmes/infrastructure/lis/funding_opportunities/call_proposal_software/">
                            https://www.dfg.de/en/research_funding/programmes/infrastructure/lis/funding_opportunities/call_proposal_software/</url><msc>www.dfg.de [Internet]. [cited 3 Jul 2023]</msc></e-host></bib-reference><bib-reference id="bib_soltwedel_and_haase_2023"><label>Soltwedel and Haase, 2023</label><journal><aus><au><snm>Soltwedel</snm><fnm>J. R.</fnm></au></aus><atl>Challenges and opportunities for bio-image analysis core-facilities</atl><stl>J. Microsc.</stl><doi>10.1111/jmi.13192</doi></journal></bib-reference><bib-reference id="bib_tinevez_et_al_2017"><label>Tinevez et al., 2017</label><journal><aus><au><snm>Tinevez</snm><fnm>J-Y.</fnm></au><au><snm>Perry</snm></au><au><snm>Hoopes</snm><fnm>G. M.</fnm></au><au><snm>Reynolds</snm><fnm>G. D.</fnm></au><au><snm>Laplantine</snm></au></aus><atl>TrackMate: An open and extensible platform for single-particle tracking</atl><stl>Methods</stl><vol>115</vol><first-page>80</first-page><last-page>90</last-page><doi>10.1016/j.ymeth.2016.09.016</doi></journal></bib-reference><bib-reference id="bib_wikipedia_contributorsbus_2023"><label>Wikipedia contributorsBus factor, 2023</label><e-host><aus><au><snm>Wikipedia contributors</snm></au><x>,<query>Q17: Ref. Wikipedia contributorsBus factor, 2023: Please
                                provide the initial(s) for all the authors.</query> and </x><au><snm>Bus factor</snm></au></aus><atl>: Wikipedia, the free encyclopedia [internet]</atl><url url="https://en.wikipedia.org/w/index.php?title=Bus_factor&amp;oldid=1154218987" title="https://en.wikipedia.org/w/index.php?title=Bus_factor&amp;oldid=1154218987">
                            https://en.wikipedia.org/w/index.php?title=Bus_factor&amp;oldid=1154218987</url><msc>11 May 2023</msc></e-host></bib-reference><bib-reference id="bib_wilkinson_et_al_2016"><label>Wilkinson et al., 2016</label><journal><aus><au><snm>Wilkinson</snm><fnm>M. D.</fnm></au><au><snm>Dumontier</snm></au><au><snm>Ijj</snm><fnm>Aalbersberg</fnm></au><au><snm>Appleton</snm><fnm>G.</fnm></au><au><snm>Axton</snm></au><au><snm>Baak</snm></au></aus><adate>2016</adate><atl>The FAIR Guiding Principles for scientific data management and
                            stewardship</atl><first-page>160018</first-page><doi>10.1038/sdata.2016.18</doi></journal></bib-reference></bibliography-sec></bibreference><fn id="fn1"><label>1</label><text>The bus factor<del rule="20052_single_actor"> </del> (<xref id="bib_wikipedia_contributorsbus_2023" title="bib_wikipedia_contributorsbus_2023">Wikipedia contributorsBus factor,
                2023</xref>) is a commonly used measurement of the risk resulting from information
                and capabilities not being shared among team members, or such team members not
                existing in the first place. It is derived from the hypothetical question <ins rule="ICEtool_Change_double quotes to left curly quote">“</ins><del rule="ICEtool_Change_double quotes to left curly quote">"</del>How many team
                members have to get hit by a bus before the project can<ins rule="ACEtool_LE_Negative_word_contractions_to_be_expanded">no</ins><del rule="ACEtool_LE_Negative_word_contractions_to_be_expanded">’</del>t
                persist?<ins rule="20052_single_actor">
                ”</ins></text></fn></tail></article><article><meta><jid>fbioe</jid><aid>fbioe-2022-1043130</aid><pit>research-article</pit><doi>10.3389/fbioe.2022.1043130</doi><subject>Bioengineering and Biotechnology</subject><subject>Original Research</subject></meta><head><lrh><query>LRH: Man et al.</query></lrh><rrh><query>RRH: <url url="https://doi.org/10.3389/fbioe.2022.1043130" title="https://doi.org/10.3389/fbioe.2022.1043130">10.3389/fbioe.2022.1043130</url></query></rrh><articletitle>Engineered small extracellular vesicles as a versatile platform to efficiently
            load ferulic acid <i>via</i> an “esterase-responsive active loading”
            strategy<query>Q1: Confirm whether the insertion of the article title is correct.</query></articletitle><aug><authors><au id="au1"><fnm>Fulong</fnm><snm>Man</snm></au><au id="au2"><fnm>Huaran</fnm><snm>Xing</snm></au><au id="au3"><fnm>Haoran</fnm><snm>Wang</snm><sup><xref id="aff2" title="aff2">2</xref></sup></au><au id="au4"><fnm>Junfeng</fnm></au><au id="au5"><fnm>Rong</fnm><snm>Lu</snm></au><query>Q2: The citation and surnames of all of the authors have been highlighted.
                    Check that they are correct and consistent with the authors’ previous
                    publications, and correct if need be. Please note that this may affect the
                    indexing of your article in repositories such as PubMed.</query><query>Q3: If the following authors would like their LOOP profile to be linked to
                    the final published version, please ensure they register with Frontiers (at )
                    and please provide us with the URLs of their profile link(s) (not email
                    addresses) when submitting the proof corrections. Non-registered authors and
                    authors with profiles set to private mode will have the default profile image
                    displayed. Please note: We won't be able to add profile links after publication
                    . Fulong Man Huaran Xing Haoran Wang Junfeng Wang</query></authors><aff id="aff1"><text><affnorg>Marine College, Shandong University</affnorg><affncity>Weihai</affncity><affncountry>China</affncountry><query>Q4: Confirm that all author affiliations are correctly listed. Note that
                        affiliations are listed sequentially as per journal style and requests for
                        non-sequential listing will not be applied. Note that affiliations should
                        reflect those at the time during which the work was undertaken.</query></text></aff><aff id="aff2"><label/><text><affnorg>Weihai Neoland Biosciences Co.,Ltd.</affnorg></text></aff><cor id="corlowast"><text>Correspondence:<query>Q5: Confirm that the email address in your
                    correspondence section is accurate. Please note that any changes to the
                    corresponding authorship would require individual confirmation from all original
                    and added/removed corresponding authors.</query> Rong Lu, <e-address type="email">lurong@sdu.edu.cn</e-address></text></cor><fneditedby><url url="https://loop.frontiersin.org/people/1925740/overview" title="https://loop.frontiersin.org/people/1925740/overview">Gang Chen</url>,
                University of Health and Rehabilitation Sciences, China</fneditedby><fneditedby><url url="https://loop.frontiersin.org/people/782864/overview" title="https://loop.frontiersin.org/people/782864/overview">Yangjun Chen</url>,
                Wenzhou Medical University, China<br/><url url="https://loop.frontiersin.org/people/2013883/overview" title="https://loop.frontiersin.org/people/2013883/overview">Chason Chen</url>,
                Jimei University, China<url url="https://loop.frontiersin.org/people/696549/overview" title="https://loop.frontiersin.org/people/696549/overview">Sandra Jesus</url>,
                University of Coimbra, Portugal</fneditedby><fnother><p xmlns:m="http://www.w3.org/1998/Math/MathML/">This article was submitted to
                    Nanobiotechnology, a section of the journal Frontiers in Bioengineering and
                    Biotechnology</p></fnother></aug><abs><abstract-sec><simple-para>As nano-drug carriers, small extracellular vesicles (sEVs) have shown
                    unique advantages, but their drug loading and encapsulation efficiency are far
                    from being satisfied, especially for the loading of hydrophilic small-molecule
                    drugs. Inspired by the strategies of active loading of liposomal nanomedicines,
                    pre-drug design and immobilization enzyme, here we developed a new platform,
                    named “Esterase-responsive Active Loading” (EAL), for the
                    efficient and stable drug encapsulation of sEVs. Widely used ferulic acid ester
                    derivatives were chosen as prodrugs based on the EAL of engineered sEVs to
                    establish a continuous transmembrane ion gradient for achieving efficient
                    loading of active molecule ferulic acid into sEVs. The EAL showed that the drug
                    loading and encapsulation efficiency were around 6-fold and 5-fold higher than
                    passive loading, respectively. Moreover, characterization by nano-flow cytometry
                    and Malvern particle size analyzer showed that differential ultracentrifugation
                    combined with multiple types of membrane filtration methods can achieve
                    large-scale and high-quality production of sEVs. Finally, extracellular and
                    intracellular assessments further confirmed the superior performance of the
                    EAL-prepared sEVs-loaded ferulic acid preparation in terms of slow release and
                    low toxicity. Taken together, these findings will provide an instructive insight
                    into the development of sEV-based delivery systems.</simple-para></abstract-sec></abs><keywordsdefault><kwd>esterase-responsive active loading</kwd><kwd>small extracellular vesicles</kwd><kwd>drug delivery</kwd><kwd>isolation and purification</kwd><kwd>ferulic acid esterase A</kwd><kwd>ferulic acid</kwd><query>Q6: Confirm that the keywords are correct and keep them to a maximum of eight and
                a minimum of five. (Note: a keyword can be comprised of one or more words.) Note
                that we have used the keywords provided at Submission. If this is not the latest
                version, please let us know.</query></keywordsdefault></head><body><seca id="sec1"><sectitle><no>1</no>Introduction<query>Q7: Check if the section headers (i.e.,
                section leveling) were correctly captured.</query></sectitle><paragraph>Due to low bioavailability and toxic side effects, free drugs alone are often
                unable to meet the needs of clinical treatment. To solve this problem, Drug Delivery
                System (DDS) has emerged as a technology that can regulate the delivery rate of
                drugs, prolong the systemic circulation time, and deliver drugs to the desired
                target (<xref id="bib_peer_et_al_2007" title="bib_peer_et_al_2007">Peer et al., 2007</xref>
                ; <xref id="bib_wang_et_al_2021b" title="bib_wang_et_al_2021b">Wang et al., 2021b</xref>).
                To date, many drug carriers, such as liposomes, nanoparticles and micelles, have
                been developed to ameliorate the shortcomings of therapeutic drugs (<xref id="bib_ozpolat_et_al_2014" title="bib_ozpolat_et_al_2014">Ozpolat et al., 2014</xref>
                ; <xref id="bib_moosavian_et_al_2021" title="bib_moosavian_et_al_2021">Moosavian et
                al., 2021</xref>). However, these drug carriers accumulate outside the targets,
                which not only produces certain side effects on the human body but also depletes the
                amount of drug delivered to the desired location, resulting in a significant
                reduction in drug delivery efficiency to meet the expected clinical needs (<xref id="bib_blanco_et_al_2015" title="bib_blanco_et_al_2015">Blanco et al., 2015</xref>
                ; <xref id="bib_wang_et_al_2015" title="bib_wang_et_al_2015">Wang et al., 2015</xref>).
                Therefore, there is an urgent need to find a more suitable drug carrier to eliminate
                the drawbacks associated with conventional synthetic nanocarriers.</paragraph><paragraph>Small extracellular vesicles (sEVs) are extracellular nanoscale vesicles with
                lipid-bilayer enclosures and biomolecule contents formed by most cells through a
                series of precise regulation processes such as
                “endocytosis-fusion-efflux”, which play an important role in
                intercellular information communication (<xref id="bib_mathieu_et_al_2019" title="bib_mathieu_et_al_2019">Mathieu et al., 2019</xref>; <xref id="bib_kalluri_and_lebleu_2020" title="bib_kalluri_and_lebleu_2020">Kalluri and
                LeBleu, 2020</xref>; <xref id="bib_van_niel_et_al_2022" title="bib_van_niel_et_al_2022">van Niel et al., 2022</xref>). As novel
                nanocarriers, sEVs have shown great potential in drug delivery systems due to their
                excellent characteristics such as low immunogenicity, good biocompatibility, and
                intrinsic targeting (<xref id="bib_abhange_et_al_2021" title="bib_abhange_et_al_2021">Abhange et al., 2021</xref>; <xref id="bib_isaac_et_al_2021" title="bib_isaac_et_al_2021">Isaac et al., 2021</xref>).
                Up to now, there have been several sEV-based preclinical trials investigating the
                feasibility of delivering protein, RNA or other chemotherapeutic drugs to treat
                diseases (<xref id="bib_de_jong_et_al_2019" title="bib_de_jong_et_al_2019">de Jong
                et al., 2019</xref>; <xref id="bib_walker_et_al_2019" title="bib_walker_et_al_2019">Walker
                et al., 2019</xref>). Importantly, sEVs can cross biological barriers more easily,
                suggesting that sEVs should be more efficiently internalized than synthetic
                nanocarriers (<xref id="bib_heusermann_et_al_2016" title="bib_heusermann_et_al_2016">Heusermann
                et al., 2016</xref>; <xref id="bib_yang_et_al_2020" title="bib_yang_et_al_2020">Yang
                et al., 2020</xref>). Despite the desirable advantages of sEVs as drug carriers, the
                application of sEVs in drug delivery is just getting attention and some issues still
                need to be addressed: 1) which cells should be selected as the donors of sEVs; 2)
                how to modify the targeting of sEVs; 3) how to improve the drug loading efficiency
                of sEVs; and 4) how to achieve mass production of sEVs (<xref id="bib_soekmadji_et_al_2020" title="bib_soekmadji_et_al_2020">Soekmadji et al.,
                2020</xref>; <xref id="bib_wang_et_al_2021a" title="bib_wang_et_al_2021a">Wang et
                al., 2021a</xref>). Stable encapsulation of a large number of therapeutic molecules
                is a prerequisite for the use of sEVs as delivery vehicles (<xref id="bib_jang_et_al_2013" title="bib_jang_et_al_2013">Jang et al., 2013</xref>; <xref id="bib_lu_and_huang_2020" title="bib_lu_and_huang_2020">Lu and Huang, 2020</xref>).
                Current drug loading methods using sEVs are divided into two categories, pre-loading
                and post-loading (<xref id="bib_shao_et_al_2018" title="bib_shao_et_al_2018">Shao et
                al., 2018</xref>; <xref id="bib_herrmann_et_al_2021" title="bib_herrmann_et_al_2021">Herrmann
                et al., 2021</xref>; <xref id="bib_kuriyama_et_al_2021" title="bib_kuriyama_et_al_2021">Kuriyama et al., 2021</xref>). Pre-loading is
                endogenous drug loading, relying on parental cells co-incubate with small molecule
                drugs or transfect with drug-encoding DNA, followed by loading of therapeutic drugs
                into sEVs through intracellular self-assembly behavior (<xref id="bib_armstrong_and_stevens_2018" title="bib_armstrong_and_stevens_2018">Armstrong
                and Stevens, 2018</xref>; <xref id="bib_liu_and_su_2019" title="bib_liu_and_su_2019">Liu
                and Su, 2019</xref>). This approach is used for drug loading by hijacking sEV
                biogenesis and is particularly suitable for loading biological therapeutics such as
                proteins or oligonucleotides. In contrast, post-loading is exogenous drug loading,
                that is, after sEVs are isolated from the parent cell cultures, the therapeutic
                drugs are loaded into sEVs using physical or chemical methods, such as ultrasound,
                electroporation and incubation (<xref id="bib_kim_et_al_2016" title="bib_kim_et_al_2016">Kim et al., 2016</xref>; <xref id="bib_goh_et_al_2017" title="bib_goh_et_al_2017">Goh et al., 2017</xref>).
                Nonetheless, whether loaded with biological drugs or chemical therapeutic agents,
                these methods shared a common problem: poor loading capacity, especially for the
                encapsulation of hydrophilic molecules (<xref id="bib_donoso_quezada_et_al_2020" title="bib_donoso_quezada_et_al_2020">Donoso-Quezada et al., 2020</xref>; <xref id="bib_chen_et_al_2021" title="bib_chen_et_al_2021">Chen et al., 2021</xref>).
                Therefore, the development of more advanced drug loading methods to improve the
                encapsulation of therapeutic agents is critical in sEV-based drug delivery systems.</paragraph><paragraph>In addition, a high yield of sEVs is essential for large-scale use or
                clinical studies. (<xref id="bib_sharma_et_al_2021" title="bib_sharma_et_al_2021">Sharma
                et al., 2021</xref>; <xref id="bib_pirisinu_et_al_2022" title="bib_pirisinu_et_al_2022">Pirisinu et al., 2022</xref>). Currently, a
                variety of sEVs isolation methods have been developed, such as differential
                ultracentrifugation, polymer precipitation, and size exclusion chromatography (<xref id="bib_vader_et_al_2016" title="bib_vader_et_al_2016">Vader et al., 2016</xref>
                ; <xref id="bib_buschmann_et_al_2021" title="bib_buschmann_et_al_2021">Buschmann et
                al., 2021</xref>). However, these methods are either time-consuming and costly or
                furnishing sEVs low in concentration and purity, and it is very difficult to meet
                the requirements for industrial production of sEVs (<xref id="bib_gardiner_et_al_2016" title="bib_gardiner_et_al_2016">Gardiner et al.,
                2016</xref>; <xref id="bib_tieu_et_al_2020" title="bib_tieu_et_al_2020">Tieu et al.,
                2020</xref>). It has been shown that sEVs obtained using a combination of isolation
                methods are of better quality than one isolation method (<xref id="bib_nordin_et_al_2015" title="bib_nordin_et_al_2015">Nordin et al., 2015</xref>
                ; <xref id="bib_shu_et_al_2020" title="bib_shu_et_al_2020">Shu et al., 2020</xref>).
                Therefore, the establishment of a more scientific and convenient sEV isolation
                process, which can rapidly purify and enrich high-quality sEVs from large volumes of
                cell cultures, will facilitate sEVs toward market translation and clinical
                applications.</paragraph><paragraph>Ferulic acid (FA) has various pharmacological effects such as
                anti-inflammatory, anti-oxidant, and anti-thrombotic, and has been widely used in
                the fields of medicine, food and cosmetics (<xref id="bib_klepacka_and_fornal_2006" title="bib_klepacka_and_fornal_2006">Klepacka and Fornal, 2006</xref>; <xref id="bib_dosb_2017" title="bib_dosb_2017">de Oliveira Silva and Batista, 2017</xref>
                ; <xref id="bib_antonopoulou_et_al_2021" title="bib_antonopoulou_et_al_2021">Antonopoulou
                et al., 2021</xref>). However, its hydrophilic characteristics limit its
                applicability in the pharmaceutical industry due to its low stability and low
                bioavailability (<xref id="bib_han_et_al_2019" title="bib_han_et_al_2019">Han et
                al., 2019</xref>; <xref id="bib_wang_et_al_2021c" title="bib_wang_et_al_2021c">Wang
                et al., 2021c</xref>). Until now, several types of nanocarriers loaded with FA have
                been reported for myeloid regeneration, wound healing, skin repair and
                neuroprotection (<xref id="bib_cheng_et_al_2011" title="bib_cheng_et_al_2011">Cheng
                et al., 2011</xref>; <xref id="bib_wu_et_al_2014" title="bib_wu_et_al_2014">Wu et
                al., 2014</xref>; <xref id="bib_ou_et_al_2021" title="bib_ou_et_al_2021">Ou et al.,
                2021</xref>). Nevertheless, due to the feature of the carriers themselves, all of
                these carrier delivery strategies exhibited some degree of toxic side effects.
                Instead, due to the excellent characteristics of sEVs such as crossing biological
                barriers and biosafety, the drug delivery system composed of sEVs loaded with FA
                (sEVs-FA) can not only improve the stability of ferulic acid but also achieve well <i>in
                vivo</i> delivery. Therefore, it has become a promising direction to explore the
                application of sEVs-FA in skin repair.</paragraph><paragraph>Inspired by the strategies of active loading of liposomal nanomedicines,
                pre-drug design and immobilization enzyme, here we are developing an
                esterase-responsive active loading (EAL) sEV-based drug loading platform for
                improved loading efficiency of the active molecules into sEVs, and establishing a
                scientific method for the large-scale isolation and purification of sEVs from
                cultures, as well as providing a delivery strategy for the application of ferulic
                acid in anti-aging and skin repair. (<xref id="fig1" title="fig1">Figure 1</xref><citation>
                fig1</citation>). In the present study, we modified the <i>Pichia pastoris</i> X33
                genome to incorporate the function of expressing ferulic acid esterase through
                modular genetic engineering techniques. The recombinant yeast expression product was
                subjected to structural analysis, and it was verified that the expressed ferulic
                acid esterase is biological activity. Engineered small extracellular vesicles
                (FaeA@sEVs) derived from recombinant yeast cells were isolated by differential
                ultracentrifugation combined with multiple types of membrane filtration methods.
                Corresponding FaeA@sEVs were characterized based on their morphology, particle size
                distribution and potential distribution. Furthermore, the storage stability at
                different temperatures, the hydrolysis function and the kinetic parameters of the
                enzymatic reaction of FaeA@sEVs were also investigated. Then, the loading efficiency
                of FaeA@sEVs for the water-soluble drug ferulic acid was determined by
                high-performance liquid chromatography (HPLC) and compared with blank small
                extracellular vesicles (X33@sEVs) to highlight the advantages of the EAL strategy.
                In addition, the physicochemical properties of engineered small extracellular
                vesicles loaded with ferulic acid (FaeA@sEVs-FA) were identified. Finally, the
                formulation process evaluation and cytotoxicity experiments involving FaeA@sEVs-FA
                were further conducted to evaluate the <i>in vitro</i> release characteristics and
                biosafety of FaeA@sEVs-FA, which laid the foundation for the subsequent development
                of FaeA@sEVs-FA into skin repair products.</paragraph></seca><seca id="sec2"><sectitle><no>2</no>Materials and methods</sectitle><secb id="sec2_1"><sectitle><no>2.1</no>Cell and strain culture</sectitle><paragraph>Human embryonic kidney (HEK) 293T cells were purchased from Weihai
                    Newland Biological Company and were cultured in RPMI-1640 containing 10% fetal
                    bovine serum, penicillin (100 μg/ml), and streptomycin
                    (100 μg/ml) at 37°C in a 5% CO<sub>2</sub> humidified incubator;
                    digested with 0.25% trypsin for passage. The <i>Escherichia coli</i> (<i>E. coli</i>)
                    was cultured in an LB culture medium (37°C, 220 rpm). The <i>Pichia
                    pastoris</i> X33 was cultured in a BMGY culture medium (30°C,
                    250 rpm).</paragraph></secb><secb id="sec2_2"><sectitle><no>2.2</no>Plasmid design</sectitle><paragraph>According to the ferulic acid esterase A (FaeA) gene sequence
                    (XM_025603867.1) (Miaoling, Wuhan) and the multiple cloning site on plasmid
                    pPICZA (Jinweizhi, Suzhou), two pairs of specific upstream and downstream
                    primers (Jinweizhi, Suzhou) were designed to construct the coding DNA sequence
                    of FaeA. Upstream primer 1 (FaeA-F-1):
                    5′-ATGAAGCAATTCTCTGCAAAATAC-3′; Downstream primer 2 (FaeA-R-2):
                    5′-<u>GCCACCGCCACCAGA</u>CCAAGTACAAGCTCCGCT-3′ (underlined as
                    linker sequence); upstream primer 3 (FaeA-F-3):
                    5′-TCAAAAAACAACTAATTATTCGAAACGAG<u>GAATTC</u>ATGAAGCAATTCTCTGCAAAATACGC-3′
                    (underlined as EcoRI restriction site); downstream primer 4 (FaeA-F-4):
                    5′-GCTAAAACTCAATGATGATGATGATGATG<u>GTCGAC</u>GCCACCGCCACCAGAC-3′
                    (underlined as Sal I restriction site).</paragraph><paragraph>The construction steps of the expression plasmid were as follows: In the
                    first step, the FaeA gene with a linker sequence at the 3′ end was
                    amplified by PCR from the pEnCMV-FAEA-3×FLAG plasmid (Miaoling, Wuhan)
                    using the upstream primer 1 and the downstream primer 2; in the second step, the
                    EcoR I restriction site, the Sal I restriction site and the 6xHis-tag were
                    introduced through the upstream primer 3 and the downstream primer 4; in the
                    third step, the expression vector pPICZA was digested with EcoR I and Sal I
                    restriction enzymes, and the FaeA gene containing the 6xHis-tag was spliced into
                    the expression vector by seamless cloning. As shown in <xref id="sec9" title="sec9">Supplementary Figure S1</xref>.</paragraph></secb><secb id="sec2_3"><sectitle><no>2.3</no>Recombinant expression plasmid cloning, linearization
                    and transformation of yeast</sectitle><paragraph>After two rounds of PCR reactions and a seamless cloning kit (Beyotime,
                    Shanghai) ligation, the ligation mixture was obtained, as shown in <xref id="sec9" title="sec9">Supplementary Table S2</xref>. The ligation mixture
                    was subsequently electro-transferred into <i>E.coli</i> DH5α competent
                    cells (Angyu, Shanghai) using electroporation. Transformed colonies were
                    selected on LB agar medium containing Zeocin Selection Reagent
                    (25 μg/ml) (Sangon, Shanghai). Bacteria liquid was performed with
                    universal primers (5′AOX1: 5′-GACTGGTTCCAATTGACAAGC-3′ and
                    3′AOX1: 5′-GCAAATGGCATTCTGACATCC-3′) of the pPICZA vector
                    (Invitrogen, United States) were subjected to a polymerase chain reaction, and
                    colonies containing recombinant vectors were screened. Positive colonies were
                    collected and cultured overnight in LB medium for plasmid cloning. A high
                    concentration of recombinant expression plasmid named pPICZA-FaeA-6H was
                    obtained using plasmid mid-extraction and plasmid concentration methods.</paragraph><paragraph>The recombinant expression plasmid pPICZA-FaeA-6H was incubated at
                    37°C for 18 h with restriction endonucleases SacⅠ(Beyotime,
                    Shanghai) for single-enzyme digestion linearization. Similarly, the linearized
                    product was electro-transferred to  X33 competent cells by
                    electroporation. Transformed colonies were selected on a YPD agar medium
                    containing Zeocin Selection Reagent (25 μg/ml). Colonies containing
                    the recombinant vector were initially screened by fungal liquid polymerase chain
                    reaction using universal primers of the pPICZA vector mentioned above. Further,
                    the screened colonies are identified by genome sequencing, and the colonies with
                    correct sequences are preserved as high-copy recombinant yeast. As shown in <xref id="sec9" title="sec9">Supplementary Figure S3</xref>.</paragraph></secb><secb id="sec2_4"><sectitle><no>2.4</no>Expression and identification of exogenous protein</sectitle><paragraph>200 μL of high-copy recombinant yeast liquid was taken out of
                    the refrigerator at -80°C, transferred into 10 ml BMGY medium, and
                    cultured in a shaker at 250 rpm and 30°C for 24 h. The next day,
                    the OD600 of yeast liquid was detected, and a proper amount of yeast liquid was
                    added to about 200 ml BMGY culture medium. The initial OD600 of yeast
                    liquid was controlled to be about 1, and the yeast liquid was cultured in a
                    shaker at 250 rpm and 30°C for 24 h. On the third day, the yeast
                    liquid obtained on the second day was centrifuged at 6,100 rpm for
                    5 min. The precipitate was transferred to a 200 ml BMMY culture
                    medium, and it was cultured in a shaker at 250 rpm and 30°C for
                    24 h. On the fourth day, 5‰ methanol was added to the culture
                    medium, that is, 1 ml methanol was directly added, and the culture was
                    continued cultured in a shaker at 250 rpm and 30°C for 24 h. On
                    the fifth day, the culture medium obtained on the fourth day was collected and
                    centrifuged at 6,100 rpm for 5 min. The supernatant was used to
                    extract the engineered small extracellular vesicles (FaeA@sEVs), and the
                    precipitate was used to extract the exogenous protein expressed by recombinant
                    yeast cells.</paragraph><paragraph>Take 2 ml of the above precipitate in a 4 ml EP tube, add
                    1 ml of  X33 cell lysate (1 mM EDTA-2Na,
                    50 mM NaHPO<sub>4</sub>, 5% glycerol) containing 1% protease
                    inhibitor. After mixing, the mixture was placed in an ice bath for 30 min.
                    The cell wall of the above suspension was broken by ultrasound with a cell
                    breaker (Bannuo, Shanghai). The parameters of the cell breaker were as follows:
                    power 120 W, 10 s interval for each cycle of ultrasound, and 60 cycles
                    in total. After centrifugation at 6,100 rpm for 5 min, the supernatant
                    named intracellular protein was transferred to a new EP tube. Intracellular
                    protein concentration was detected by a protein analysis kit (Beyotime,
                    Shanghai). As the exogenous protein feruloyl esterase is linked to the fusion
                    protein 6xHis-tag, the expression of exogenous protein feruloyl esterase can be
                    verified by western blot with 6xHis-tag antibody.</paragraph></secb><secb id="sec2_5"><sectitle><no>2.5</no>Determination of enzyme activity and its influencing
                    factors</sectitle><paragraph>The enzymatic properties of intracellular proteins were investigated
                    using a classical reaction system (<xref id="bib_zhang_et_al_2012" title="bib_zhang_et_al_2012">Zhang et al., 2012</xref>): 800 μL
                    of PBS (0.1×, pH 6.4) and 100 μL of ethyl ferulate (EF) solution
                    were added to 2 ml EP tubes, mixed evenly, and incubated at 40°C
                    for 10 min. After that, 100 μL enzyme solution at appropriate
                    dilutions was added, sealed with a sealing membrane, and incubated in the dark
                    at 40°C for 10 min. After the reaction was completed,
                    400 μL glacial acetic acid was added to quench the reaction
                    immediately, and then passed through a 0.45-μm pore size PES filter
                    membrane for HPLC analysis. The reaction solution with pre-added glacial acetic
                    acid was used as a blank control. The specific chromatographic conditions were
                    as follows: C18–4.6 mm × 250 mm, 1% glacial acetic acid:
                    methanol = 70:30, detection wavelength for 313 nm, detection time for
                    25 min, flow rate for 1 ml/min, and column temperature for 30°C.
                    One unit (U) of enzyme activity was defined as the amount of enzyme required to
                    release 1 μmol ferulic acid per minute under the experimental
                    conditions above.</paragraph><paragraph>The optimum reaction temperature of the enzyme was determined by
                    measuring the enzyme activity at different temperatures (25–60°C) in
                    phosphate buffer solution (PBS) with pH 6.4. To study the thermal stability of
                    the enzyme, the residual activity was detected after incubation at different
                    temperatures for 1 h. Similarly, PBS of different pH (pH 3.0–9.0)
                    was prepared to determine the optimum pH of the enzyme. To test the pH stability
                    of the enzyme, the residual activity of the enzyme was assayed after
                    pre-incubation in the above buffer at 50°C for 1 h.</paragraph></secb><secb id="sec2_6"><sectitle><no>2.6</no>Isolation and purification of FaeA@sEVs</sectitle><paragraph>The collected recombinant yeast culture suspension (≥3 L)
                    after induction and expression of recombinant yeast was poured into a sterile
                    centrifuge bucket, and the supernatant was collected after centrifugation at
                    5,000 <i>g</i> for 45 min at 4°C. A vacuum filtration device was
                    assembled and the supernatant was filtered with a 0.8-μm pore size PES
                    membrane under the action of a vacuum pump to remove large cell debris and large
                    impurities. Subsequently, the filtrate passed through a tangential flow
                    filtration system (TFF) with a 100-kDa mPES hollow fiber membrane module to
                    concentrate the sample solution to 300 ml and the permeate was discarded to
                    remove small impurities such as interfering proteins. Then the concentrated
                    sample solution was centrifuged at 15,000 g for 30 min at 4°C,
                    and the obtained supernatant was successively filtered through a 0.8-μm
                    and 0.45-μm pore size PES membrane. Next, the filtrate was purified by a
                    sucrose cushion according to the volume ratio of 32.5 ml of filtrate per
                    tube and 6 ml 0.971 M sucrose solution (<xref id="bib_ramakrishnaiah_et_al_2013" title="bib_ramakrishnaiah_et_al_2013">Ramakrishnaiah
                    et al., 2013</xref>) at 100,000 g for 70 min at 4°C. At the end
                    of the centrifugation, 6 ml sucrose cushion at the bottom of each tube was
                    removed and combined into a new centrifuge tube. Finally, the collected sucrose
                    cushion was purified and concentrated in a 15 ml ultrafiltration tube
                    (Millipore, United States) to remove sucrose at 4,000 g for 20 min at
                    4°C and the concentrated solution was the suspension of the FaeA@sEVs. The
                    sEVs obtained from unmodified yeast in the same way were recorded as X33@sEVs
                    and used as a blank control group.</paragraph></secb><secb id="sec2_7"><sectitle><no>2.7</no>Physicochemical characterization of FaeA@sEVs</sectitle><paragraph>To detect the particle concentration and particle size of FaeA@sEVs, the
                    sEV solution was diluted with fresh PBS at appropriate multiples and assayed by
                    nano-flow cytometry (NanoFCM, Xiamen). At the same time, the same sample
                    solution was treated with 0.1% Triton X-100 (Sigma-Aldrich) to rupture the sEV
                    membrane structure (<xref id="bib_lorincz_et_al_2020" title="bib_lorincz_et_al_2020">Lorincz et al., 2020</xref>; <xref id="bib_zhou_et_al_2021" title="bib_zhou_et_al_2021">Zhou et al., 2021</xref>).
                    Changes in particle number of three sEVs before and after lysis with 0.1% Triton
                    X-100 in <xref id="sec9" title="sec9">Supplementary Table S4</xref>. The purity
                    of sEVs was expressed by the ratio of the difference of the particle number
                    concentration values before and after membrane rupture to that before membrane
                    rupture. To compare the accuracy of different detection instruments and the
                    stability of FaeA@sEVs, the particle size and zeta potential size of the
                    FaeA@sEVs were further analyzed by a Malvern particle size analyzer (Malvern
                    PANalytical, United kingdom). The BCA protein concentration determination kit
                    was used to detect the protein concentration of the FaeA@sEVs. To detect the
                    morphological characteristics of the FaeA@sEVs, 20 μL sEV suspension
                    was dropped onto a copper mesh with a carbon-supported membrane. After adsorbing
                    naturally for 5 min at room temperature, the excess liquid was removed
                    using filter paper. Then 20 μL 2% phosphotungstic acid solution was
                    added to the copper mesh and the membrane was stained for 3 min Afterward,
                    the excess liquid was removed using filter paper and the copper mesh was placed
                    under an incandescent lamp to dry naturally. Finally, the morphology of sEVs was
                    observed under the transmission electron microscope (FEI, United States). In
                    addition, western blot analysis confirmed the existence of ferulic acid esterase
                    in FaeA@sEVs. X33@sEVs and FaeA@sEVs-FA were characterized in the same way as
                    described above.</paragraph></secb><secb id="sec2_8"><sectitle><no>2.8</no>Enzyme activity of FaeA@sEVs</sectitle><paragraph>The enzyme activity of FaeA@sEVs and intracellular protein were measured
                    according to the optimum temperature and pH of FaeA obtained above. The
                    procedure was essentially the same as that described in <xref id="sec2_5" title="sec2_5">section 2.5</xref>, except that the temperature was adjusted
                    to 50°C and pH was adjusted to 4.0 in the enzymatic reaction conditions,
                    and the reaction time was extended to 3 h for the FaeA@sEVs group.</paragraph></secb><secb id="sec2_9"><sectitle><no>2.9</no>Kinetic parameters of FaeA in free and FaeA@sEVs
                    states</sectitle><paragraph>A series of reaction systems containing different concentrations of EF
                    (substrate) were prepared, so that the final concentration of substrate in the
                    system was set to 10.2–102 μg/ml. Then, 100 μL
                    intracellular protein solution or FaeA@sEVs solution was added to the system,
                    and the reaction was carried out at 50°C and pH 4.0 for 10 min or
                    3 h. After the reaction was completed, 400 μL glacial acetic
                    acid was added to the system to quench the reaction. The concentrations of FA
                    (product) in different substrate concentration systems were quantified by HPLC,
                    and the corresponding enzyme activities were calculated. In the blank control
                    groups, buffer solution, intracellular protein solution obtained from unmodified  X33 and blank sEV solution were used instead of enzyme solution.
                    Kinetic parameters (Km, Vmax, and Kcat) were estimated using the curve fitting
                    to the Michaelis–Menten equation (Origin 2021).</paragraph></secb><secb id="sec2_10"><sectitle><no>2.10</no>Storage stability of FaeA@sEVs</sectitle><paragraph>X33@sEVs and FaeA@sEVs from the same batch were stored at three
                    temperatures of 4°C, -20°C and -80°C for 1, 3, 6, 9, 12, 15 and
                    30 days, respectively. The particle size distribution of these samples was
                    detected at the set time point by nano-flow cytometry.</paragraph></secb><secb id="sec2_11"><sectitle><no>2.11</no>Loading efficiency of engineered sEV-loaded active
                    molecules</sectitle><paragraph>We previously investigated the effect of the mass ratio of FaeA@sEVs to
                    EF on the drug loading efficiency. The results showed that the drug loading
                    efficiency increases with the increase of EF input in a certain concentration
                    range. Finally, we selected the condition that the mass ratio of FaeA@sEVs to EF
                    is 1:2 to determine the advantage of drug loading efficiency of the EAL
                    platform.</paragraph><paragraph>First, 100 μL EF (0.800 mg/ml) was added to
                    100 μL FaeA@sEVs (0.400 mg/ml). Then, 800 μL PBS
                    (0.1×, pH 4.0) was added to the above-mixed system to constitute the
                    reaction system. The reaction system was sealed with a sealing film and
                    incubated in a water bath at 50°C for 3 h. After co-incubation, the
                    enzyme reaction was immediately terminated on ice, and the whole reaction system
                    was subsequently incubated at 4 °C for 0.5 h to restore the
                    stability of the sEV membrane. Then, the reaction mixture was transferred to a
                    100-kDa ultrafiltration tube followed by the addition of 1 ml PBS and then
                    centrifuged at 4,000 g for 10 min at 4°C to remove unloaded free
                    drug molecules. Subsequently, the liquid in the inner tube (T<sub>in</sub>) of
                    the ultrafiltration tube (FaeA@sEVs-FA) and the liquid in the outer tube (T<sub>
                    out</sub>) of the ultrafiltration tube (free drug) were collected separately in
                    new 1.5 ml EP tubes. The volume of T and T<sub>out</sub>
                    was recorded. An equal volume of methanol was added to the T and
                    sonicated for 1 h in a water bath to break the membrane structure of the
                    FaeA@sEVs-FA to release the internal drug. At the same time, the free drug in
                    the T was diluted by a certain multiple. Finally, the samples of T<sub>
                    in</sub> and T were analyzed by HPLC for the content of EF and FA.
                    The specific chromatographic conditions were as follows: C18–4.6 mm
                    × 250 mm, 1% glacial acetic acid - methanol (0 min: 40–60,
                    15 min: 50–50, 18 min: 40–60) as mobile phase, detection
                    wavelength for 325 nm, detection time for 18 min, and column temperature
                    for 30°C. The drug loading efficiency of the FaeA@sEVs was calculated by
                    converting EF into FA content using n (EF): n (FA) = 1:1. The loading efficiency
                    was expressed in terms of drug loading and encapsulation efficiency:<query>Q8:
                    Verify that all the equations and special characters are displayed correctly.</query></paragraph><displaymath><math><mrow><mo>%</mo><mi mathvariant="normal">D</mi><mi mathvariant="normal">r</mi><mi mathvariant="normal">u</mi><mi mathvariant="normal">g</mi><mtext> </mtext><mi mathvariant="normal">l</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">d</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi><mo>=</mo><mfrac><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">t</mi><mi mathvariant="normal">f</mi><mi mathvariant="normal">s</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">V</mi></mrow><mrow><mi mathvariant="normal">p</mi><mi mathvariant="normal">e</mi></mrow></mfrac><mo>×</mo><mn>100</mn></mrow></math></displaymath><displaymath><math><mrow><mi mathvariant="normal">c</mi><mi mathvariant="normal">y</mi><mfrac><mrow/></mfrac></mrow></math></displaymath><paragraph>The same process was used to analyze the drug loading efficiency of
                    X33@sEVs loaded EF, and the results were used as a blank control group. In
                    addition, since EF is hydrolyzed to an equal amount of FA by the action of
                    esterase, the drug loading efficiency of EF will eventually be calculated in the
                    form of FA. Using the same method as described above, EF was replaced with FA to
                    explore whether loading FA with FaeA@sEVs and X33@sEVs had an impact on the
                    results of assessing loading EF.</paragraph></secb><secb id="sec2_12"><sectitle><no>2.12</no><i>In vitro</i> drug release pattern of FaeA@sEVs-FA</sectitle><paragraph>Precisely aspirate 100 μL FaeA@sEVs-FA and 900 μL
                    PBS into a dialysis bag (MW = 8,000). After tying the ends of the bag tightly,
                    the dialysis bag was placed in 8 ml PBS (pH 7.4). The temperature was set
                    at 32 ± 0.5°C, and the stirring speed was set at 200 r/min.
                    1 ml of release medium was taken from the outside of the dialysis bag at
                    10, 30, 60, 90, 120, and 150 min, while an equal volume of blank release
                    medium was added at the same temperature. The contents of EF and FA in the
                    release medium at different moments were measured according to the method
                    described in . The cumulative
                    release Q was calculated by converting EF into FA content using n (EF): n (FA) =
                    1: 1.</paragraph></secb><secb id="sec2_13"><sectitle><no>2.13</no>Cytotoxicity analysis of FaeA@sEVs-FA</sectitle><paragraph>The cytotoxicity of free FA, FaeA@sEVs-FA, FaeA@sEVs and X33@sEVs at
                    different concentrations was assessed by CCK-8 assay. HEK 293T cells were seeded
                    at 1×10<sup>4</sup>/well in 96-well plates and cultured for 24 h. Then
                    free FA solution and sEV with the concentration of 0.1–10.0 μM
                    were added to the cells, and incubation was carried out for 24 h. All
                    samples were diluted in complete medium. The concentration of FA in FaeA@sEVs-FA
                    was the same as that of the free FA, and the particle concentration of FaeA@sEVs
                    and X33@sEVs was the same as that of the FaeA@sEVs-FA. The cells were incubated
                    with 10 μL CCK-8 reagent in the dark for 2 h. The cells were
                    immediately placed in a microplate reader (Bio-Tek, United States) and the
                    absorbance value at 450 nm was measured. The measurement was repeated three
                    times. Cell viability (%)=(A2-A0)/(A1-A0)×100%, where A0 referred to the
                    absorbance of the well containing medium and CCK-8 solution without cells, A1
                    referred to the absorbance of the well containing cells and CCK-8 solution
                    without drug, and A2 referred to the absorbance of well containing cells, drug
                    and CCK-8 solution.</paragraph></secb><secb id="sec2_14"><sectitle><no>2.14</no>Statistical analysis</sectitle><paragraph>Above experimental data were repeated three times (<i>n</i> = 3) and
                    analyzed by GraphPadPrism 8.0 and Origin 2021 for data analysis, statistical
                    analysis and image processing. The measurement data were expressed as mean
                    ± standard deviation (Mean ± SD), and the data between groups were
                    analyzed by one-way ANOVA to assess the difference between various groups: <i>
                    ∗p</i> &lt; 0.05, <i>∗∗p</i> &lt; 0.01, <i>
                    ∗∗∗p</i> &lt; 0.001.</paragraph></secb></seca><seca id="sec3"><sectitle><no>3</no>Results and discussion</sectitle><secb id="sec3_1"><sectitle><no>3.1</no>Clonal expression and enzymatic properties of FaeA
                    gene</sectitle><paragraph>In this experiment, we modified the genome of  X33
                    by modular genetic engineering techniques, and successfully obtained an
                    engineered strain capable of expressing the exogenous protein FaeA (<xref id="fig2" title="fig2">Figure 2A</xref><citation>fig2</citation>). The
                    recombinant yeast growth state was observed under an inverted microscope (Caisi,
                    China), and the result showed that the recombinant yeast divided in a typical
                    budding manner (<xref id="fig2" title="fig2">Figure 2B</xref>). The results of
                    western blot analysis of the intracellular protein from recombinant yeast
                    confirmed that recombinant yeast was able to express the exogenous protein FaeA
                    with an apparent molecular weight of 40.0 kDa (<xref id="fig2" title="fig2">Figure
                    2C</xref>). The apparent molecular weight was larger than the theoretical value
                    of 32.0 kDa, which may be due to post-translational modifications such as
                    phosphorylation and glycosylation of FaeA during recombinant yeast expression.
                    Software NetPhosYeast 1.0, NetNGlyc 1.0 and NetOGlyc 4.0 (<url url="http://www.cbs.dtu.dk/services/" title="http://www.cbs.dtu.dk/services/">http://www.cbs.dtu.dk/services/</url>)
                    were used to predict the phosphorylation and N and O-glycosylation sites of the
                    FaeA gene, respectively. The results showed the presence of an O-glycosylation
                    site at amino acid position 272. Further analysis of the enzymatic properties of
                    FaeA showed that the optimum temperature was 50°C, and the enzyme remained
                    stable below 40°C; the optimum pH was 4.0, and the enzyme was more stable
                    between pH 3.0 and 5.0 (<xref id="fig2" title="fig2">Figure 2D</xref>).</paragraph></secb><secb id="sec3_2"><sectitle><no>3.2</no>Isolation and characterization of FaeA@sEVs</sectitle><paragraph>Application of sEVs as nano-drug carriers requires high purity, otherwise
                    their drug loading capacity or physiological processes <i>in vivo</i> will be
                    compromised (<xref id="bib_batrakova_and_kim_2015" title="bib_batrakova_and_kim_2015">Batrakova and Kim, 2015</xref>; <xref id="bib_hettich_et_al_2020" title="bib_hettich_et_al_2020">Hettich et al.,
                    2020</xref>). Additionally, rapid and large-scale production of sEVs is critical
                    to extending their practical application including the need for clinical
                    applications (<xref id="bib_zhang_et_al_2021" title="bib_zhang_et_al_2021">Zhang
                    et al., 2021</xref>). Hence, we performed differential ultracentrifugation
                    combined with multiple types of membrane filtration methods to isolate and
                    purify FaeA@sEVs from large volumes of recombinant yeast culture supernatant (<xref id="fig3" title="fig3">Figure 3A</xref><citation>fig3</citation>), and
                    characterized their morphology, particle size distribution, zeta potential
                    distribution and concentration. Notably, due to the density of sEVs of
                    1.13–1.19 g/cm<sup>3</sup> (<xref id="bib_van_der_pol_et_al_2012" title="bib_van_der_pol_et_al_2012">van der Pol et al., 2012</xref>; <xref id="bib_xie_et_al_2019" title="bib_xie_et_al_2019">Xie et al., 2019</xref>),
                    we used a 0.971 M sucrose cushion in the isolation process to obtain
                    high-quality FaeA@sEVs. Under transmission electron microscopy, we observed that
                    the FaeA@sEVs exhibited a typical saucer-like and relatively clean background (<xref id="fig3" title="fig3">Figure 3B</xref>). This low background without
                    contamination by other impurities indicated that FaeA@sEVs were of high purity.
                    To verify the presence of FaeA in the FaeA@sEVs, we performed a western blot
                    analysis, and the result confirmed that FaeA was successfully loaded into the
                    sEVs (<xref id="fig3" title="fig3">Figure 3C</xref>). The complete western blot
                    image in <xref id="sec9" title="sec9">Supplementary Figure S5</xref>.</paragraph><paragraph>Since transmission electron microscopy has disadvantages such as
                    time-consuming, limited field of view (<xref id="bib_lai_et_al_2022" title="bib_lai_et_al_2022">Lai et al., 2022</xref>), and possible imaging
                    artifacts, we further employed nano-flow cytometry and Malvern particle size
                    analyzer to fully reveal the heterogeneity of FaeA@sEVs. <xref id="fig3" title="fig3">Figure 3D</xref> showed that the side scatter (SS) signal
                    occurred when a single particle passed through the tightly focused laser beam of
                    nano-flow cytometry in sequence. <xref id="fig3" title="fig3">Figure 3E</xref>
                    displayed the particle size of X33@sEVs and FaeA@sEVs were 69.48 ±
                    11.91 nm and 71.91 ± 14.59 nm, respectively. The particle size
                    distribution diagrams of three sEVs were included in Supporting Information, see <xref id="sec9" title="sec9">Supplementary Figure S6</xref>. <xref id="fig3" title="fig3">Figure 3F</xref> reflected the particle concentration of
                    X33@sEVs and FaeA@sEVs were 3.98E+10 particles/mL and 1.21E+11 particles/mL,
                    respectively. The change in particle number after triton treatment represented
                    the purity of the sEVs (<xref id="bib_lim_et_al_2022" title="bib_lim_et_al_2022">Lim
                    et al., 2022</xref>), and the result showed that the purity of the FaeA@sEVs was
                    close to 90%. Nano-flow cytometry could better reflect the physicochemical
                    properties of a single particle, and these results also suggested that the
                    engineered operation did not lead to significant differences in the morphology
                    and particle size distribution of the sEVs.</paragraph><paragraph>Meanwhile, the results of the Malvern particle size analyzer showed that
                    sample particles of single-peaked distribution. The particle size for X33@sEVs
                    and FaeA@sEVs was 137.00 ± 42.50 nm and 205.50 ± 53.69 nm,
                    respectively (<xref id="fig3" title="fig3">Figure 3G</xref>). The particle size
                    increased after the modification, which may be influenced by the content FaeA. <xref id="fig3" title="fig3">Figure 3H</xref> suggested that the average potential
                    and PDI values of X33@sEVs were -11.20 ± 10.60 mV and 0.330,
                    respectively, while the average potential and PDI values of FaeA@sEVs were
                    -13.20 ± 15.70 mV and 0.303, respectively. This indicates that the
                    FaeA@sEVs have a more stable dispersion state. Due to the limitations of the
                    experimental conditions, the Malvern particle size system is more widely
                    applicable compared to the nano-flow cytometry system. Above sEV
                    characterization experiments indicated inconsistent results of the two detection
                    systems, which may be related to the detected sample volumes. The relatively
                    larger volume of samples detected by the Malvern particle size analyzer
                    presented interference between particles, which leads to a larger detection of
                    sEV hydrodynamic diameter. In conclusion, the nano-flow cytometry provides more
                    accurate results for the identification of sEVs. However, the Malvern particle
                    size analyzer can easily measure the dispersion state of sEVs.</paragraph><paragraph>Further, the results of the characterization of the FaeA@sEVs-FA were as
                    follows. Transmission electron microscopy showed typical saucer-like morphology
                    of the FaeA@sEVs-FA (). The results
                    of nano-flow cytometry showed that after loading drug FaeA@sEVs-FA particles
                    displayed a single-peaked distribution with a mean particle size of 70.01 ±
                    10.92 nm, which was not significantly different from that before the
                    loading (). The results of the
                    Malvern particle size analyzer showed that the average particle size of the
                    FaeA@sEVs-FA was 193.00 ± 39.31 nm, and the average potential of
                    -17.70 ± 14.60 mV and PDI values of 0.400, as shown in <xref id="fig3" title="fig3">Figures 3G,H</xref>. These results indicated that there was no
                    significant change in the morphology and particle size of sEVs before and after
                    loading the drug, and the FaeA@sEVs-FA was more dispersed and stable. We
                    speculated that the addition of the FA may have stabilized the membrane
                    structure of the sEVs. The characterization data of FaeA@sEVs-FA are summarized
                    in <xref id="sec9" title="sec9">Supplementary Table S7</xref>.</paragraph></secb><secb id="sec3_3"><sectitle><no>3.3</no>Esterase hydrolysis and storage stability of FaeA@sEVs</sectitle><paragraph>To further verify whether the FaeA@sEVs possess esterase hydrolysis, the
                    enzymatic activity of FaeA@sEVs using EF as substrate was measured, and it was
                    found as 267.63 mU/mL. In addition, the enzymatic activity data for
                    intracellular proteins and sEVs indicated that FaeA maintains high hydrolytic
                    capacity after being successfully incorporated into sEVs, as shown in <xref id="fig4" title="fig4">Figure 4A</xref><citation>fig4</citation>. It has
                    been reported that the physicochemical properties of mammalian-derived sEVs have
                    not changed much when stored at 4°C for 2 weeks and can even be stored
                    longer unchanged at -80°C (<xref id="bib_yuan_et_al_2021" title="bib_yuan_et_al_2021">Yuan et al., 2021</xref>; <xref id="bib_gelibter_et_al_2022" title="bib_gelibter_et_al_2022">Gelibter et
                    al., 2022</xref>). However, the storage stability of yeast-derived sEVs has not
                    been reported in the literature. We used a nano-flow cytometry to determine the
                    change in particle size of X33@sEVs and FaeA@sEVs stored at different
                    temperatures for several days. <xref id="fig4" title="fig4">Figures 4B</xref>–E
                    showed that the particle size and particle concentration of X33@sEVs and
                    FaeA@sEVs did not change significantly within 30 days at 4°C,
                    -20°C and -80°C, which indicated a wide range of storage conditions
                    for the FaeA@sEVs and suggested that FaeA did not affect the storage conditions
                    of the sEVs. Since the enzyme is usually kept at low temperatures, we have
                    chosen to store the sEV suspensions at -80°C.</paragraph></secb><secb id="sec3_4"><sectitle><no>3.4</no>Kinetic parameters of FaeA in different states</sectitle><paragraph>The affinity and reaction rate of FaeA for the substrate were different
                    in the naked and encapsulated states. sEVs as an encapsulated carriers affect
                    the reaction rate of FaeA. To better understand the enzymatic activity of the
                    FaeA@sEVs, we determined the kinetic parameters (Km, Vmax and Kcat) for the
                    reaction of FaeA on EF in both states, and the results were shown in <xref id="tbl1" title="tbl1">Table 1</xref><citation>tbl1</citation>. The results
                    displayed: intracellular protein (Vmax of 1,340.94 ± 489.12 U/mg) &gt;
                    FaeA@sEVs (Vmax value of 12.80 ± 3.88 U/mg) and intracellular protein
                    (Km of 0.17 ± 0.09 mM) &gt; FaeA@sEVs (Km of 0.10 ±
                    0.05 mM). Smaller Km values indicated a higher affinity of the enzyme for
                    the substrate (<xref id="bib_dulong_et_al_2018" title="bib_dulong_et_al_2018">Dulong
                    et al., 2018</xref>; <xref id="bib_schmitz_et_al_2022" title="bib_schmitz_et_al_2022">Schmitz et al., 2022</xref>). These data
                    suggested that the immobilized enzyme system, which is formed by the method of
                    FaeA being loaded into engineered sEVs, has an increased affinity for EF.
                    However, in terms of the Kcat/Km ratio, the enzymatic reaction efficiency of the
                    FaeA@sEVs was approximately 50-fold lower than that of the intracellular
                    protein. This pattern is consistent with the characteristics of embedded
                    immobilized enzymes (<xref id="bib_grant_et_al_2018" title="bib_grant_et_al_2018">Grant et al., 2018</xref>), and suggests that
                    FaeA is encapsulated inside the sEVs rather than adhering to the surface of the
                    sEVs.</paragraph></secb><secb id="sec3_5"><sectitle><no>3.5</no>Loading efficiency of FaeA@sEVs for active molecules</sectitle><paragraph>The principle of the co-incubation method is that the drug enters into
                    the lipid bilayer of sEVs through hydrophobic intercalation, and its transport
                    power is determined by the difference in the concentration gradient of the drug
                    between the two sides of the membrane. The higher the concentration difference
                    between the two sides of the membrane, the higher the transport power (<xref id="bib_haney_et_al_2015" title="bib_haney_et_al_2015">Haney et al., 2015</xref>
                    ; <xref id="bib_zhong_et_al_2021" title="bib_zhong_et_al_2021">Zhong et al.,
                    2021</xref>). The process of the EAL is as follows: when the EF with high
                    concentration from the outside of the membrane to the inside of the membrane, it
                    will undergo esterase hydrolysis to produce FA catalyzed by FaeA. This step is
                    equivalent to closing the “switch” for the balance of EF
                    concentration between the two sides of the membrane. As long as EF is present
                    outside the membrane, it will enter the membrane based on the concentration
                    difference between the two sides of the membrane and release FA. At the same
                    time, the ion trapping effect of biofilm can block the outward leakage of FA (<xref id="bib_sun_et_al_2021" title="bib_sun_et_al_2021">Sun et al., 2021</xref>),
                    thus indirectly achieving the efficient loading of FA in sEVs (<xref id="fig5" title="fig5">Figure 5A</xref><citation>fig5</citation>).</paragraph><paragraph>Based on the previous methods for detecting FA content (<xref id="bib_khezeli_et_al_2016" title="bib_khezeli_et_al_2016">Khezeli et al.,
                    2016</xref>; <xref id="bib_oliveira_et_al_2019" title="bib_oliveira_et_al_2019">Oliveira
                    et al., 2019</xref>), we successfully obtained a chromatogram of EF and FA
                    standards by HPLC (<xref id="sec9" title="sec9">SupplementaryFigure S8</xref>).
                    By analyzing the change in the amount of the enzymatic action substrate (EF) and
                    the hydrolysis product (FA), the amount of the final active component in the
                    FaeA@sEVs can be determined according to the formula that 1 mol of EF
                    produces 1 mol of FA. First, to find the optimal mass ratio of sEVs to the
                    drug, we tested five combinations of mass ratios. The results showed that the
                    highest drug loading of sEVs was achieved at a mass ratio of 1:2 between sEVs
                    and EF (<xref id="sec9" title="sec9">Supplementary Figure S9</xref>). Under the
                    same conditions described above, we obtained the drug loading efficiency of
                    X33@sEVs for EF, and the drug loading efficiency of X33@sEVs and FaeA@sEVs for
                    FA (the molar amount of FA was equal to that of EF). The results showed that the
                    EAL platform could significantly increase the drug (ferulic acid) loading (from
                    less than 10% to nearly 60%) and encapsulation efficiency (from less than 8% to
                    nearly 40%) of the drug active molecule ferulic acid (<xref id="fig5" title="fig5">Figure 5B</xref>; <xref id="tbl2" title="tbl2">Table 2</xref><citation>
                    tbl2</citation> and <xref id="sec9" title="sec9">Supplementary Table S10</xref>).
                    Remarkably, since loading ferulic acid does not initiate the esterase response,
                    the drug loading efficiency of the EAL platform is approximately 2-fold higher
                    than using X33@sEVs (X33@sEVs-#FA) or FaeA@sEVs (FaeA@sEVs-#FA) for loading an
                    equivalent amount of ferulic acid. The data above suggest that the EAL platform
                    can significantly improve the drug loading and encapsulation efficiency of sEVs
                    for water-soluble active drugs. Although classical drug loading methods, such as
                    ultrasonication, electroporation and freeze-thaw cycles, could also improve drug
                    loading to some extent, they may cause damage to the membrane structure of sEVs
                    (<xref id="bib_nasiri_kenari_et_al_2020" title="bib_nasiri_kenari_et_al_2020">Nasiri
                    Kenari et al., 2020</xref>). In addition, some studies have shown that
                    electroporation could lead to aggregation and precipitation of therapeutic
                    drugs, which can lead to misinterpretation of drug loading efficiency (<xref id="bib_kooijmans_et_al_2013" title="bib_kooijmans_et_al_2013">Kooijmans et
                    al., 2013</xref>). The EAL platform provides drug loading power 
                    biocatalysis and could protect the active drugs and carriers from damage by
                    external mechanical conditions. Therefore, the EAL platform developed in this
                    study has mild conditions and could maintain the morphology of sEVs well
                    compared to other widely used drug loading methods, thus achieving a good
                    loading efficiency.</paragraph></secb><secb id="sec3_6"><sectitle><no>3.6</no> drug release pattern and cytotoxicity
                    of FaeA@sEVs-FA</sectitle><paragraph>To further evaluate the potential of FaeA@sEVs-FA in skin repair, we
                    performed  drug release assay and cytotoxicity analysis. With <i>in
                    vitro</i> drug release curve of FaeA@sEVs-FA was shown in <xref id="fig6" title="fig6">Figure 6A</xref><citation>fig6</citation>. The curve was fitted
                    with zero-level kinetic equation, first-level kinetic equation, Weibull
                    distribution, Higuchi equation and Ritger-Peppas equation, respectively, and the
                    results were shown in <xref id="tbl3" title="tbl3">Table 3</xref><citation>tbl3</citation>.
                    The results showed that the first-order kinetic equation and Weibull model fit
                    results were good, and the  drug release pattern of the
                    FaeA@sEVs-FA formulation was closest to the Weibull equation, indicating that
                    the FaeA@sEVs-FA formulation has a certain sustained-release effect. This is
                    consistent with the previously reported sEV drug release pattern (<xref id="bib_wang_et_al_2017" title="bib_wang_et_al_2017">Wang et al., 2017</xref>
                    ; <xref id="bib_hu_et_al_2021" title="bib_hu_et_al_2021">Hu et al., 2021</xref>).
                    Previously, the biosafety of  X33-derived sEVs has not
                    been thoroughly examined. The results of the CCK-8 assay showed that X33@sEVs,
                    FaeA@sEVs and FaeA@sEVs-FA all had a wide range of safe concentrations, and
                    could promote the growth of HEK 293T cells within a certain concentration range
                    (<xref id="fig6" title="fig6">Figure 6B</xref>). sEV is characterized as
                    nano-sized and biocompatible characteristics (<xref id="bib_kutralam_muniasamy_et_al_2015" title="bib_kutralam_muniasamy_et_al_2015">Kutralam-Muniasamy et al., 2015</xref>
                    ; <xref id="bib_henriques_antunes_et_al_2019" title="bib_henriques_antunes_et_al_2019">Henriques-Antunes et al., 2019</xref>),
                    which not only improve the stability of FA but also enhance the uptake of FA by
                    cells. Notably, in the FA concentration range of 0.1–1.0 μM,
                    both free FA and FaeA@sEVs-FA showed the promotion of cell proliferation.
                    However, in the FA concentration range of 1.0–5.0 μM, the
                    FaeA@sEVs-FA promoted cell proliferation, which was opposite to the inhibition
                    of cell growth exhibited by free FA. Therefore, in the range of FA concentration
                    of 1.0–5.0 μM, FaeA@sEVs-FA may reverse or alleviate the
                    toxicity of FA to cells, which may be due to the fact that certain nutrients in
                    sEVs interfere with the toxicity of FA to cells. However, when the FA
                    concentration exceeded 5.0 μM, this effect of FaeA@sEVs-FA gradually
                    weakened or even disappeared, which may be due to the too high sEV concentration
                    beyond its safe concentration range.</paragraph></secb></seca><seca id="sec4"><sectitle><no>4</no>Conclusion</sectitle><paragraph>In summary, inspired by the strategies of active loading of liposomal
                nanomedicines, pre-drug design and immobilization enzyme, this study developed a
                high loading capacity and high performance small extracellular vesicle-based drug
                delivery platform, which is based on esterase-responsive active loading (EAL). The
                drug loading capacity is significantly better than that of conventional methods.
                Compared with the classical passive incubation, the EAL can provide a sustainable
                transmembrane ion concentration gradient and maximize the encapsulation of active
                molecules into engineered small extracellular vesicles. Furthermore, given the
                complex heterogeneity of small extracellular vesicles, we designed an isolation
                method that satisfies the purification of high concentrations of engineered small
                extracellular vesicles (FaeA@sEVs) from large volumes of cell cultures. Multiple
                characterization tools were employed to study the physicochemical properties of
                FaeA@sEVs in depth. Finally, extracellular and intracellular assessments further
                confirmed its superior performance in terms of slow-release and low toxicity for the
                sEVs-loaded ferulic acid using the EAL-prepared method. Although a small
                extracellular vesicle-ferulic acid esterase-ethyl ferulate was used in the study, it
                should not limit the platform potential for its wide application. In the future, the
                low loading efficiency of drugs loaded into small extracellular vesicles (sEVs) can
                be addressed by modifying the inactive part of the target drug with ester bonds <i>
                via</i> various enzymatic reactions. Additionally, this platform suggested that
                natural components presented in sEVs, such as biological enzymes, may act as
                “power sources” to facilitate the loading of corresponding active
                small molecule drugs into sEVs. However, in this experiment, the rough estimation of
                esterase content in sEVs by enzyme viability assay does not accurately reflect the
                esterase content in individual FaeA@sEVs obtained by the self-assembling, which
                poses some difficulties in understanding the self-assembly efficiency. The strategy
                of fusing target proteins by genetic modification of donor cells and application of
                membrane localization elements or photo localization elements currently received
                wide attraction for the engineering of sEVs. The loading efficiency of target
                esterase should be evaluated if it is applied to the construction of the EAL. In
                conclusion, we believe that the small extracellular vesicle drug-loading platform
                based on the EAL in this study complements the existing nanomedicine loading
                methods, especially to solve the problem of low loading efficiency of water-soluble
                drugs. The method for separating and purifying high-quality sEVs from large-volume
                cell cultures provides a feasible tool for the industrial production of sEVs. At the
                same time, the small extracellular vesicle-loaded ferulic acid offers an improved
                delivery strategy for its application in anti-aging and skin repair.</paragraph></seca><seca id="sec5"><sectitle>Data availability statement<role>data_availability</role></sectitle><paragraph>The datasets presented in this study can be found in online repositories. The
                names of the repository/repositories and accession number(s) can be found below: <url url="https://www.ncbi.nlm.nih.gov" title="https://www.ncbi.nlm.nih.gov">
                https://www.ncbi.nlm.nih.gov</url>/, XM_025603867.1.<query>Q9: Confirm that the Data
                Availability statement is accurate. Note that we have used the statement provided at
                Submission. If this is not the latest version, please let us know.</query></paragraph></seca><seca id="sec6"><sectitle>Author contributions</sectitle><paragraph>Conceptualization, RL; investigation, FM; methodology, FM and HX; project
                administration, RL; data curation, HW and JW; writing—original draft, FM and
                HX; writing—review and editing, FM. All authors have read and agreed to the
                published version of the manuscript.<query>Q10: Confirm that the details in the
                “Author Contributions” section are correct and note that we have added
                the sentence “All authors contributed to the article and approved the
                submitted version.”</query></paragraph></seca><seca id="sec7"><sectitle>Conflict of interest</sectitle><paragraph>HW, JW, and RL were employed by the company Weihai Neoland Biosciences
                Co.,Ltd. China.</paragraph><paragraph>The remaining authors declare that the research was conducted in the absence
                of any commercial or financial relationships that could be construed as a potential
                conflict of interest.<query>Q11: Confirm if the text included in the Conflict of
                Interest statement is correct.</query></paragraph></seca><seca id="sec8"><sectitle>Publisher’s note</sectitle></seca><seca id="sec9"><sectitle>Supplementary <query>Q12: Ensure that any supplementary material is correctly
                published at this link: If the link does not work, you can check the file(s)
                directly in the production forum; the published supplementary files appear in green.
                Provide new files if you have any corrections and make sure all Supplementary files
                are cited. Please also provide captions for these files, if relevant. Frontiers will
                deposit ALL supplementary files to FigShare and they will receive a DOI. Notify us
                of any previously deposited material. If the Supplementary Material files contain
                identifiable images, please keep in mind that it is your responsibility, as the
                author, to ensure you have permission to use the images in the article. Please check
                this for author’s responsibility for publication of identifiable images.</query>
                material<role>supplementary-material</role></sectitle><paragraph>The Supplementary Material for this article can be found online at: <url url="https://www.frontiersin.org/articles/10.3389/fbioe.2022.1043130/full#supplementary-material" title="https://www.frontiersin.org/articles/10.3389/fbioe.2022.1043130/full#supplementary-material">
                https://www.frontiersin.org/articles/10.3389/fbioe.2022.1043130/full#supplementary-material</url></paragraph></seca></body><tail><bibreference><bibliography-sec><bib-reference id="bib_abhange_et_al_2021"><label>ABHANGE et al., 2021</label><journal><aus><au><snm>Abhange</snm></au><au><snm>Makler</snm></au><au><snm>Wen</snm><fnm>Y.</fnm></au><au><snm>Ramnauth</snm></au><au><snm>Mao</snm></au><au><snm>Asghar</snm></au></aus><atl>Small extracellular vesicles in cancer</atl><stl>Bioact. Mat.</stl><vol>6</vol><iss>11</iss><x>), </x><first-page>3705</first-page><last-page>3743</last-page><doi>10.1016/j.bioactmat.2021.03.015</doi></journal></bib-reference><bib-reference id="bib_antonopoulou_et_al_2021"><label>ANTONOPOULOU et al., 2021</label><journal><aus><au><snm>Antonopoulou</snm></au><au><snm>Sapountzaki</snm></au><au><snm>Rova</snm><fnm>U.</fnm></au><au><snm>Christakopoulos</snm></au></aus><atl>Ferulic acid from plant biomass: A phytochemical with promising
                            antiviral properties</atl><stl>Front. Nutr.</stl><vol>8</vol><first-page>777576</first-page><doi>10.3389/fnut.2021.777576</doi></journal></bib-reference><bib-reference id="bib_armstrong_and_stevens_2018"><label>ARMSTRONG and STEVENS, 2018</label><journal><aus><au><snm>Armstrong</snm><fnm>J. P. K.</fnm></au><au><snm>Stevens</snm><fnm>M. M.</fnm></au></aus><atl>Strategic design of extracellular vesicle drug delivery systems</atl><stl>Adv. Drug Deliv. Rev.</stl><vol>130</vol><first-page>12</first-page><last-page>16</last-page><doi>10.1016/j.addr.2018.06.017</doi></journal></bib-reference><bib-reference id="bib_batrakova_and_kim_2015"><label>BATRAKOVA and KIM, 2015</label><journal><aus><au><snm>Batrakova</snm><fnm>E. V.</fnm></au><au><snm>Kim</snm><fnm>M. S.</fnm></au></aus><atl>Using exosomes, naturally-equipped nanocarriers, for drug delivery</atl><stl>J. Control. Release</stl><vol>219</vol><first-page>396</first-page><last-page>405</last-page><doi>10.1016/j.jconrel.2015.07.030</doi></journal></bib-reference><bib-reference id="bib_blanco_et_al_2015"><label>BLANCO et al., 2015</label><journal><aus><au><snm>Blanco</snm></au><au><snm>Shen</snm></au><au><snm>Ferrari</snm></au></aus><atl>Principles of nanoparticle design for overcoming biological barriers to
                            drug delivery</atl><stl>Nat. Biotechnol.</stl><vol>33</vol><iss>9</iss><first-page>941</first-page><last-page>951</last-page><doi>10.1038/nbt.3330</doi></journal></bib-reference><bib-reference id="bib_buschmann_et_al_2021"><label>BUSCHMANN et al., 2021</label><journal><aus><au><snm>Buschmann</snm></au><au><snm>Mussack</snm></au><au><snm>Byrd</snm><fnm>J. B.</fnm></au></aus><atl>Separation, characterization, and standardization of extracellular
                            vesicles for drug delivery applications</atl><vol>174</vol><first-page>348</first-page><last-page>368</last-page><doi>10.1016/j.addr.2021.04.027</doi></journal></bib-reference><bib-reference id="bib_chen_et_al_2021"><label>CHEN et al., 2021</label><journal><aus><au><snm>Chen</snm></au><au><snm>Sun</snm></au><au/><au><snm>Su</snm></au><au><snm>Lin</snm></au><au><snm>Yan</snm><fnm>X.</fnm></au></aus><atl>Active cargo loading into extracellular vesicles: Highlights the
                            heterogeneous encapsulation behaviour</atl><stl>J. Extracell. Vesicles</stl><iss>13</iss><first-page>e12163</first-page><doi>10.1002/jev2.12163</doi></journal></bib-reference><bib-reference id="bib_cheng_et_al_2011"><label>CHENG et al., 2011</label><journal><aus><au><snm>Cheng</snm><fnm>Y. H.</fnm></au><au><snm>Yang</snm><fnm>S. H.</fnm></au><au><fnm>F. H.</fnm></au></aus><adate>2011</adate><atl>Thermosensitive chitosan-gelatin-glycerol phosphate hydrogel as a
                            controlled release system of ferulic acid for nucleus pulposus
                            regeneration</atl><stl>Biomaterials</stl><vol>32</vol><iss>29</iss><first-page>6953</first-page><last-page>6961</last-page><doi>10.1016/j.biomaterials.2011.03.065</doi></journal></bib-reference><bib-reference id="bib_de_jong_et_al_2019"><label>DE JONG et al., 2019</label><journal><aus><au><snm>De Jong</snm><fnm>O. G.</fnm></au><au><snm>Kooijmans</snm><fnm>S. A. A.</fnm></au><au><snm>Murphy</snm><fnm>D. E.</fnm></au><au><snm>Jiang</snm><fnm>L. L.</fnm></au><au><snm>Evers</snm><fnm>M. J. W.</fnm></au><au><snm>Sluijter</snm><fnm>J. P. G.</fnm></au></aus><atl>Drug delivery with extracellular vesicles: From imagination to
                            innovation</atl><stl>Acc. Chem. Res.</stl><vol>52</vol><iss>7</iss><first-page>1761</first-page><last-page>1770</last-page><doi>10.1021/acs.accounts.9b00109</doi></journal></bib-reference><bib-reference id="bib_dosb_2017"><label>DE OLIVEIRA SILVA and BATISTA, 2017</label><journal><aus><au><snm>De Oliveira Silva</snm></au><au><snm>Batista</snm></au></aus><atl>Ferulic acid and naturally occurring compounds bearing a feruloyl
                            moiety: A review on their structures, occurrence, and potential Health
                            benefits</atl><stl>Compr. Rev. Food Sci. Food Saf.</stl><iss>4</iss><first-page>580</first-page><last-page>616</last-page><doi>10.1111/1541-4337.12266</doi></journal></bib-reference><bib-reference id="bib_donoso_quezada_et_al_2020"><label>DONOSO-QUEZADA et al., 2020</label><journal><aus><au><snm>Donoso-Quezada</snm></au><au><snm>Ayala-Mar</snm></au><au><snm>Gonzalez-Valdez</snm></au></aus><atl>State-of-the-art exosome loading and functionalization techniques for
                            enhanced therapeutics: A review</atl><stl>Crit. Rev. Biotechnol.</stl><vol>40</vol><iss>6</iss><first-page>804</first-page><last-page>820</last-page><doi>10.1080/07388551.2020.1785385</doi></journal></bib-reference><bib-reference id="bib_dulong_et_al_2018"><label>DULONG et al., 2018</label><journal><aus><au><snm>Dulong</snm></au><au><snm>Kouassi</snm></au><au><snm>Labat</snm><fnm>B.</fnm></au><au><snm>Le Cerf</snm></au><au><snm>Picton</snm></au></aus><atl>Antioxidant properties and bioactivity of Carboxymethylpullulan grafted
                            with ferulic acid and of their hydrogels obtained by enzymatic reaction</atl><stl>Food Chem. x.</stl><vol>262</vol><first-page>21</first-page><last-page>29</last-page><doi>10.1016/j.foodchem.2018.04.046</doi></journal></bib-reference><bib-reference id="bib_gardiner_et_al_2016"><label>GARDINER et al., 2016</label><journal><aus><au><snm>Gardiner</snm></au><au><snm>Di Vizio</snm></au><au><snm>Sahoo</snm></au><au><snm>Thery</snm></au><au><snm>Witwer</snm></au><au><snm>Wauben</snm></au></aus><atl>Techniques used for the isolation and characterization of extracellular
                            vesicles: Results of a worldwide survey</atl><vol>5</vol><first-page>32945</first-page><doi>10.3402/jev.v5.32945</doi></journal></bib-reference><bib-reference id="bib_gelibter_et_al_2022"><label>GELIBTER et al., 2022</label><journal><aus><au><snm>Gelibter</snm></au><au><snm>Marostica</snm></au><au><snm>Mandelli</snm></au><au><snm>Siciliani</snm></au><au><snm>Podini</snm></au><au><snm>Finardi</snm></au></aus><atl>The impact of storage on extracellular vesicles: A systematic study</atl><iss>2</iss><first-page>e12162</first-page><doi>10.1002/jev2.12162</doi></journal></bib-reference><bib-reference id="bib_goh_et_al_2017"><label>GOH et al., 2017</label><journal><aus><au><snm>Goh</snm><fnm>W. J.</fnm></au><au><snm>Lee</snm><fnm>C. K.</fnm></au><au><snm>Zou</snm></au><au><snm>Woon</snm><fnm>E. C.</fnm></au><au><snm>Czarny</snm></au><au><snm>Pastorin</snm></au></aus><atl>Doxorubicin-loaded cell-derived nanovesicles: An alternative targeted
                            approach for anti-tumor therapy</atl><stl>Int. J. Nanomedicine</stl><first-page>2759</first-page><last-page>2767</last-page><doi>10.2147/IJN.S131786</doi></journal></bib-reference><bib-reference id="bib_grant_et_al_2018"><label>GRANT et al., 2018</label><journal><aus><au><snm>Grant</snm></au><au><snm>Modica</snm><fnm>J. A.</fnm></au><au><snm>Roll</snm></au><au><snm>Perkovich</snm></au><au><snm>Mrksich</snm></au></aus><atl>An immobilized enzyme reactor for spatiotemporal control over reaction
                            products</atl><stl>Small</stl><vol>14</vol><first-page>e1800923</first-page><doi>10.1002/smll.201800923</doi></journal></bib-reference><bib-reference id="bib_han_et_al_2019"><label>HAN et al., 2019</label><journal><aus><au><snm>Han</snm></au><au><snm>Zhang</snm><fnm>Z.</fnm></au><au><snm>Zheng</snm></au><au/></aus><atl>Comparison of structures, physicochemical properties and 
                            bioactivity between ferulic acid-beta-cyclodextrin conjugate and the
                            corresponding inclusion complex</atl><stl>Food Res. Int.</stl><vol>125</vol><first-page>108619</first-page><doi>10.1016/j.foodres.2019.108619</doi></journal></bib-reference><bib-reference id="bib_haney_et_al_2015"><label>HANEY et al., 2015</label><journal><aus><au><snm>Haney</snm><fnm>M. J.</fnm></au><au><snm>Klyachko</snm><fnm>N. L.</fnm></au><au><snm>Zhao</snm></au><au><snm>Gupta</snm></au><au><snm>Plotnikova</snm><fnm>E. G.</fnm></au><au><snm>He</snm></au></aus><atl>Exosomes as drug delivery vehicles for Parkinson's disease therapy</atl><vol>207</vol><first-page>18</first-page><last-page>30</last-page><doi>10.1016/j.jconrel.2015.03.033</doi></journal></bib-reference><bib-reference id="bib_henriques_antunes_et_al_2019"><label>HENRIQUES-ANTUNES et al., 2019</label><journal><aus><au><snm>Henriques-Antunes</snm></au><au><snm>Cardoso</snm><fnm>R. M. S.</fnm></au><au><snm>Zonari</snm></au><au><snm>Correia</snm></au><au><snm>Leal</snm></au><au><snm>Jimenez-Balsa</snm></au></aus><atl>The kinetics of small extracellular vesicle delivery impacts skin
                            tissue regeneration</atl><stl>ACS Nano</stl><vol>13</vol><iss>8</iss><first-page>8694</first-page><last-page>8707</last-page><doi>10.1021/acsnano.9b00376</doi></journal></bib-reference><bib-reference id="bib_herrmann_et_al_2021"><label>HERRMANN et al., 2021</label><journal><aus><au><snm>Herrmann</snm><fnm>I. K.</fnm></au><au><snm>Wood</snm><fnm>M. J. A.</fnm></au><au><snm>Fuhrmann</snm></au></aus><atl>Extracellular vesicles as a next-generation drug delivery platform</atl><stl>Nat. Nanotechnol.</stl><first-page>748</first-page><last-page>759</last-page><doi>10.1038/s41565-021-00931-2</doi></journal></bib-reference><bib-reference id="bib_hettich_et_al_2020"><label>HETTICH et al., 2020</label><journal><aus><au><snm>Hettich</snm><fnm>B. F.</fnm></au><au><snm>Ben-Yehuda Greenwald</snm></au><au><snm>Werner</snm></au><au><snm>Leroux</snm></au></aus><atl>Exosomes for wound healing: Purification optimization and
                            identification of bioactive components</atl><stl>Adv. Sci. (Weinh).</stl><vol>7</vol><iss>23</iss><first-page>2002596</first-page><doi>10.1002/advs.202002596</doi></journal></bib-reference><bib-reference id="bib_heusermann_et_al_2016"><label>HEUSERMANN et al., 2016</label><journal><aus><au><snm>Heusermann</snm></au><au><snm>Hean</snm></au><au><snm>Trojer</snm></au><au><snm>Steib</snm></au><au><snm>Von Bueren</snm></au><au><snm>Graff-Meyer</snm></au></aus><atl>Exosomes surf on filopodia to enter cells at endocytic hot spots,
                            traffic within endosomes, and are targeted to the ER</atl><stl>J. Cell Biol.</stl><vol>213</vol><first-page>173</first-page><last-page>184</last-page><doi>10.1083/jcb.201506084</doi></journal></bib-reference><bib-reference id="bib_hu_et_al_2021"><label>HU et al., 2021</label><journal><aus><au><snm>Hu</snm></au><au><snm>Li</snm></au><au/><au><snm>Zhu</snm></au><au><snm>Huang</snm></au><au/></aus><atl>Exosome-eluting stents for vascular healing after ischaemic injury</atl><stl>Nat. Biomed. Eng.</stl><iss>10</iss><first-page>1174</first-page><last-page>1188</last-page><doi>10.1038/s41551-021-00705-0</doi></journal></bib-reference><bib-reference id="bib_isaac_et_al_2021"><label>ISAAC et al., 2021</label><journal><aus><au><snm>Isaac</snm></au><au><snm>Reis</snm><fnm>F. C. G.</fnm></au><au><snm>Ying</snm></au><au><snm>Olefsky</snm><fnm>J. M.</fnm></au></aus><atl>Exosomes as mediators of intercellular crosstalk in metabolism</atl><stl>Cell Metab.</stl><first-page>1744</first-page><last-page>1762</last-page><doi>10.1016/j.cmet.2021.08.006</doi></journal></bib-reference><bib-reference id="bib_jang_et_al_2013"><label>JANG et al., 2013</label><journal><aus><au><snm>Jang</snm><fnm>S. C.</fnm></au><au><fnm>O. Y.</fnm></au><au><snm>Yoon</snm><fnm>C. M.</fnm></au><au><snm>Choi</snm></au><au><snm>Roh</snm><fnm>T. Y.</fnm></au><au><snm>Park</snm></au></aus><atl>Bioinspired exosome-mimetic nanovesicles for targeted delivery of
                            chemotherapeutics to malignant tumors</atl><first-page>7698</first-page><last-page>7710</last-page><doi>10.1021/nn402232g</doi></journal></bib-reference><bib-reference id="bib_kalluri_and_lebleu_2020"><label>KALLURI and LEBLEU, 2020</label><journal><aus><au><snm>Kalluri</snm></au><au><snm>Lebleu</snm><fnm>V. S.</fnm></au></aus><atl>The biology, function, and biomedical applications of exosomes</atl><stl>Science</stl><vol>367</vol><iss>6478</iss><first-page>eaau6977</first-page><doi>10.1126/science.aau6977</doi></journal></bib-reference><bib-reference id="bib_khezeli_et_al_2016"><label>KHEZELI et al., 2016</label><journal><aus><au><snm>Khezeli</snm></au><au><snm>Daneshfar</snm></au><au><snm>Sahraei</snm></au></aus><atl>A green ultrasonic-assisted liquid-liquid microextraction based on deep
                            eutectic solvent for the HPLC-UV determination of ferulic, caffeic and
                            cinnamic acid from olive, almond, sesame and cinnamon oil</atl><stl>Talanta</stl><vol>150</vol><first-page>577</first-page><last-page>585</last-page><doi>10.1016/j.talanta.2015.12.077</doi></journal></bib-reference><bib-reference id="bib_kim_et_al_2016"><label>KIM et al., 2016</label><journal><aus><au><snm>Mahajan</snm></au><au><snm>Deygen</snm></au></aus><atl>Development of exosome-encapsulated paclitaxel to overcome MDR in
                            cancer cells</atl><stl>Nanomedicine Nanotechnol. Biol. Med.</stl><iss>3</iss><first-page>655</first-page><last-page>664</last-page><doi>10.1016/j.nano.2015.10.012</doi></journal></bib-reference><bib-reference id="bib_klepacka_and_fornal_2006"><label>KLEPACKA and FORNAL, 2006</label><journal><aus><au><snm>Klepacka</snm></au><au><snm>Fornal</snm></au></aus><adate>2006</adate><atl>Ferulic acid and its position among the phenolic compounds of wheat</atl><stl>Crit. Rev. Food Sci. Nutr.</stl><vol>46</vol><first-page>639</first-page><last-page>647</last-page><doi>10.1080/10408390500511821</doi></journal></bib-reference><bib-reference id="bib_kooijmans_et_al_2013"><label>KOOIJMANS et al., 2013</label><journal><aus><au><snm>Stremersch</snm></au><au><snm>Braeckmans</snm></au><au><snm>De Smedt</snm></au><au><snm>Hendrix</snm></au></aus><atl>Electroporation-induced siRNA precipitation obscures the efficiency of
                            siRNA loading into extracellular vesicles</atl><iss>1</iss><first-page>229</first-page><last-page>238</last-page><doi>10.1016/j.jconrel.2013.08.014</doi></journal></bib-reference><bib-reference id="bib_kuriyama_et_al_2021"><label>KURIYAMA et al., 2021</label><journal><aus><au><snm>Kuriyama</snm></au><au><snm>Yoshioka</snm></au><au><snm>Kikuchi</snm></au><au><snm>Okamura</snm></au><au><snm>Azuma</snm></au><au><snm>Ochiya</snm></au></aus><atl>Challenges for the development of extracellular vesicle-based nucleic
                            acid medicines</atl><stl>Cancers (Basel).</stl><first-page>6137</first-page><doi>10.3390/cancers13236137</doi></journal></bib-reference><bib-reference id="bib_kutralam_muniasamy_et_al_2015"><label>KUTRALAM-MUNIASAMY et al., 2015</label><journal><aus><au><snm>Kutralam-Muniasamy</snm></au><au><snm>Flores-Cotera</snm><fnm>L. B.</fnm></au><au><snm>Perez-Guevara</snm></au></aus><atl>Potential of yeast secretory vesicles in biodelivery systems</atl><stl>Drug Discov. Today</stl><first-page>659</first-page><last-page>666</last-page><doi>10.1016/j.drudis.2015.03.014</doi></journal></bib-reference><bib-reference id="bib_lai_et_al_2022"><label>LAI et al., 2022</label><journal><aus><au><snm>Lai</snm><fnm>J. J.</fnm></au><au><snm>Chau</snm><fnm>Z. L.</fnm></au><au><fnm>S. Y.</fnm></au><au><snm>Hill</snm></au><au><snm>Korpany</snm><fnm>K. V.</fnm></au><au><snm>Liang</snm><fnm>N. W.</fnm></au></aus><atl>Exosome processing and characterization approaches for research and
                            technology development</atl><iss>15</iss><first-page>e2103222</first-page><doi>10.1002/advs.202103222</doi></journal></bib-reference><bib-reference id="bib_lim_et_al_2022"><label>LIM et al., 2022</label><journal><aus><au><snm>Lim</snm></au><au><snm>Kang</snm></au><au><snm>Son</snm><fnm>H. Y.</fnm></au><au><snm>Mun</snm></au><au><snm>Huh</snm><fnm>Y. M.</fnm></au><au><snm>Rho</snm><fnm>H. W.</fnm></au></aus><atl>Microfluidic device for one-step detection of breast cancer-derived
                            exosomal mRNA in blood using signal-amplifiable 3D nanostructure</atl><stl>Biosens. Bioelectron. X.</stl><vol>197</vol><first-page>113753</first-page><doi>10.1016/j.bios.2021.113753</doi></journal></bib-reference><bib-reference id="bib_liu_and_su_2019"><label>LIU and SU, 2019</label><journal><aus><au><snm>Liu</snm></au><au/></aus><atl>Design strategies and application progress of therapeutic exosomes</atl><stl>Theranostics</stl><first-page>1015</first-page><last-page>1028</last-page><doi>10.7150/thno.30853</doi></journal></bib-reference><bib-reference id="bib_lorincz_et_al_2020"><label>LORINCZ et al., 2020</label><journal><aus><au><snm>Lorincz</snm><fnm>A. M.</fnm></au><au><snm>Bartos</snm></au><au><snm>Szombath</snm></au><au><snm>Szeifert</snm></au><au><snm>Timar</snm><fnm>C. I.</fnm></au><au><snm>Turiak</snm></au></aus><atl>Role of Mac-1 integrin in generation of extracellular vesicles with
                            antibacterial capacity from neutrophilic granulocytes</atl><first-page>1698889</first-page><doi>10.1080/20013078.2019.1698889</doi></journal></bib-reference><bib-reference id="bib_lu_and_huang_2020"><label>LU and HUANG, 2020</label><journal><aus><au/><au/></aus><atl>Bioinspired exosome-like therapeutics and delivery nanoplatforms</atl><vol>242</vol><first-page>119925</first-page><doi>10.1016/j.biomaterials.2020.119925</doi></journal></bib-reference><bib-reference id="bib_mathieu_et_al_2019"><label>MATHIEU et al., 2019</label><journal><aus><au><snm>Mathieu</snm></au><au><snm>Martin-Jaular</snm></au><au><snm>Lavieu</snm></au></aus><atl>Specificities of secretion and uptake of exosomes and other
                            extracellular vesicles for cell-to-cell communication</atl><stl>Nat. Cell Biol.</stl><vol>21</vol><first-page>9</first-page><last-page>17</last-page><doi>10.1038/s41556-018-0250-9</doi></journal></bib-reference><bib-reference id="bib_moosavian_et_al_2021"><label>MOOSAVIAN et al., 2021</label><journal><aus><au><snm>Moosavian</snm><fnm>S. A.</fnm></au><au><snm>Bianconi</snm></au><au><snm>Pirro</snm></au><au><snm>Sahebkar</snm></au></aus><atl>Challenges and pitfalls in the development of liposomal delivery
                            systems for cancer therapy</atl><stl>Semin. Cancer Biol.</stl><vol>69</vol><first-page>337</first-page><last-page>348</last-page><doi>10.1016/j.semcancer.2019.09.025</doi></journal></bib-reference><bib-reference id="bib_nasiri_kenari_et_al_2020"><label>NASIRI KENARI et al., 2020</label><journal><aus><au><snm>Nasiri Kenari</snm></au><au/><au><fnm>A. F.</fnm></au></aus><atl>Methods for loading therapeutics into extracellular vesicles and
                            generating extracellular vesicles mimetic-nanovesicles</atl><vol>177</vol><first-page>103</first-page><last-page>113</last-page><doi>10.1016/j.ymeth.2020.01.001</doi></journal></bib-reference><bib-reference id="bib_nordin_et_al_2015"><label>NORDIN et al., 2015</label><journal><aus><au><snm>Nordin</snm><fnm>J. Z.</fnm></au><au/><au><snm>Vader</snm></au><au><snm>Mager</snm></au><au><snm>Johansson</snm><fnm>H. J.</fnm></au></aus><atl>Ultrafiltration with size-exclusion liquid chromatography for high
                            yield isolation of extracellular vesicles preserving intact biophysical
                            and functional properties</atl><first-page>879</first-page><last-page>883</last-page><doi>10.1016/j.nano.2015.01.003</doi></journal></bib-reference><bib-reference id="bib_oliveira_et_al_2019"><label>OLIVEIRA et al., 2019</label><journal><aus><au><snm>Oliveira</snm><fnm>D. M.</fnm></au><au><snm>Mota</snm></au><au><snm>Oliva</snm></au><au><snm>Segato</snm></au><au><snm>Marchiosi</snm></au><au><snm>Ferrarese-Filho</snm><fnm>O.</fnm></au></aus><atl>Feruloyl esterases: Biocatalysts to overcome biomass recalcitrance and
                            for the production of bioactive compounds</atl><stl>Bioresour. Technol.</stl><vol>278</vol><first-page>408</first-page><last-page>423</last-page><doi>10.1016/j.biortech.2019.01.064</doi></journal></bib-reference><bib-reference id="bib_ou_et_al_2021"><label>OU et al., 2021</label><journal><aus><au><snm>Ou</snm><fnm>Q.</fnm></au><au/><au><snm>Fu</snm></au><au><snm>Yu</snm></au><au><snm>Xin</snm></au><au><snm>Gu</snm></au></aus><atl>More natural more better: Triple natural anti-oxidant puerarin/ferulic
                            acid/polydopamine incorporated hydrogel for wound healing</atl><stl>J. Nanobiotechnology</stl><first-page>237</first-page><doi>10.1186/s12951-021-00973-7</doi></journal></bib-reference><bib-reference id="bib_ozpolat_et_al_2014"><label>OZPOLAT et al., 2014</label><journal><aus><au><snm>Ozpolat</snm></au><au><snm>Sood</snm><fnm>A. K.</fnm></au><au><snm>Lopez-Berestein</snm></au></aus><adate>2014</adate><atl>Liposomal siRNA nanocarriers for cancer therapy</atl><vol>66</vol><first-page>110</first-page><last-page>116</last-page><doi>10.1016/j.addr.2013.12.008</doi></journal></bib-reference><bib-reference id="bib_peer_et_al_2007"><label>PEER et al., 2007</label><journal><aus><au><snm>Peer</snm></au><au><snm>Karp</snm></au><au/><au><snm>Farokhzad</snm><fnm>O. C.</fnm></au><au><snm>Margalit</snm></au><au><snm>Langer</snm></au></aus><adate>2007</adate><atl>Nanocarriers as an emerging platform for cancer therapy</atl><vol>2</vol><iss>12</iss><first-page>751</first-page><last-page>760</last-page><doi>10.1038/nnano.2007.387</doi></journal></bib-reference><bib-reference id="bib_pirisinu_et_al_2022"><label>PIRISINU et al., 2022</label><journal><aus><au><snm>Pirisinu</snm></au><au><snm>Pham</snm><fnm>T. C.</fnm></au><au><fnm>D. X.</fnm></au><au><fnm>T. N.</fnm></au><au><snm>Nguyen</snm><fnm>L. T.</fnm></au><au><snm>Le</snm><fnm>M. T.</fnm></au></aus><atl>Extracellular vesicles as natural therapeutic agents and innate drug
                            delivery systems for cancer treatment: Recent advances, current
                            obstacles, and challenges for clinical translation</atl><vol>80</vol><first-page>340</first-page><last-page>355</last-page><doi>10.1016/j.semcancer.2020.08.007</doi></journal></bib-reference><bib-reference id="bib_ramakrishnaiah_et_al_2013"><label>RAMAKRISHNAIAH et al., 2013</label><journal><aus><au><snm>Ramakrishnaiah</snm></au><au><snm>Thumann</snm></au><au><snm>Fofana</snm></au><au><snm>Habersetzer</snm></au><au><snm>Pan</snm></au><au><snm>De Ruiter</snm><fnm>P. E.</fnm></au></aus><atl>Exosome-mediated transmission of hepatitis C virus between human
                            hepatoma Huh7.5 cells</atl><stl>Proc. Natl. Acad. Sci. U. S. A.</stl><vol>110</vol><iss>32</iss><first-page>13109</first-page><last-page>13113</last-page><doi>10.1073/pnas.1221899110</doi></journal></bib-reference><bib-reference id="bib_schmitz_et_al_2022"><label>SCHMITZ et al., 2022</label><journal><aus><au><snm>Schmitz</snm></au><au><snm>Leontakianakou</snm></au><au><snm>Norlander</snm></au><au><snm>Nordberg Karlsson</snm></au><au><snm>Adlercreutz</snm></au></aus><atl>Lignocellulose degradation for the bioeconomy: The potential of enzyme
                            synergies between xylanases, ferulic acid esterase and laccase for the
                            production of arabinoxylo-oligosaccharides</atl><vol>343</vol><first-page>126114</first-page><doi>10.1016/j.biortech.2021.126114</doi></journal></bib-reference><bib-reference id="bib_shao_et_al_2018"><label>SHAO et al., 2018</label><journal><aus><au><snm>Shao</snm></au><au><snm>Im</snm></au><au><snm>Castro</snm></au><au><snm>Breakefield</snm></au><au><snm>Weissleder</snm></au><au/></aus><atl>New technologies for analysis of extracellular vesicles</atl><stl>Chem. Rev.</stl><vol>118</vol><first-page>1917</first-page><last-page>1950</last-page><doi>10.1021/acs.chemrev.7b00534</doi></journal></bib-reference><bib-reference id="bib_sharma_et_al_2021"><label>SHARMA et al., 2021</label><journal><aus><au><snm>Sharma</snm></au><au><snm>Masud</snm><fnm>M. K.</fnm></au><au><snm>Kaneti</snm><fnm>Y. V.</fnm></au><au><snm>Rewatkar</snm></au><au><snm>Koradia</snm></au><au><snm>Hossain</snm><fnm>M. S. A.</fnm></au></aus><atl>Extracellular vesicle nanoarchitectonics for novel drug delivery
                            applications</atl><vol>17</vol><iss>42</iss><first-page>e2102220</first-page><doi>10.1002/smll.202102220</doi></journal></bib-reference><bib-reference id="bib_shu_et_al_2020"><label>SHU et al., 2020</label><journal><aus><au><snm>Shu</snm></au><au/><au><snm>Allen</snm><fnm>C. L.</fnm></au><au><snm>Hurley</snm></au><au><snm>Tung</snm><fnm>K. H.</fnm></au><au><snm>Minderman</snm></au></aus><atl>Purity and yield of melanoma exosomes are dependent on isolation method</atl><first-page>1692401</first-page><doi>10.1080/20013078.2019.1692401</doi></journal></bib-reference><bib-reference id="bib_soekmadji_et_al_2020"><label>SOEKMADJI et al., 2020</label><journal><aus><au><snm>Soekmadji</snm></au><au/><au/><au><snm>An</snm></au></aus><atl>The future of Extracellular Vesicles as Theranostics - an ISEV meeting
                            report</atl><first-page>1809766</first-page><doi>10.1080/20013078.2020.1809766</doi></journal></bib-reference><bib-reference id="bib_sun_et_al_2021"><label>SUN et al., 2021</label><journal><aus><au/><au/><au/><au><snm>Weng</snm></au><au><snm>Wu</snm></au><au><snm>Kerns</snm></au></aus><atl>Bioinspired oil-infused slippery surfaces with water and ion barrier
                            properties</atl><stl>ACS Appl. Mat. Interfaces</stl><iss>28</iss><first-page>33464</first-page><last-page>33476</last-page><doi>10.1021/acsami.1c06632</doi></journal></bib-reference><bib-reference id="bib_tieu_et_al_2020"><label>TIEU et al., 2020</label><journal><aus><au><snm>Tieu</snm></au><au><snm>Lalu</snm></au><au><snm>Slobodian</snm></au><au><snm>Gnyra</snm></au><au><snm>Fergusson</snm><fnm>D. A.</fnm></au><au><snm>Montroy</snm></au></aus><atl>An analysis of mesenchymal stem cell-derived extracellular vesicles for
                            preclinical use</atl><first-page>9728</first-page><last-page>9743</last-page><doi>10.1021/acsnano.0c01363</doi></journal></bib-reference><bib-reference id="bib_vader_et_al_2016"><label>VADER et al., 2016</label><journal><aus><au><snm>Mol</snm><fnm>E. A.</fnm></au><au><snm>Pasterkamp</snm></au><au><snm>Schiffelers</snm><fnm>R. M.</fnm></au></aus><atl>Extracellular vesicles for drug delivery</atl><vol>106</vol><first-page>148</first-page><last-page>156</last-page><doi>10.1016/j.addr.2016.02.006</doi></journal></bib-reference><bib-reference id="bib_van_der_pol_et_al_2012"><label>VAN DER POL et al., 2012</label><journal><aus><au><snm>Van Der Pol</snm></au><au><snm>Boing</snm><fnm>A. N.</fnm></au><au><snm>Harrison</snm></au><au><snm>Sturk</snm></au><au><snm>Nieuwland</snm></au></aus><atl>Classification, functions, and clinical relevance of extracellular
                            vesicles</atl><stl>Pharmacol. Rev.</stl><vol>64</vol><last-page>705</last-page><doi>10.1124/pr.112.005983</doi></journal></bib-reference><bib-reference id="bib_van_niel_et_al_2022"><label>VAN NIEL et al., 2022</label><journal><aus><au><snm>Van Niel</snm></au><au><snm>Carter</snm><fnm>D. R. F.</fnm></au><au><snm>Clayton</snm></au><au><snm>Lambert</snm><fnm>D. W.</fnm></au><au><snm>Raposo</snm></au></aus><atl>Challenges and directions in studying cell-cell communication by
                            extracellular vesicles</atl><stl>Nat. Rev. Mol. Cell Biol.</stl><vol>23</vol><iss>5</iss><first-page>369</first-page><last-page>382</last-page><doi>10.1038/s41580-022-00460-3</doi></journal></bib-reference><bib-reference id="bib_walker_et_al_2019"><label>WALKER et al., 2019</label><journal><aus><au><snm>Walker</snm></au><au><snm>Busatto</snm></au><au/><au><snm>Tian</snm></au><au><snm>Suh</snm></au><au><snm>Carson</snm></au></aus><atl>Extracellular vesicle-based drug delivery systems for cancer treatment</atl><iss>26</iss><first-page>8001</first-page><last-page>8017</last-page><doi>10.7150/thno.37097</doi></journal></bib-reference><bib-reference id="bib_wang_et_al_2015"><label>WANG et al., 2015</label><journal><aus><au/><au><snm>Tu</snm></au><au/><au/><au><snm>Greiser</snm></au><au/></aus><atl>Supramolecularly engineered phospholipids constructed by nucleobase
                            molecular recognition: Upgraded generation of phospholipids for drug
                            delivery</atl><stl>Chem. Sci.</stl><first-page>3775</first-page><last-page>3787</last-page><doi>10.1039/c5sc01188d</doi></journal></bib-reference><bib-reference id="bib_wang_et_al_2021a"><label>WANG et al., 2021a</label><journal><aus><au/><au><snm>Ho</snm></au></aus><adate>2021a</adate><atl>Challenges in the development and establishment of exosome-based drug
                            delivery systems</atl><vol>329</vol><first-page>894</first-page><last-page>906</last-page><doi>10.1016/j.jconrel.2020.10.020</doi></journal></bib-reference><bib-reference id="bib_wang_et_al_2021b"><label>WANG et al., 2021b</label><journal><aus><au/><au><snm>Ni</snm><fnm>Q. K.</fnm></au><au><fnm>Y. F.</fnm></au><au><fnm>Y. X.</fnm></au><au/><au><snm>Gao</snm></au></aus><adate>2021b</adate><atl>Nanoscale drug delivery systems for controllable drug behaviors by
                            multi-stage barrier penetration</atl><vol>331</vol><first-page>282</first-page><last-page>295</last-page><doi>10.1016/j.jconrel.2020.08.045</doi></journal></bib-reference><bib-reference id="bib_wang_et_al_2017"><label>WANG et al., 2017</label><journal><aus><au><snm>Yeung</snm><fnm>B. Z.</fnm></au><au><snm>Cui</snm></au><au><fnm>C. J.</fnm></au><au/><au><snm>Figg</snm><fnm>W. D.</fnm></au></aus><atl>Exosome is a mechanism of intercellular drug transfer: Application of
                            quantitative pharmacology</atl><vol>268</vol><first-page>147</first-page><last-page>158</last-page><doi>10.1016/j.jconrel.2017.10.020</doi></journal></bib-reference><bib-reference id="bib_wang_et_al_2021c"><label>WANG et al., 2021c</label><journal><aus><au><fnm>Z. W.</fnm></au><au><fnm>Z. H.</fnm></au><au><snm>Qiao</snm><fnm>Z. R.</fnm></au><au><snm>Cai</snm></au><au><fnm>J. K.</fnm></au></aus><adate>2021c</adate><atl>Construction and characterization of antioxidative ferulic acid-grafted
                            carboxylic curdlan conjugates and their contributions on beta-carotene
                            storage stability</atl><vol>349</vol><first-page>129166</first-page><doi>10.1016/j.foodchem.2021.129166</doi></journal></bib-reference><bib-reference id="bib_wu_et_al_2014"><label>WU et al., 2014</label><journal><aus><au/><au/><au/><au><snm>Tyler</snm><fnm>J. Y.</fnm></au><au><snm>Ouyang</snm></au></aus><atl>Neuroprotective ferulic acid (FA)-glycol chitosan (GC) nanoparticles
                            for functional restoration of traumatically injured spinal cord</atl><vol>35</vol><first-page>2355</first-page><last-page>2364</last-page><doi>10.1016/j.biomaterials.2013.11.074</doi></journal></bib-reference><bib-reference id="bib_xie_et_al_2019"><label>XIE et al., 2019</label><journal><aus><au><snm>Xie</snm></au><au><snm>Zhou</snm></au><au><snm>Fang</snm></au><au/><au/></aus><atl>Extracellular vesicles in cancer immune microenvironment and cancer
                            immunotherapy</atl><iss>24</iss><first-page>1901779</first-page><doi>10.1002/advs.201901779</doi></journal></bib-reference><bib-reference id="bib_yang_et_al_2020"><label>YANG et al., 2020</label><journal><aus><au/><au><snm>Shi</snm></au><au/><au/><au/><au/></aus><atl>Large-scale generation of functional mRNA-encapsulating exosomes via
                            cellular nanoporation</atl><first-page>69</first-page><last-page>83</last-page><doi>10.1038/s41551-019-0485-1</doi></journal></bib-reference><bib-reference id="bib_yuan_et_al_2021"><label>YUAN et al., 2021</label><journal><aus><au><snm>Yuan</snm></au><au/><au/></aus><atl>Preserving extracellular vesicles for biomedical applications:
                            Consideration of storage stability before and after isolation</atl><stl>Drug Deliv. (Lond).</stl><vol>28</vol><first-page>1501</first-page><last-page>1509</last-page><doi>10.1080/10717544.2021.1951896</doi></journal></bib-reference><bib-reference id="bib_zhang_et_al_2012"><label>ZHANG et al., 2012</label><journal><aus><au><fnm>S. B.</fnm></au><au><snm>Pei</snm><fnm>X. Q.</fnm></au><au/></aus><atl>Multiple amino acid substitutions significantly improve the
                            thermostability of feruloyl esterase A from Aspergillus Niger</atl><vol>117</vol><first-page>140</first-page><last-page>147</last-page><doi>10.1016/j.biortech.2012.04.042</doi></journal></bib-reference><bib-reference id="bib_zhang_et_al_2021"><label>ZHANG et al., 2021</label><journal><aus><au/><au/><au/><au/><au/><au><snm>Qian</snm></au></aus><atl>Engineered extracellular vesicles for cancer therapy</atl><stl>Adv. Mat.</stl><iss>14</iss><first-page>e2005709</first-page><doi>10.1002/adma.202005709</doi></journal></bib-reference><bib-reference id="bib_zhong_et_al_2021"><label>ZHONG et al., 2021</label><journal><aus><au><snm>Zhong</snm></au><au><snm>Xia</snm></au><au><snm>Shan</snm></au><au/><au/></aus><atl>High-quality milk exosomes as oral drug delivery system</atl><vol>277</vol><first-page>121126</first-page><doi>10.1016/j.biomaterials.2021.121126</doi></journal></bib-reference><bib-reference id="bib_zhou_et_al_2021"><label>ZHOU et al., 2021</label><journal><aus><au/><au/></aus><atl>Exosome-derived long non-coding RNA ADAMTS9-AS2 suppresses progression
                            of oral submucous fibrosis via AKT signalling pathway</atl><stl>J. Cell. Mol. Med.</stl><vol>25</vol><first-page>2262</first-page><last-page>2273</last-page><doi>10.1111/jcmm.16219</doi></journal></bib-reference></bibliography-sec></bibreference><tablegroup><tablecaption id="tbl1"><label>TABLE 1</label><x> | </x><text>Kinetic parameters of FaeA in different states.<query>Q13: Ensure that all the
                    figures, tables and captions are correct, and that all figures are of the
                    highest quality/resolution. If needed, please upload improved Figures in the
                    Production Forum. Please note that Figures and Tables must be cited
                    sequentially, as per section 2.2 of the .</query></text></tablecaption><table frame="topbot"><colgroup><col colnum="1" colname="col1"/></colgroup><thead><tr><td colspan="1" rowspan="2"><p/></td><td colspan="1"><p>Km</p></td><td colspan="1"><p>Vmax</p></td><td colspan="1"><p>Kcat</p></td><td colspan="1"><p>Kcat/Km</p></td><td colspan="1"><p>Enzyme activity</p></td></tr><tr><td colspan="1"><p>mM</p></td><td colspan="1"><p>U·mg<sup>−</sup><text-color Shade="FE0191"/></p></td><td colspan="1"><p>s</p></td><td colspan="1"><p>mM·s<sup>
                                −</sup></p></td><td colspan="1"><p>mU·mg</p></td></tr></thead><tbody><tr><td colspan="1"><p>Intracellular protein</p></td><td colspan="1"><p>0.17 ± 0.09</p></td><td colspan="1"><p>1,340.94 ± 489.12</p></td><td colspan="1"><p>1,570.19</p></td><td colspan="1"><p>9,236.40</p></td><td colspan="1"><p>148.47 ± 1.23</p></td></tr><tr><td colspan="1"><p>FaeA@sEVs</p></td><td colspan="1"><p>0.10 ± 0.05</p></td><td colspan="1"><p>12.80 ± 3.88</p></td><td colspan="1"><p>19.02</p></td><td colspan="1"><p>190.19</p></td><td colspan="1"><p>4.09 ± 0.07</p></td></tr></tbody></table></tablegroup><tablegroup><tablecaption id="tbl2"><label>TABLE 2</label><text>Loading efficiency of sEVs for active molecules.</text></tablecaption><table frame="topbot"><thead><tr><td colspan="1"><p>Group</p></td><td colspan="1"><p>Drug loading (μg/40<text-color Shade="FE0191"> </text-color>μg
                                sEVs)</p></td><td colspan="1"><p>Encapsulation efficiency (%)</p></td></tr></thead><tbody><tr><td colspan="1"><p>X33@sEVs-FA</p></td><td colspan="1" align="char" char="±"><p>9.92 ± 1.28</p></td><td colspan="1" align="char" char="±"><p>7.18 ± 0.92</p></td></tr><tr><td colspan="1"><p>FaeA@sEVs-FA</p></td><td colspan="1" align="char" char="±"><p>54.10 ± 7.47**</p></td><td colspan="1" align="char" char="±"><p>30.96 ± 4.28**</p></td></tr><tr><td colspan="1"><p>X33@sEVs-#FA</p></td><td colspan="1" align="char" char="±"><p>22.19 ± 3.18</p></td><td colspan="1" align="char" char="±"><p>16.07 ± 2.31</p></td></tr><tr><td colspan="1"><p>FaeA@sEVs-#FA</p></td><td colspan="1" align="char" char="±"><p>29.39 ± 5.15</p></td><td colspan="1" align="char" char="±"><p>16.82 ± 2.95</p></td></tr></tbody></table></tablegroup><tablegroup><tablecaption id="tbl3"><label>TABLE 3</label><text>The regression equation of the release profile of FA from FaeA@sEVs-FA .</text></tablecaption><table frame="topbot"><thead><tr><td colspan="1"><p>Model</p></td><td colspan="1"><p>Regression equation</p></td><td colspan="1"><p><i>R</i></p></td></tr></thead><tbody><tr><td colspan="1"><p>Zero-order kinetics</p></td><td colspan="1"><p><i>Q</i> = 21.11t+8.57</p></td><td colspan="1" align="char" char="."><text-color>Tcolor: 008000</text-color><p>0.9013</p></td></tr><tr><td colspan="1"><p>First-order kinetics</p></td><td colspan="1"><p> = 59.27 (1-e<text-color Shade="FE0191"><sup>0</sup></text-color><sup>
                                .99t</sup>)</p></td><td colspan="1" align="char" char="."><p>0.9959</p></td></tr><tr><td colspan="1"><p>Higuchi</p></td><td colspan="1"><p> = 36.61t<sup>1/2</sup>–1.45</p></td><td colspan="1" align="char" char="."><p>0.9886</p></td></tr><tr><td colspan="1"><p>Weibull</p></td><td colspan="1"><p> = 65.64 (1-e<sup>-(0.79(t+0.0015))^0.87</sup>)</p></td><td colspan="1" align="char" char="."><p>0.9960</p></td></tr><tr><td colspan="1"><p>Ritger-Peppas</p></td><td colspan="1"><p> = 34.77t<sup>0.54</sup></p></td><td colspan="1" align="char" char="."><p>0.9889</p></td></tr></tbody></table></tablegroup><figuregroup id="fig1"><figcaption id="fig1"><label>FIGURE 1</label><text>Scheme of sEV delivery system for efficient loading of hydrophilic drugs.</text></figcaption><link locator="gr1"/></figuregroup><figuregroup id="fig2"><figcaption id="fig2"><label>FIGURE 2</label><text>Clonal expression and enzymatic properties of FaeA gene. <b>(A)</b> The
                    construction process of recombinant yeast expressing FaeA gene. <b>(B)</b>
                    Inverted microscope imaging of how recombinant yeast grows. <b>(C)</b>
                    Identification of FaeA in modified cell lysates by western blotting. <b>(D)</b>
                    The enzymatic properties of FaeA. ( = 3, mean ± SD).</text></figcaption></figuregroup><figuregroup id="fig3"><figcaption id="fig3"><label>FIGURE 3</label><text>Isolation and characterization of sEVs.  Schematic protocol of
                    isolation and purification of sEVs.  TEM images of three sEVs, scale
                    bars represent 100 nm.  Identification of FaeA in engineered sEVs
                    by western blotting.  Representative SS signal of three sEVs by
                    nano-flow cytometry. <b>(E)</b> Particle size distribution and event percentage
                    of three sEVs by nano-flow cytometry. <b>(F)</b> Particle concentration and
                    purity of the three sEVs were measured by nanoflow cytometry. <b>(G)</b>
                    Particle size distribution and PDI values of three sEVs by Malvern particle size
                    analyzer. <b>(H)</b> Zeta potential distribution of three sEVs by Malvern
                    particle size analyzer. ( = 3, mean ± SD).</text></figcaption></figuregroup><figuregroup id="fig4"><figcaption id="fig4"><label>FIGURE 4</label><text>Esterase hydrolysis and storage stability of FaeA@sEVs.  Enzymatic
                    activity of intracellular proteins and FaeA@sEVs.  Changes in the
                    particle size distribution of X33@sEVs stored at 4, −20 and
                    −80°C within 30 d.  Changes in the particle size
                    distribution of FaeA@sEVs stored at 4, −20 and −80°C within
                    30 days  Changes in the particle concentration of X33@sEVs stored
                    at 4, −20 and −80°C within 30 d.  Changes in
                    the particle concentration of FaeA@sEVs stored at 4, −20 and
                    −80°C within 30 d ( = 3, mean ± SD).</text></figcaption></figuregroup><figuregroup id="fig5"><figcaption id="fig5"><label>FIGURE 5</label><text>Loading efficiency of FaeA@sEVs loaded with active molecules. 
                    Schematic representation of the EAL platform. When the EF with high
                    concentration from the outside of the membrane to the inside of the membrane, it
                    will undergo esterase hydrolysis to produce FA under the action of FaeA. This
                    step is equivalent to closing the “switch” for the balance of EF
                    concentration between the two sides of the membrane. As long as EF is present
                    outside the membrane, it will enter the membrane depending on the concentration
                    difference between the two sides of the membrane and release FA. At the same
                    time, the ion trapping effect of biofilm can block the outward leakage of FA,
                    thus indirectly achieving the efficient loading of FA in sEVs. 
                    Loading efficiency of engineered sEVs loaded with active molecules. Note:
                    X33@sEVs-#FA and FaeA@sEVs-#FA represent the drug loading efficiency obtained by
                    replacing the loaded drug EF with FA, respectively. ( = 3, mean ±
                    SD, <i>**p</i> &lt;00.01)</text></figcaption></figuregroup><figuregroup id="fig6"><figcaption id="fig6"><label>FIGURE 6</label><text>Transdermal administration  drug release pattern and
                    cytotoxicity of FaeA@sEVs-FA.  Cumulative release Q of active drug
                    molecules from FaeA@sEVs-FA within 2.5 h  CCK-8 based viability
                    measurement of HEK293T cells incubated with free FA, FaeA@sEVs-FA, FaeA@sEVs and
                    X33@sEVs at various concentrations ranging from 0.1 to 10 μM,
                    respectively. Note: the particle concentration of X33@sEVs and FaeA@sEVs was
                    identical to FaeA@sEVs-FA. ( = 3, mean ± SD).</text></figcaption></figuregroup></tail></article><article><meta><aid>fbioe-2022-1064605</aid><doi>10.3389/fbioe.2022.1064605</doi></meta><head><lrh><query>LRH: Yu et al.</query></lrh><rrh><query>RRH: <url url="https://doi.org/10.3389/fbioe.2022.1064605" title="https://doi.org/10.3389/fbioe.2022.1064605">10.3389/fbioe.2022.1064605</url></query></rrh><articletitle>Mechanical property analysis and design parameter optimization of a novel
            nitinol nasal stent based on numerical simulation<query>Q1: Confirm whether the
            insertion of the article title is correct.</query></articletitle><aug><authors><au id="au1"><fnm>Hui</fnm><sup><xref id="fndagger" title="fndagger">†</xref></sup></au><au id="au2"><fnm>Lingling</fnm></au><au id="au3"><fnm>Jikuan</fnm><snm>Qiu</snm></au><au id="au4"><fnm>Jiayue</fnm></au><au id="au5"><fnm>Yaoke</fnm><snm>Xu</snm></au><au id="au6"><fnm>Baoshi</fnm><snm>Fan</snm></au><au id="au7"><fnm>Rui</fnm></au><au id="au8"><fnm>Junxiu</fnm></au><au id="au9"><fnm>Chao</fnm></au><au id="au10"><fnm>Yubo</fnm></au><query>Q2: The citation and surnames of all of the authors have been highlighted.
                    Check that they are correct and consistent with the authors ’ previous
                    publications, and correct if need be. Please note that this may affect the
                    indexing of your article in repositories such as PubMed.</query><query>Q3: If the following authors would like their LOOP profile to be linked to
                    the final published version, please ensure they register with Frontiers (at )
                    and please provide us with the URLs of their profile link(s) (not email
                    addresses) when submitting the proof corrections. Non-registered authors and
                    authors with profiles set to private mode will have the default profile image
                    displayed. Please note: We won ’ t be able to add profile links after
                    publication.  Lingling Zheng   Jikuan Qiu   Jiayue Wang
                      Baoshi Fan   Rui Li   Junxiu Liu</query></authors><aff id="aff1"><text><affnorg>Department of Otolaryngology Head and Neck Surgery</affnorg><affnorg>Peking University Third Hospital</affnorg><affncity>Haidian</affncity></text></aff><aff id="aff2"><text><affnorg>Key Laboratory of Biomechanics and Mechanobiology</affnorg><affnorg>Ministry of Education</affnorg><affnorg>Beijing Advanced Innovation Center for Biomedical Engineering</affnorg><affnorg>School of Biological Science and Medical Engineering</affnorg><affnorg>School of Engineering Medicine</affnorg><affnorg>Beihang University</affnorg><affncity>Beijing</affncity></text></aff><cor id="corlowast"><text>Correspondence: Junxiu Liu, <e-address type="email">junxiuliu@bjmu.edu.cn</e-address>;
                    Chao Wang, <e-address type="email">10896@buaa.edu.cn</e-address><query>Q5:
                    Confirm that the email address in your correspondence section is accurate.
                    Please note that any changes to the corresponding authorship would require
                    individual confirmation from all original and added/removed corresponding
                    authors.</query></text></cor><fnequal id="fndagger"><label/><p>These authors have contributed equally to this work and share first authorship</p></fnequal><fneditedby><url url="https://loop.frontiersin.org/people/1901435/overview" title="https://loop.frontiersin.org/people/1901435/overview">Joao Miranda</url>,
                University of Porto, Portugal</fneditedby><fneditedby><url url="https://loop.frontiersin.org/people/735166/overview" title="https://loop.frontiersin.org/people/735166/overview">Aike Qiao</url>,
                Beijing University of Technology, China<url url="https://loop.frontiersin.org/people/2052373/overview" title="https://loop.frontiersin.org/people/2052373/overview">Hélder Puga</url>,
                University of Minho, Portugal</fneditedby><fnother><p xmlns:m="http://www.w3.org/1998/Math/MathML/">This article was submitted to
                    Biomechanics, a section of the journal Frontiers in Bioengineering and
                    Biotechnology</p></fnother></aug><abs><abstract-sec><simple-para><b>Background:</b> A novel braided nasal stent is an effective
                    alternative to nasal packing after septoplasty that can be used to manage the
                    mucosal flap after septoplasty and expand the nasal cavity. This study aimed to
                    investigate the influence of design parameters on the mechanical properties of
                    the nasal stent for optimal performance.</simple-para><text><b>Methods:</b> A braided nasal stent modeling method was proposed and 27
                    stent models with a range of different geometric parameters were built. The
                    compression behavior and bending behavior of these stent models were numerically
                    analyzed using a finite element method (FEM). The orthogonal test was used as an
                    optimization method, and the optimized design variables of the stent with
                    improved performance were obtained based on range analysis and weight grade
                    method.</text><text><b>Results:</b> The reaction force and bending stiffness of the braided stent
                    increased with the wire diameter, braiding density, and external stent diameter,
                    while wire diameter resulted as the most important determining parameter. The
                    external stent diameter had the greatest influence on the elongation
                    deformation. The influence of design parameters on von-Mises stress distribution
                    of bent stent models was visualized. The stent model with geometrical parameters
                    of 25 mm external diameter, 30° braiding angle, and 0.13 mm wire
                    diameter (A3B3C3) had a greater reaction force but a considerably smaller
                    bending stiffness, which was the optimal combination of parameters.</text><text><b>Conclusion:</b> Firstly, among the three design parameters of braided stent
                    models, wire diameter resulted as the most important parameter determining the
                    reaction force and bending stiffness. Secondly, the external stent diameter
                    significantly influenced the elongation deformation during the compression
                    simulation. Finally, 25 mm external diameter, 30° braiding angle, and
                    0.13 mm wire diameter (A3B3C3) was the optimal combination of stent
                    parameters according to the orthogonal test results.</text></abstract-sec></abs><keywordsdefault><kwd>nasal stent</kwd><kwd>mechanical properties</kwd><kwd>parametric analysis</kwd><kwd>finite element method</kwd><kwd>orthogonal optimization</kwd></keywordsdefault><funding-group><award-group><awardrecipient>10.13039/501100001809</awardrecipient><x>; </x><fundsource>National Natural Science Foundation of China</fundsource><awardid>11872135</awardid><awardid>2072055</awardid><awardid>U20A20390</awardid></award-group><award-group><awardrecipient>10.13039/501100004826</awardrecipient><fundsource>Natural Science Foundation of Beijing Municipality</fundsource><awardid>L212063</awardid></award-group><award-group><awardrecipient>10.13039/501100018537</awardrecipient><fundsource>National Science and Technology Major Project</fundsource><awardid>2018AAA0102101</awardid><awardid>2020AAA0109602</awardid></award-group><award-group><awardrecipient>10.13039/501100012226</awardrecipient><fundsource>Fundamental Research Funds for the Central Universities</fundsource></award-group></funding-group></head><body><seca id="sec1"><sectitle>Introduction<query>Q7: Check if the section headers (i.e., section leveling)
                were correctly captured.</query></sectitle><paragraph>Septoplasty is one of the most commonly performed operations by
                otorhinolaryngologists (<xref id="bib_ey_2015" title="bib_ey_2015">Eşki and
                Yılmaz, 2015</xref>). Packing insertion after septoplasty is a common practice
                used to stabilize the postoperative septum and to prevent complications such as
                bleeding, hematoma, and adhesion (<xref id="bib_weber_et_al_2001" title="bib_weber_et_al_2001">Weber et al., 2001</xref>; <xref id="bib_chevillard_et_al_2006" title="bib_chevillard_et_al_2006">Chevillard et
                al., 2006</xref>). However, nasal packing can cause a range of symptoms such as
                nasal obstruction, pain, headache, and epiphora, which can be quite uncomfortable
                and can severely affect patient′s quality of life, increasing their risk of
                infection (<xref id="bib_dalgic_et_al_2016" title="bib_dalgic_et_al_2016">Dalgic et
                al., 2016</xref>). In order to minimize the discomfort and improve the quality of
                life in patients after septoplasty, various materials have been tested, but only a
                few were found to be able to avoid nasal obstruction (). Therefore, rhinologists have been obstinately searching for a
                proper practice to be used after septoplasty.</paragraph><paragraph>Recently, our research group has invented a novel braided nasal stent to
                manage mucosal flap after septoplasty and expand the nasal cavity, which can be used
                as an effective alternative to nasal packing (<xref id="bib_yu_et_al_2022" title="bib_yu_et_al_2022">Yu et al., 2022</xref>). Nickel–titanium alloy
                (Nitinol) was used as the braiding material of the stent as it can offer superior
                implant characteristics due to its superelastic and shape memory properties (<xref id="bib_stoeckel_et_al_2004" title="bib_stoeckel_et_al_2004">Stoeckel et al.,
                2004</xref>). The self-expanding nitinol stent can reduce the extent of canal recoil
                and restenosis and provide a less invasive alternative for the treatment of
                endovascular or non-vascular diseases (<xref id="bib_azaouzi_et_al_2013" title="bib_azaouzi_et_al_2013">Azaouzi et al., 2013</xref>). To adapt the
                complex geometry of the nasal cavity and exert an adjustable centripetal pressure on
                septal mucoperiosteal flaps and lateral nasal wall, the novel nasal stent was
                designed with an expanded gourd-shaped head. The smaller sphere of the stent was
                located in the nasal vestibule, while the larger one was expanded in septal
                cartilage area and the neck portion of the gourd was placed in the nasal valve area.
                The special structure design could fit nasal cavity structure and avoid falling off
                (<citation>fig1</citation>).<query>Q8:
                Ensure that all the figures, tables and captions are correct, and that all figures
                are of the highest quality/resolution. If needed, please upload improved Figures in
                the Production Forum. Please note that Figures and Tables must be cited
                sequentially, as per section 2.2 of the .</query> Compared with previous nasal
                stents, this Nitinol nasal stent is an innovational device. Firstly, unlike
                traditional ones which are used for treating sleep apnea, this novel stent is
                applied to stable septum and avoid bleeding after nasal septoplasty. Secondly, they
                work in different ways. The traditional ones are designed to prevent upper airway
                collapse, while this stent is designed to support nasal mucosal flap and prevent
                hematoma formation. Finally, as application scenarios and demands are not the same,
                the designs of the stents are different. Usually, traditional stents are preformed
                tube-shaped silicon devices which have uniform structure.</paragraph><paragraph>Numerical simulation is an effective method for analyzing the mechanical
                performances of stents. It has high accuracy and requires fewer resources (<xref id="bib_zaccaria_et_al_2021" title="bib_zaccaria_et_al_2021">Zaccaria et al.,
                2021</xref>), and it can also be used to design and optimize stents (<xref id="bib_balossino_et_al_2008" title="bib_balossino_et_al_2008">Balossino et al.,
                2008</xref>). Záhora <i>et al.</i> derived the equations of the physical model
                for the spiral stent to describe the mutual transformation between the axial force
                and the radial pressure (<xref id="bib_záhora_et_al_2007" title="bib_záhora_et_al_2007">Záhora et al., 2007</xref>). Wang et al.
                investigated the relationship between the transitory nonuniform expansion of the
                stent/balloon system and different stent structures and balloon lengths under
                internal pressure using the finite element method (<xref id="bib_wang_et_al_2006" title="bib_wang_et_al_2006">Wang et al., 2006</xref>). De Beule and colleagues
                proposed a modeling strategy as a promising optimization methodology for braided
                stent design (<xref id="bib_de_beule_et_al_2009" title="bib_de_beule_et_al_2009">De
                Beule et al., 2009</xref>). Indeed, their research results provided useful and
                valuable information that further the understanding of the mechanical properties of
                the braided stent. However, there are significant differences between nasal and
                endovascular stents. First, as the nasal stent is located in the nasal cavity, a
                narrow and irregular canal, the nasal stent is subjected to a flat compression force
                rather than a radial compression force. Second, the environment in which the stent
                exerts its function is different, as the vessel walls are relatively soft while the
                lateral nasal walls are more rigid. Also, there is a property difference between
                blood flow and airflow. Finally, the clinical demands are different; the
                endovascular stent is subjected to a long-term cyclic pulsating load, and fatigue
                endurance is a major design requirement. In addition, the nasal stent is applied
                after septoplasty and is taken off 2 days later. Therefore, studies on nasal
                stent can be quite different and great improvements need to be made based on the
                previous work.</paragraph><paragraph>Sufficient supporting strength, good flexibility, and biocompatibility are
                needed for a suitable nasal stent to support nasal structure, maintain nasal
                ventilation and reduce secondary injury (<xref id="bib_weber_et_al_2000" title="bib_weber_et_al_2000">Weber et al., 2000</xref>). In addition, the
                mechanical behavior of a stent is an important factor in ensuring its opening within
                the conduits (<xref id="bib_kim_et_al_2008" title="bib_kim_et_al_2008">Kim et al.,
                2008</xref>), where reaction force (<xref id="bib_garcía_et_al_2012" title="bib_garcía_et_al_2012">García et al., 2012</xref>) and bending
                stiffness (<xref id="bib_mori_and_saito_2005" title="bib_mori_and_saito_2005">Mori
                and Saito, 2005</xref>) are the most important indicators. Thus far, the influence
                of geometric features of braided metal stents, including wire diameter and wire
                density, have been predicted under radial compression (<xref id="bib_fu_et_al_2018" title="bib_fu_et_al_2018">Fu et al., 2018</xref>), localized radial compression
                (<xref id="bib_kim_et_al_2008" title="bib_kim_et_al_2008">Kim et al., 2008</xref>),
                bending (
                ; <xref id="bib_zaccaria_et_al_2020" title="bib_zaccaria_et_al_2020">Zaccaria et
                al., 2020</xref>) and elongation (<xref id="bib_de_beule_et_al_2009" title="bib_de_beule_et_al_2009">De Beule et al., 2009</xref>). Furthermore, the
                finite element method (FEM) has been widely used to investigate stent mechanics (<xref id="bib_tan_et_al_2001" title="bib_tan_et_al_2001">Tan et al., 2001</xref>; <xref id="bib_mckenna_and_vaughan_2021" title="bib_mckenna_and_vaughan_2021">McKenna
                and Vaughan, 2021</xref>; <xref id="bib_zaccaria_et_al_2021" title="bib_zaccaria_et_al_2021">Zaccaria et al., 2021</xref>). Yet, there are
                still no studies on the mechanical properties of the nasal stent, and the influence
                of geometric parameters on the performance of the stent remains unclear.</paragraph><paragraph>The aim of this study was to investigate the effects of structure parameters
                such as wire diameter, braiding angle, and stent size on the mechanical performances
                of the stent so as to improve the efficiency and quality of the nasal stent. In this
                study, 3 types of nasal stent models were constructed, and the compression and
                bending behavior of the nasal stent were simulated by the finite element method. The
                orthogonal experimental method was used to determine the optimal combination of
                structure parameters. The nasal stent with the optimal parameters was braided, and
                the accuracy of the simulation model was verified by  mechanical
                property test. The reported results contribute to the efforts to obtain a nasal
                stent with excellent mechanical performance and lay the foundation for further
                clinical application of nasal stents.</paragraph></seca><seca id="sec2"><sectitle>Materials and methods</sectitle><secb id="sec2_1"><sectitle>Design of nasal stent models</sectitle><paragraph>Unlike endovascular stent, the nasal stent is designed with three parts:
                    small sphere portion, large sphere portion, and cylinder portion, i.e., the head
                    of the nasal stent is uniquely expanded as the shape of a gourd. The radial
                    diameter of the three parts was expressed in terms of d<sub>1</sub>, d<sub>2,</sub>
                    and d<sub>3,</sub> respectively. The axial diameter of the three parts was
                    expressed in terms of l, l and l
                    respectively. In this study, 3 types of diamond weave pattern braided stent
                    models were designed, which were named stent model S, stent model M, and stent
                    model L. For stent model S, d = 12 mm, d =
                    15 mm, d<sub>3</sub> = 10 mm, l = 10 mm, l
                    = 15 mm, l = 35 mm. For stent model M, d =
                    12 mm, d = 20 mm, d = 10 mm, l
                    = 10 mm, l = 20 mm, l = 30 mm. For stent
                    model L, d = 14 mm, d = 25 mm, d =
                    14 mm, l = 12 mm, l = 22 mm, l
                    = 25 mm. The length of the stent was 60 mm; the detailed sizes are
                    shown in .
                    The braided stent geometries were fabricated in the CAD modeling software
                    Rhino3D NURBS (Robert McNeel, American). Firstly, the model contour line was
                    drawn in the sketch according to the drawing size and rotated to a surface
                    model. Consequently, based on the model parameters (braiding angle, wire
                    diameter), the braided curves were drawn using a diamond weave pattern (). Finally, the braided curves were
                    projected on the surface model. The 3 types of braided stent had max external
                    diameter of <i>D</i> = 15 mm,  = 20 mm,  = 25 mm,
                    respectively. Each braided stent had a one-over-one braid pattern with braiding
                    angle <i>β</i> = 60°,  = 45°,  =
                    30° and the wire diameter of each braided stent was <i>d</i> =
                    0.09 mm,  = 0.11 mm,  = 0.13 mm, as shown in <xref id="fig2" title="fig2">Figure 2</xref>.</paragraph></secb><secb id="sec2_2"><sectitle>Material properties of nitinol</sectitle><paragraph>The self-expandable stent introduced in this study was made of
                    superelastic Nitinol. The equations for its superelastic mechanical model were
                    provided by (<xref id="bib_he_et_al_2022" title="bib_he_et_al_2022">He et al.,
                    2022</xref>); the model parameters are shown in <xref id="tbl1" title="tbl1">Table
                    1</xref>. Here, <i>ρ</i> is the density, <i>E</i><sub><i>A</i></sub>, <i>υ</i><sub><i>A,</i></sub> and <sub><i>M</i></sub>,  are the Young’s moduli, the
                    Poisson’s ratios of the austenite and martensite, respectively; <i>
                    ε</i><sup><i>L</i></sup> is the uniaxial transformation strain; <i>σ,
                    σ</i>, <i>σ, σ</i> are the stresses, at which the phase
                    transformation starts and ends during loading (subscript L) and unloading (U) in
                    tension, respectively; <i>σ</i> is the stress, at which the phase
                    transformation begins in compression. The material data () required to calibrate the Abaqus material model
                    can be obtained from the uniaxial behavior () (<xref id="bib_azaouzi_et_al_2013" title="bib_azaouzi_et_al_2013">Azaouzi
                    et al., 2013</xref>) in terms of loading, unloading, reverse loading, and
                    temperature effects.</paragraph></secb><secb id="sec2_3"><sectitle>Numerical simulation and boundary conditions</sectitle><paragraph>The diamond weave pattern braided stents models were imported into Abaqus
                    2020 software by Initial Graphics Exchange Specification (IGES) format for
                    Finite Element (FE) calculation, which included two working conditions, i.e.,
                    compression simulation and bending simulation. Geometric meshes were constructed
                    for braided stents with Nitinol wires, and each wire meshed with linear
                    Timoshenko beam elements (B31), which allowed for large axial strains and
                    transverse shear deformation. An average beam element size of 0.1 mm was
                    adopted for all stent models to ensure the mesh division quality and the
                    accuracy of the simulation results. ﻿“General contact” type
                    (option in ABAQUS/explicit solver) was used to treat the friction and slippage
                    among beam elements and the contact between the braided stents and the rigid
                    bodies. A friction coefficient of 0.2 was assumed at wire crossover points (). In
                    addition, the ABAQUS/explicit solver was chosen to effectively treat the contact
                    problem between beam elements and solve the divergence problem due to contact
                    instability, which is known to frequently occur in ABAQUS/standard solvers.</paragraph><paragraph>To simulate the compression test, a pressing plane and a supporter plane
                    () were
                    assumed as a rigid body, and one dynamic (explicit) step was applied on the
                    pressing plane to compress the stent’s external diameter to 5 mm. As
                    for the boundary condition, the nodes of the braided stent contacting the rigid
                    supporter plane were fixed, while no boundary condition was applied to the two
                    ends of the braided stents.</paragraph><paragraph>The bending behavior is one of the important indicators used to evaluate
                    the mechanical performances of the stent, which can prevent stent collapses or
                    folding after being installed and affect the conduit functions. The same
                    geometric mesh as that employed in the compression simulation was used, and a
                    boundary condition was imposed at both ends of the stent, thus inducing a
                    bending deformation (). A
                    rotational boundary condition with the same magnitude but a different
                    orientation of rotation angle (0.25 rad) was applied to both ends of the
                    braided stent. The bending stiffness of the stent, <i>EI,</i> the reciprocal of
                    flexibility, was calculated using the following equation:<query>Q9: Verify that
                    all the equations and special characters are displayed correctly.</query></paragraph><displaymath><math><mrow><mi>I</mi><mfrac><mrow><mi>M</mi><mi>L</mi></mrow><mrow><mn>2</mn><mi>α</mi></mrow></mfrac></mrow></math></displaymath><paranoindent>where <i>α</i> is the rotation angle of the center axis of the
                    stent under the action of bending moment,  is the distance between the
                    two operating points where the bending moment is applied, and  is the
                    bending moment applied on the stent.</paranoindent></secb><secb id="sec2_4"><sectitle>Orthogonal experimental design</sectitle><paragraph>When designing Nitinol nasal stent, it is necessary to consider various
                    design requirements. Also, sometimes contradictory criteria must be satisfied to
                    improve the stent’s performance. In order to seek the rule of mechanical
                    results influenced by the structural parameter and obtain the optimal
                    combination of the structural parameters of the nasal stent, orthogonal tests,
                    which analyze the force reaction, elongation deformation, and bending stiffness
                    of the nasal stents, are required. The diameter of the nitinol wire, the
                    braiding angle, and the stent max external diameter were selected as three
                    factors of the orthogonal test, and indicated by codes A, B, and C,
                    respectively. Orthogonal numerical simulation tests were designed for three
                    factors, each with three levels; the orthogonal factor level table is shown in <citation>tbl2</citation>.</paragraph><paragraph>In consideration of the paradoxical results of the multi-index orthogonal
                    test, the weight grade method was used to determine the best combination of
                    parameters. Reaction force and bending stiffness were taken as the main
                    indicators to be analyzed. Firstly, the grade values of both indexes were
                    calculated using the following equation:</paragraph><displaymath><math><mrow><msup><msub><mrow><mi>j</mi></mrow></msub><mo>′</mo></msup><mfrac><mrow><mo>−</mo><msub><mi mathvariant="italic">min</mi></msub></mrow><mrow><msub><mi mathvariant="italic">max</mi></msub></mrow></mfrac></mrow></math></displaymath><paranoindent>where <i>y</i><sub><i>ij</i></sub> is the value of the <i>j</i> experiment
                    index of a stent at <i>i</i> level, <sub>max</sub> and <sub>min</sub>
                    are the maximum and minimum of the index, respectively, and <i>’</i> represents the grade
                    value of the experiment index as shown in <citation>
                    tbl3</citation>,<query>Q10: Note that Table 3 has been changed to Table 4 and
                    Table 4 has been changed to Table 3.</query>’ is the
                    grade value of reaction force and ’ is the grade
                    value of bending stiffness. <sub>i</sub>* means the weighted aggregative
                    grade of the experiment index and is calculated as:</paranoindent><displaymath><math><mrow><msup><msub/><mo>*</mo></msup><mo>∑</mo><msub><mi>w</mi></msub></mrow></math></displaymath><paranoindent>where <i>w</i><sub/> is the weighting coefficient of the 
                    experiment index; the weighting coefficient of reaction force 
                    was set as 0.7 and the weighting coefficient of bending stiffness 
                    was set as 0.3. As the smaller value of bending stiffness is considered
                    superior,  was set to a negative value.</paranoindent></secb><secb id="sec2_5"><sectitle>Design experimental verification</sectitle><paragraph>In order to assess the accuracy of the mechanical simulation of the
                    stent, we used the compression test, which provides information on whether the
                    stent has sufficient strength when deployed inside the nasal cavity to push its
                    wall outward. As shown in <citation>
                    fig4</citation>, a compression test was conducted by a universal testing machine
                    (ZQ Ltd., China) on a nasal stent sample (stent model L,  =
                    0.13 mm,  = 30°). In this test, the stent sample was
                    fixed on the inferior clamp. The superior clamp was used to apply a load to the
                    sample at room temperature, and the reaction force of the stents was recorded
                    until it was compressed to 5 mm in diameter. The curve of force
                    displacement was compared between the simulation and experiment (<xref id="fig4" title="fig4">Figure 4B</xref>).</paragraph></secb></seca><seca id="sec3"><sectitle>Results</sectitle><secb id="sec3_1"><sectitle>Simulation of compression behavior</sectitle><paragraph>The compression simulation was the primary indicator used to investigate
                    the mechanical behavior of the braided stents according to the wire diameter and
                    the braiding angle. In order to quantify the supporting force of the stent, the
                    reaction force of the superior plane was compared when it was moved to compress
                    the stent’s external diameter to 5 mm. As shown in the response
                    surface diagram of reaction force (<citation>
                    fig5</citation>), as the wire diameter increased from 0.09 mm to
                    0.13 mm, the reaction force gradually increased, while as the braiding
                    angle increased from 30° to 60°, it decreased. Of the three types of
                    stent models, the external diameter of the stent could also influence the
                    reaction force, as all the stents were compressed to the same diameter as the
                    average width of the common nasal cavity. The maximum reaction force values of
                    the stent model L, M, and S were 5.41 N, 5.30 N, and 4.87 N, respectively, which
                    is slightly less than the pressure of common nasal packing materials.</paragraph><paragraph>The relationship between elongation deformation and structural parameters
                    is shown in  for 60°,
                    45°, and 30° braiding angles, respectively. It was found that the
                    diameter of the stent significantly influenced the elongation deformation of the
                    braided stent. When the diameter increased from 15 mm to 20 mm, the
                    elongation deformation increased relatively slowly, while when the diameter was
                    &gt;20 mm, the elongation deformation rapidly increased from 33.6 mm
                    to 72.2 mm. Wire diameter had no significant influence on elongation
                    deformation. The elongation deformation was calculated using the following
                    equation:</paragraph><displaymath><math><mrow><msup><mo>´</mo></msup></mrow></math></displaymath><paranoindent>where  represents the length of the original stent and <i>
                    L′</i> represents the length of the compressed stent, as shown in .</paranoindent></secb><secb id="sec3_2"><sectitle>Simulation of bending behavior</sectitle><paragraph>Bending stiffness is inversely proportional to the stent flexibility,
                    which can be measured by bending simulation. <xref id="fig6" title="fig6">Figure
                    6A</xref> illustrates the relationship between the
                    bending performance of the stent and the geometric parameters. As the wire
                    diameter increased, the bending stiffness gradually increased. Also, bending
                    stiffness was inversely related to braiding angle. These results demonstrated
                    that stent model S was the most flexible stent and that stent model L was the
                    most rigid one. The relationship between the maximum von Mises and structural
                    parameters is shown in  for
                    60°, 45°, and 30° braiding angle, respectively; the statistical
                    diagram illustrates the maximum von-Mises stress of the bent stent model
                    increases as the wire diameter and the external stent diameter increase.</paragraph><paragraph>The contour plots of von-Mises stress distribution on 27 bent stent
                    models are shown in <xref id="fig7" title="fig7 fig8 fig9">Figures 7–9</xref><citation>
                    fig7</citation><citation>fig8</citation><citation>fig9</citation>. Higher stress
                    was mainly distributed in the middle of the stent, and lower stress was
                    distributed at the ends of the stent. With the diminution of the braiding angle,
                    the von-Mises stress increased. In addition, the maximum of von-Mises stress
                    increased with the increase of outer diameter. Also, among the 27 stent models,
                    the stress maximum was 47.3 MPa, which was far less than the stress
                    observed when the transformation started during loading (520 MPa).</paragraph></secb><secb id="sec3_3"><sectitle>Orthogonal experimental results</sectitle><paragraph>According to the aforementioned formula of the FE analysis of the nasal
                    stent, the relationship between stent structural parameters and mechanical
                    performance was found. Therefore, to obtain the stent with the best mechanical
                    performance, numerical simulation and orthogonal tests were used for the nasal
                    stent structural parameter optimization. The L<sub>9</sub> (3)
                    orthogonal test design form was selected, and 9 test schemes of different
                    structural parameters were obtained. The numerical simulation of the compression
                    and the bending behavior of the nasal stent was carried out in nine groups, and
                    the results of reaction force, elongation deformation, and bending stiffness
                    were taken as the test indexes. The results are shown in <xref id="tbl4" title="tbl4">Table 4</xref><citation>tbl4</citation>.</paragraph><paragraph>Differential analysis was used to study the influence of the structural
                    parameters on the stent’s reaction force, elongation deformation, and
                    bending stiffness. The range analysis of the orthogonal test of the nasal stent
                    is shown in <xref id="sec11" title="sec11">Supplementary Table S1</xref>, where <i>
                    K</i> is the average of the experiment index of
                    a stent at the  level. The <i>K</i> value can judge the merits of this factor
                    at the  level;  is the difference between the maximum and the
                    minimum of the three levels of a structure factor. <i>Ki</i> value and the <i>R-</i>value
                    size can determine the impact of this factor on the simulation results.</paragraph><paragraph>As shown in ,
                    the range analysis result of the orthogonal test revealed that the main order of
                    the influence on the reaction force and bending stiffness was ABC. The wire
                    diameter had the greatest impact, followed by the braiding angle and the
                    external stent diameter. The best combination of the reaction force was A3B3C3,
                    which included a wire diameter of 0.13 mm, braiding angle of 30° and stent
                    external diameter of 25 mm, while for the bending stiffness, a stent with
                    good flexibility was more comfortable for patients, so the smaller the bending
                    stiffness, the better. Also, the best combination was A1B1C1, including the wire
                    diameter of 0.09 mm, braiding angle of 60°, and external stent
                    diameter of 15 mm, which was opposite to the reaction force. Concerning the
                    elongation deformation, the stent diameter had the greatest impact, followed by
                    the wire diameter and the braiding angle, where the best combination was A3B3C1.
                    Weighted aggregative results of the two experiment indexes indicated that the
                    combination A3B3C3 obtained the highest value (<xref id="tbl5" title="tbl5">Table
                    5</xref><citation>tbl5</citation>).</paragraph></secb><secb id="sec3_4"><sectitle>Experimental compression behavior of braided stents</sectitle><paragraph>According to the optimal results, the stent model L, braided with
                    0.13 mm wire diameter and braiding angle of 30°, had the best
                    mechanical property. The stent was braided with a braiding machine, and the
                    compression test was performed to investigate the reaction force of the braided
                    stent according to the displacement to compare its behavior with that of the
                    stent model. As the displacement increased, the force of the braided stent to
                    the compressive loading increased, and the curve of force displacement was flat
                    when the displacement was &lt;15 mm, while it increased sharply when it was
                    &gt;15 mm (). The validation
                    result showed that the computational model correctly predicted the reaction
                    force trend of the entitative braided Nitinol stent, suggesting that the present
                    model was successfully constructed and the FE analysis results were accurate.</paragraph></secb></seca><seca id="sec4"><sectitle>Discussion</sectitle><paragraph>The novel Nitinol nasal stent was designed to be inserted into the nasal
                cavity and support the mucosal flap in case of hematoma and deviation recurrence. A
                controlled clinical trial showed that compared with traditional nasal packing, the
                nasal stent not only leads to effective hemostasis but also satisfies the demand for
                nasal ventilation and improves the quality of life in patients after septoplasty (). As the
                stenting technique for the nasal cavity is a new approach, there is still a lack of
                research on its mechanic performances. In this study, we established nasal stent
                models with different design parameters and simulated their compression and bending
                behaviors. The FEA results initially revealed the impact of different structural
                parameters. To optimize the performance of nasal stents, we designed an orthogonal
                experiment to explore further the primary and secondary relationship of the
                influence of structural parameters on the indexes and obtain the optimal combination
                of structural parameters for the nasal stent.</paragraph><paragraph>The designs of commercial stents currently available on the market are
                uniform, with repeating patterns (<xref id="bib_ni_et_al_2015" title="bib_ni_et_al_2015">Ni et al., 2015</xref>). However, for the special
                anatomy of the nasal cavity and the postoperative demands, it is not possible to
                achieve desired treatment outcomes with a uniform stent design. Therefore, the nasal
                stent was designed with a head of gourd shape uniquely expanded (). The reasons for this novel design are as follows:
                firstly, the geometry of the nasal cavity is irregular. Limen nasi is the narrowest
                region, and this is also where the nasal resistance is greatest (<xref id="bib_san_nicoló_et_al_2020" title="bib_san_nicoló_et_al_2020">San
                Nicoló et al., 2020</xref>). The junctional zone between the small and large
                sphere portions can fit this region well and reduce nasal resistance. Secondly,
                sufficient supporting strength and coverage area of the stent is needed in order to
                exert proper pressure and avoid hematoma, especially for the septal cartilage region
                where the large sphere portion is located. Finally, the ingenious design can help to
                prevent the stent from falling off.</paragraph><paragraph>Self-expanding Nitinol stents are widely used to treat occluded diseases in
                lumens (<xref id="bib_mcgrath_et_al_2014" title="bib_mcgrath_et_al_2014">McGrath et
                al., 2014</xref>). The unique self-expandable shape memory property allows the
                device to expand to a pre-set shape once released from the catheter (<xref id="bib_maleckis_et_al_2018" title="bib_maleckis_et_al_2018">Maleckis et al.,
                2018</xref>). Consequently, the Nitinol stent can offer a constant and steady
                outward expansion force. As the failure of interventional treatment caused by the
                migration of the braided stent has been reported in previous studies (<xref id="bib_chalouhi_et_al_2013" title="bib_chalouhi_et_al_2013">Chalouhi et al.,
                2013</xref>), it is of great importance to properly increase the reaction force of
                the nasal stent in clinical practice. In the present work, the influence of wire
                diameter, braiding angle, and stent diameter on reaction force was explored, and the
                results demonstrated that wire diameter had the greatest influence on reaction force
                among the three parameters. Given the mucosal tolerance, it is not possible to
                infinitely increase the reaction force. The peak force of the experimental nasal
                stent is 5.6 N, which is less than the reaction force of the packing sponge and does
                not cause capillary occlusion (<xref id="bib_klinger_and_siegert_1997" title="bib_klinger_and_siegert_1997">Klinger and Siegert, 1997</xref>).
                Therefore, the larger the reaction force is within the safe range, the better
                outcomes are. During the compression progress, the change of the stent elongation
                deformation, which determines the accuracy of stent positioning, must be considered
                (<xref id="bib_de_beule_et_al_2009" title="bib_de_beule_et_al_2009">De Beule et al.,
                2009</xref>). As shown in this study (),
                stent diameter was the most significant factor affecting elongation deformation.</paragraph><paragraph>Excellent flexibility is another characteristic of braided nitinol stent (<xref id="bib_shi_et_al_2020" title="bib_shi_et_al_2020">Shi et al., 2020</xref>),
                promoting adaptation to the complex structure and avoiding damage to the nasal
                mucosa. Besides, the stress distribution affects the fatigue resistance of the stent
                (<xref id="bib_petrini_et_al_2016" title="bib_petrini_et_al_2016">Petrini et al.,
                2016</xref>). In this study, we considered the bending stiffness of the stent as
                another important evaluation indicator. The stent model with geometrical parameters
                of 15 mm external diameter, 60° braiding angle, and 0.09 mm wire
                diameter had the smallest bending stiffness. Besides, we visualized and quantified
                the von-Mises stress distribution of bent stents.</paragraph><paragraph>The main research methods in the present study included the finite element
                method and orthogonal optimization. FEA is widely used for the simulation of
                mechanical performances of stents, as it can save costs and optimize stent
                parameters (<xref id="bib_kelly_et_al_2019" title="bib_kelly_et_al_2019">Kelly et
                al., 2019</xref>; <xref id="bib_zaccaria_et_al_2020" title="bib_zaccaria_et_al_2020">Zaccaria
                et al., 2020</xref>; <xref id="bib_mckenna_and_vaughan_2021" title="bib_mckenna_and_vaughan_2021">McKenna and Vaughan, 2021</xref>). Ribeiro
                et al. optimized a coronary PROMUS Element stent with reduced vessel injury, radial
                recoil, and prolapse as well as improved bending, longitudinal, and radial strength
                (<xref id="bib_ribeiro_et_al_2021" title="bib_ribeiro_et_al_2021">Ribeiro et al.,
                2021</xref>). Ni et al. carried out numerical investigations of the mechanical
                properties of braided non-vascular stents using a finite element method (). The
                orthogonal experiment is a high-efficiency experimental design method that uses an
                orthogonal table to solve the test problems of multiple factors and identify the
                optimal combination of parameters (<xref id="bib_zhang_et_al_2022" title="bib_zhang_et_al_2022">Zhang et al., 2022</xref>).</paragraph><paragraph>Although this study provided a preliminary research approach to the novel
                nasal stent and obtained the mechanical characteristics of nasal stents, it has some
                limitations that should be noted. Firstly, only one weave pattern was involved, and
                other patterns should also be considered. Secondly, fatigue resistance, another
                significant characteristic of braided stents, was not calculated. Finally, as with
                other theoretical simulations, we simplified the actual progress, thus limiting the
                ability to extrapolate the results to clinical situations because of the numerical
                simulation. Therefore, more weave patterns and simulation properties need to be
                investigated, and more clinical trials should be conducted for the further
                application of nasal stents in future studies.</paragraph></seca><seca id="sec5"><sectitle>Conclusion</sectitle><paragraph>In this study, we proposed a modeling method for Nitinol braided nasal stents
                and established 27 nasal stent models through orthogonal experiments to optimize the
                design parameters. Taking into account the limitations of this study, we can draw
                the following conclusions: firstly, among the three design parameters of braided
                stent models, wire diameter resulted as the most important parameter determining the
                reaction force and bending stiffness. Secondly, the external stent diameter
                significantly influenced the elongation deformation during the compression
                simulation. Finally, 25 mm external diameter, 30° braiding angle, and
                0.13 mm wire diameter (A3B3C3) was the optimal combination of stent parameters
                according to the orthogonal test results.</paragraph></seca><seca id="sec6"><sectitle>Data availability statement </sectitle><paragraph>The original contributions presented in the study are included in the
                article/<xref id="sec11" title="sec11">Supplementary Material</xref>, further
                inquiries can be directed to the corresponding authors.<query>Q11: Confirm that the
                Data Availability statement is accurate. Note that we have used the statement
                provided at Submission. If this is not the latest version, please let us know.</query></paragraph></seca><seca id="sec7"><paragraph>All authors contributed to the research conception and design. The first
                draft of the manuscript was written by HY; FE model establishment and data
                calculation were performed by HY, LZ, and JQ. JW and YX tested the stent sample; BF
                and RL collected and analyzed the data. The work was critically revised by JL and
                CW. All authors commented on previous versions of the study and read and approved
                the final version.<query>Q12: Confirm if the edit made in the “Author
                Contributions” section is correct.</query><query>Q13: The author
                “FE” appears in the “Author Contribution” section, but
                this author does not feature in the author list. Let us know if you would like to
                add an author to the author list or if you would like to include a sentence in the
                Acknowledgments section.</query></paragraph></seca><seca id="sec8"><paragraph>This work was supported by the National Natural Science Foundation of China
                (Grant Nos. 11872135, 12072055, and U20A20390); National Science and Technology
                Major Project of the Ministry of Science and Technology of China (Grant Nos.
                2018AAA0102101 and 2020AAA0109602); Capital Health Development Scientific Research
                Project of Beijing (Grant No. 2020-2Z-40918); Natural Science Foundation of Beijing
                (Grant No. L212063) and the Fundamental Research Funds for the Central Universities.<query>Q14:
                Ensure to add all grant numbers and funding information, as after publication this
                will no longer be possible. All funders should be credited and all grant numbers
                should be correctly included in this section.</query></paragraph></seca><seca id="sec9"><paragraph>The authors declare that the research was conducted in the absence of any
                commercial or financial relationships that could be construed as a potential
                conflict of interest.<query>Q15: Confirm if the text included in the Conflict of
                Interest statement is correct.</query></paragraph></seca><seca id="sec11"><sectitle>Supplementary material </sectitle><paragraph>The Supplementary Material for this article can be found online at: <url url="https://www.frontiersin.org/articles/10.3389/fbioe.2022.1064605/full#supplementary-material" title="https://www.frontiersin.org/articles/10.3389/fbioe.2022.1064605/full#supplementary-material">
                https://www.frontiersin.org/articles/10.3389/fbioe.2022.1064605/full#supplementary-material</url><query>Q16:
                Ensure that any supplementary material is correctly published at this link: . If the
                link does not work, you can check the file(s) directly in the production forum; the
                published supplementary files appear in green. Provide new files if you have any
                corrections and make sure all Supplementary files are cited. Please also provide
                captions for these files, if relevant. Frontiers will deposit ALL supplementary
                files to FigShare and they will receive a DOI. Notify us of any previously deposited
                material. If the Supplementary Material files contain identifiable images, please
                keep in mind that it is your responsibility, as the author, to ensure you have
                permission to use the images in the article. Please check this for author’s
                responsibility for publication of identifiable images.</query></paragraph></seca></body><tail><bibreference><bibliography-sec><bib-reference id="bib_azaouzi_et_al_2013"><label>Azaouzi et al., 2013</label><journal><aus><au><snm>Azaouzi</snm></au><au><snm>Lebaal</snm></au><au><snm>Makradi</snm></au><au><snm>Belouettar</snm></au></aus><atl>Optimization based simulation of self-expanding Nitinol stent</atl><stl>Mater. Des.</stl><vol>50</vol><first-page>917</first-page><last-page>928</last-page><doi>10.1016/j.matdes.2013.03.012</doi></journal></bib-reference><bib-reference id="bib_balossino_et_al_2008"><label>Balossino et al., 2008</label><journal><aus><au><snm>Balossino</snm></au><au><snm>Gervaso</snm></au><au><snm>Migliavacca</snm></au><au><snm>Dubini</snm></au></aus><adate>2008</adate><atl>Effects of different stent designs on local hemodynamics in stented
                            arteries</atl><stl>J. Biomechanics</stl><vol>41</vol><first-page>1053</first-page><last-page>1061</last-page><doi>10.1016/j.jbiomech.2007.12.005</doi></journal></bib-reference><bib-reference id="bib_chalouhi_et_al_2013"><label>Chalouhi et al., 2013</label><journal><aus><au><snm>Chalouhi</snm></au><au><snm>Tjoumakaris</snm><fnm>S. I.</fnm></au><au><snm>Gonzalez</snm><fnm>L. F.</fnm></au><au><snm>Hasan</snm></au><au><snm>Pema</snm><fnm>P. J.</fnm></au><au><snm>Gould</snm></au></aus><atl>Spontaneous delayed migration/shortening of the pipeline embolization
                            device: Report of 5 cases</atl><stl>AJNR. Am. J. Neuroradiol.</stl><vol>34</vol><first-page>2326</first-page><last-page>2330</last-page><doi>10.3174/ajnr.A3632</doi></journal></bib-reference><bib-reference id="bib_chevillard_et_al_2006"><label>Chevillard et al., 2006</label><journal><aus><au><snm>Chevillard</snm></au><au><snm>Rugina</snm></au><au><snm>Bonfils</snm></au><au><snm>Bougara</snm></au><au><snm>Castillo</snm></au><au><snm>Crampette</snm></au></aus><atl>Evaluation of calcium alginate nasal packing (Algostéril) versus
                            Polyvinyl acetal (Merocel) for nasal packing after inferior turbinate
                            resection</atl><stl>Rhinology</stl><vol>44</vol><first-page>58</first-page><last-page>61</last-page><query>Q17: Provide the doi for “Chevillard et al., 2006, Weber et
                            al., 2000”.</query></journal></bib-reference><bib-reference id="bib_dalgic_et_al_2016"><label>Dalgic et al., 2016</label><journal><aus><au><snm>Dalgic</snm></au><au><snm>Is</snm></au><au><snm>Dinc</snm><fnm>M. E.</fnm></au><au><snm>Ulusoy</snm></au><au><snm>Avinçsal</snm><fnm>M. Ö.</fnm></au><au><snm>Kulekci</snm></au></aus><atl>The effects of nasal packing and transseptal suturing after septoplasty
                            on olfactory function, patient comfort, and mucociliary clearance</atl><stl>J. Craniofac. Surg.</stl><vol>27</vol><first-page>e487</first-page><last-page>e490</last-page><doi>10.1097/SCS.0000000000002805</doi></journal></bib-reference><bib-reference id="bib_de_beule_et_al_2009"><label>De Beule et al., 2009</label><journal><aus><au><snm>De Beule</snm></au><au><snm>Van Cauter</snm></au><au><snm>Mortier</snm></au><au><snm>Van Loo</snm></au><au><snm>Van Impe</snm></au><au><snm>Verdonck</snm></au></aus><atl>Virtual optimization of self-expandable braided wire stents</atl><stl>Med. Eng. Phys.</stl><vol>31</vol><first-page>448</first-page><last-page>453</last-page><doi>10.1016/j.medengphy.2008.11.008</doi></journal></bib-reference><bib-reference id="bib_ey_2015"><label>Eşki and Yılmaz, 2015</label><journal><aus><au><snm>Eşki</snm></au><au><snm>Yılmaz</snm><fnm>İ.</fnm></au></aus><atl>Pack free septoplasty: Functional outcomes and complications</atl><stl>Kulak. Burun. Bogaz. Ihtis. Derg.</stl><first-page>275</first-page><last-page>278</last-page><doi>10.5606/kbbihtisas.2015.01879</doi></journal></bib-reference><bib-reference id="bib_fu_et_al_2018"><label>Fu et al., 2018</label><journal><aus><au/><au/><au/><au/></aus><atl>Numerical investigations of the mechanical properties of braided
                            vascular stents</atl><stl>Biomed. Mat. Eng.</stl><vol>29</vol><first-page>81</first-page><last-page>94</last-page><doi>10.3233/BME-171714</doi></journal></bib-reference><bib-reference id="bib_garcía_et_al_2012"><label>García et al., 2012</label><journal><aus><au><snm>García</snm></au><au><snm>Peña</snm></au><au><snm>Martínez</snm><fnm>M. A.</fnm></au></aus><atl>Influence of geometrical parameters on radial force during
                            self-expanding stent deployment. Application for a variable radial
                            stiffness stent</atl><stl>J. Mech. Behav. Biomed. Mater.</stl><first-page>166</first-page><last-page>175</last-page><doi>10.1016/j.jmbbm.2012.02.006</doi></journal></bib-reference><bib-reference id="bib_he_et_al_2022"><label>He et al., 2022</label><journal><aus><au/><au/><au><snm>Silberschmidt</snm><fnm>V. V.</fnm></au><au><snm>Feng</snm></au><au><snm>Serracino-Inglott</snm></au></aus><atl>Personalised nitinol stent for focal plaques: Design and evaluation</atl><first-page>110873</first-page><doi>10.1016/j.jbiomech.2021.110873</doi></journal></bib-reference><bib-reference id="bib_kelly_et_al_2019"><label>Kelly et al., 2019</label><journal><aus><au><snm>Kelly</snm></au><au><snm>McGrath</snm><fnm>D. J.</fnm></au><au><snm>Sweeney</snm><fnm>C. A.</fnm></au><au><snm>Kurtenbach</snm></au><au><snm>Grogan</snm></au><au><snm>Jockenhoevel</snm></au></aus><atl>Comparison of computational modelling techniques for braided stent
                            analysis</atl><stl>Comput. Methods Biomechanics Biomed. Eng.</stl><vol>22</vol><iss>16</iss><first-page>1334</first-page><last-page>1344</last-page><doi>10.1080/10255842.2019.1663414</doi></journal></bib-reference><bib-reference id="bib_kim_et_al_2008"><label>Kim et al., 2008</label><journal><aus><au><fnm>J. H.</fnm></au><au><fnm>T. J.</fnm></au><au><fnm>W.-R.</fnm></au></aus><atl>Mechanical modeling of self-expandable stent fabricated using braiding
                            technology</atl><first-page>3202</first-page><last-page>3212</last-page><doi>10.1016/j.jbiomech.2008.08.005</doi></journal></bib-reference><bib-reference id="bib_klinger_and_siegert_1997"><label>Klinger and Siegert, 1997</label><journal><aus><au><snm>Klinger</snm></au><au><snm>Siegert</snm></au></aus><adate>1997</adate><atl>Microcirculation of the nasal mucosa during use of balloon tamponade</atl><stl>Laryngorhinootologie.</stl><vol>76</vol><first-page>127</first-page><last-page>130</last-page><doi>10.1055/s-2007-997400</doi></journal></bib-reference><bib-reference id="bib_maleckis_et_al_2018"><label>Maleckis et al., 2018</label><journal><aus><au><snm>Maleckis</snm></au><au><snm>Anttila</snm></au><au><snm>Aylward</snm></au><au><snm>Poulson</snm></au><au><snm>Desyatova</snm></au><au><snm>MacTaggart</snm></au></aus><atl>Nitinol stents in the femoropopliteal artery: A mechanical perspective
                            on material, design, and performance</atl><stl>Ann. Biomed. Eng.</stl><first-page>684</first-page><last-page>704</last-page><doi>10.1007/s10439-018-1990-1</doi></journal></bib-reference><bib-reference id="bib_mcgrath_et_al_2014"><label>McGrath et al., 2014</label><journal><aus><au><snm>O Brien</snm></au><au><snm>Bruzzi</snm></au><au><snm>McHugh</snm></au></aus><atl>Nitinol stent design - understanding axial buckling</atl><first-page>252</first-page><last-page>263</last-page><doi>10.1016/j.jmbbm.2014.08.029</doi></journal></bib-reference><bib-reference id="bib_mckenna_and_vaughan_2021"><label>McKenna and Vaughan, 2021</label><journal><aus><au><snm>McKenna</snm><fnm>C. G.</fnm></au><au><snm>Vaughan</snm></au></aus><atl>A finite element investigation on design parameters of bare and
                            polymer-covered self-expanding wire braided stents</atl><first-page>104305</first-page><doi>10.1016/j.jmbbm.2020.104305</doi></journal></bib-reference><bib-reference id="bib_mori_and_saito_2005"><label>Mori and Saito, 2005</label><journal><aus><au><snm>Mori</snm></au><au><snm>Saito</snm></au></aus><adate>2005</adate><atl>Effects of stent structure on stent flexibility measurements</atl><first-page>733</first-page><last-page>742</last-page><doi>10.1007/s10439-005-2807-6</doi></journal></bib-reference><bib-reference id="bib_ni_et_al_2015"><label>Ni et al., 2015</label><journal><aus><au><fnm>X.-Y.</fnm></au><au><fnm>C.-W.</fnm></au><au><snm>Gangadhara Prusty</snm></au></aus><atl>Numerical investigations of the mechanical properties of a braided
                            non-vascular stent design using finite element method</atl><first-page>1117</first-page><last-page>1125</last-page><doi>10.1080/10255842.2013.873420</doi></journal></bib-reference><bib-reference id="bib_petrini_et_al_2016"><label>Petrini et al., 2016</label><journal><aus><au><snm>Petrini</snm></au><au><snm>Trotta</snm></au><au><snm>Dordoni</snm></au><au><snm>Lawford</snm><fnm>P. V.</fnm></au></aus><atl>A computational approach for the prediction of fatigue behaviour in
                            peripheral stents: Application to a clinical case</atl><first-page>536</first-page><last-page>547</last-page><doi>10.1007/s10439-015-1472-7</doi></journal></bib-reference><bib-reference id="bib_ribeiro_et_al_2021"><label>Ribeiro et al., 2021</label><journal><aus><au><snm>Ribeiro</snm><fnm>N. S.</fnm></au><au><snm>Folgado</snm></au><au><snm>Rodrigues</snm><fnm>H. C.</fnm></au></aus><atl>Surrogate-based visualization and sensitivity analysis of coronary
                            stent performance: A study on the influence of geometric design</atl><stl>Int. J. Numer. Method. Biomed. Eng.</stl><vol>37</vol><first-page>e3125</first-page><doi>10.1002/cnm.3125</doi></journal></bib-reference><bib-reference id="bib_san_nicoló_et_al_2020"><label>San Nicoló et al., 2020</label><journal><aus><au><snm>San Nicoló</snm></au><au><snm>Berghaus</snm></au><au><snm>Jacobi</snm></au><au><snm>Kisser</snm></au><au><snm>Haack</snm></au><au><snm>Flatz</snm></au></aus><atl>The nasal valve: New insights on the static and dynamic NV with
                            MR-imaging</atl><stl>Eur. Arch. Otorhinolaryngol.</stl><first-page>463</first-page><last-page>467</last-page><doi>10.1007/s00405-019-05715-y</doi></journal></bib-reference><bib-reference id="bib_shi_et_al_2020"><label>Shi et al., 2020</label><journal><aus><au/><au/><au><snm>Jin</snm></au><au/></aus><atl>Study on the bending behavior of biodegradable metal cerebral vascular
                            stents using finite element analysis</atl><vol>108</vol><first-page>109856</first-page><doi>10.1016/j.jbiomech.2020.109856</doi></journal></bib-reference><bib-reference id="bib_stoeckel_et_al_2004"><label>Stoeckel et al., 2004</label><journal><aus><au><snm>Stoeckel</snm></au><au><snm>Pelton</snm></au><au><snm>Duerig</snm></au></aus><adate>2004</adate><atl>Self-expanding nitinol stents: Material and design considerations</atl><stl>Eur. Radiol.</stl><first-page>292</first-page><last-page>301</last-page><doi>10.1007/s00330-003-2022-5</doi></journal></bib-reference><bib-reference id="bib_tan_et_al_2001"><label>Tan et al., 2001</label><journal><aus><au><snm>Tan</snm></au><au><snm>Webb</snm><fnm>D. C.</fnm></au><au><snm>Kormi</snm></au><au><snm>Al-Hassani</snm><fnm>S. T.</fnm></au></aus><adate>2001</adate><atl>A method for investigating the mechanical properties of intracoronary
                            stents using finite element numerical simulation</atl><stl>Int. J. Cardiol.</stl><vol>78</vol><first-page>51</first-page><last-page>67</last-page><doi>10.1016/s0167-5273(00)00472-1</doi></journal></bib-reference><bib-reference id="bib_wang_et_al_2006"><label>Wang et al., 2006</label><journal><aus><au><fnm>W.-Q.</fnm></au><au><fnm>D.-K.</fnm></au><au><fnm>D.-Z.</fnm></au><au><snm>Qi</snm></au></aus><atl>Analysis of the transient expansion behavior and design optimization of
                            coronary stents by finite element method</atl><vol>39</vol><last-page>32</last-page><doi>10.1016/j.jbiomech.2004.11.003</doi></journal></bib-reference><bib-reference id="bib_weber_et_al_2000"><label>Weber et al., 2000</label><journal><aus><au><snm>Weber</snm></au><au><snm>Hochapfel</snm></au><au><snm>Draf</snm></au></aus><adate>2000</adate><atl>Packing and stents in endonasal surgery</atl><vol>38</vol><first-page>49</first-page><last-page>62</last-page></journal></bib-reference><bib-reference id="bib_weber_et_al_2001"><label>Weber et al., 2001</label><journal><aus><au><snm>Keerl</snm></au><au><snm>Toffel</snm><fnm>P. H.</fnm></au></aus><atl>Packing in endonasal surgery</atl><stl>Am. J. Otolaryngology</stl><first-page>306</first-page><last-page>320</last-page><doi>10.1053/ajot.2001.26499</doi></journal></bib-reference><bib-reference id="bib_yu_et_al_2022"><label>Yu et al., 2022</label><journal><aus><au/><au/><au/><au/></aus><atl>Clinical control study of application of nasal stent and merocel sponge
                            after nasal septoplasty</atl><stl>Chin. J. otorhinolarynglogy-skull base Surg.</stl><iss>04</iss><first-page>63</first-page></journal></bib-reference><bib-reference id="bib_zaccaria_et_al_2020"><label>Zaccaria et al., 2020</label><journal><aus><au><snm>Zaccaria</snm></au><au><snm>Pennati</snm></au></aus><atl>Modeling of braided stents: Comparison of geometry reconstruction and
                            contact strategies</atl><vol>107</vol><first-page>109841</first-page><doi>10.1016/j.jbiomech.2020.109841</doi></journal></bib-reference><bib-reference id="bib_zaccaria_et_al_2021"><label>Zaccaria et al., 2021</label><journal><aus/><atl>Analytical methods for braided stents design and comparison with FEA</atl><vol>119</vol><first-page>104560</first-page><doi>10.1016/j.jmbbm.2021.104560</doi></journal></bib-reference><bib-reference id="bib_záhora_et_al_2007"><label>Záhora et al., 2007</label><journal><aus><au><snm>Záhora</snm></au><au><snm>Bezrouk</snm></au><au><snm>Hanus</snm></au></aus><atl>Models of stents - comparison and applications</atl><stl>Physiol. Res.</stl><vol>56</vol><first-page>S115</first-page><last-page>S121</last-page><doi>10.33549/physiolres.931309</doi></journal></bib-reference><bib-reference id="bib_zhang_et_al_2022"><label>Zhang et al., 2022</label><journal><aus><au/><au/><au><snm>Ji</snm></au><au/><au/></aus><atl>Orthogonal optimization research on various nozzles of high-speed
                            centrifugal spinning</atl><stl>Front. Bioeng. Biotechnol.</stl><first-page>884316</first-page><doi>10.3389/fbioe.2022.884316</doi></journal></bib-reference></bibliography-sec></bibreference><figuregroup id="fig1"><figcaption id="fig1"><text>Scheme of nasal stent working in nasal cavity.  Digital model of
                    nasal airway with nasal stent.  Sagittal view of nasal cavity. 
                    Coronal images of nasal endoscope. <math><mrow><mo>,</mo></mrow></math>
                    nasal valve angle; MT, middle turbinate; IT, inferior turbinate; ✽,
                    choana.</text></figcaption></figuregroup><figuregroup id="fig2"><figcaption id="fig2"><text>Design parameters of nasal stent model.  Three types of nasal stent
                    model, S, M and L.  Braided geometrical parameters of nasal stent. (a)
                    Geometrical model: external stent diameter (), stent length ().
                    (b) Detail View of stent: braiding angle (), wire diameter ().
                    (c) Cross-sectional area: interlaced ﻿configuration of the braiding wires
                    inside the stents.  Material property: <sub><i>tL</i></sub><i/><sup><i>S</i></sup><i>, σ</i><sup/> loading phase transformation starts/ends
                    stress; <sub><i>tU</i></sub><sub><i>cL</i></sub><i>un</i>loading phase transformation
                    starts/ends stress; <i>ε</i> uniaxial transformation strain.</text></figcaption></figuregroup><figuregroup id="fig3"><figcaption id="fig3"><text>Schemes of the performed simulations.  Compression simulation. <b>
                    (B)</b> Bending simulation.</text></figcaption></figuregroup><figuregroup id="fig4"><figcaption id="fig4"><text>Experimental verification.  Comparation of compressive processes
                    between numerical simulation and experiment (a) Finite element analysis for
                    testing the compressive behavior of the stents (b) Configuration used for
                    testing the compressive behavior of the stents.  Comparison of
                    force-displacement curve of compression simulation with experiments.</text></figcaption></figuregroup><figuregroup id="fig5"><figcaption id="fig5"><text>Response surface diagram of reaction force and comparison of the elongation
                    deformation.  Comparison the reaction forces of different stent model
                    types in front view/top view (a) Reaction force of S stent under different wire
                    diameter () and braiding angle (). (b) Reaction force of M
                    stent under different wire diameter () and braiding angle ().
                    (c) Reaction force of L stent under different wire diameter () and
                    braiding angle ().  Comparison of the elongation
                    deformation of stent with 60°/45°/30°braiding angle respectively.</text></figcaption></figuregroup><figuregroup id="fig6"><figcaption id="fig6"><text>Response surface diagram of bending stiffness and comparison of the maximum
                    von-Mises.  Comparison the bending stiffness of different stent model
                    types in front view/top view: (a) Bending stiffness of S stent under different
                    wire diameter () and braiding angle (). (b) Bending
                    stiffness of M stent under different wire diameter () and braiding angle
                    (). (c) Bending stiffness of L stent under different wire diameter
                    () and braiding angle ().  Comparison of the
                    maximum von-Mises of stent with 60°/45°/30°braiding angle
                    respectively.</text></figcaption></figuregroup><figuregroup id="fig7"><figcaption id="fig7"><label>FIGURE 7</label><text>Contour plots of von-Mises Stress of the bended nasal stent: Stent model S.</text></figcaption></figuregroup><figuregroup id="fig8"><figcaption id="fig8"><label>FIGURE 8</label><text>Contour plots of von-Mises Stress of the bended nasal stent: Stent model M.</text></figcaption></figuregroup><figuregroup id="fig9"><figcaption id="fig9"><label>FIGURE 9</label><text>Contour plots of von-Mises Stress of the bended nasal stent: Stent model L.</text></figcaption></figuregroup><tablegroup><tablecaption id="tbl1"><text>Parameter values of superelastic model for nitinol (<xref id="bib_he_et_al_2022" title="bib_he_et_al_2022">He et al., 2022</xref>).</text></tablecaption><table frame="topbot"><thead><tr><td colspan="1"><p><sup><i>ρ(t/mm3)</i></sup></p></td><td colspan="1"><p> (MPa)</p></td><td colspan="1"><p/></td><td colspan="1"><p> (MPa)</p></td><td colspan="1"><p/></td><td colspan="1"><p/></td><td colspan="1"><p> (MPa)</p></td><td colspan="1"><p> (MPa)</p></td><td colspan="1"><p> (MPa)</p></td><td colspan="1"><p> (MPa)</p></td><td colspan="1"><p> (MPa)</p></td></tr></thead><tbody><tr><td colspan="1"><p>6.45E-09</p></td><td colspan="1"><p>68000</p></td><td colspan="1"><p>0.3</p></td><td colspan="1"><p>36000</p></td><td colspan="1"><p>0.06</p></td><td colspan="1"><p>520</p></td><td colspan="1"><p>635</p></td><td colspan="1"><p>250</p></td><td colspan="1"><p>150</p></td><td colspan="1"><p>780</p></td></tr></tbody></table></tablegroup><tablegroup><tablecaption id="tbl2"><text>Factors and levels of the orthogonal test of the nasal stent.</text></tablecaption><table frame="topbot"><thead><tr><td colspan="1" rowspan="3"><p>Level</p></td><td colspan="3"><p>Factor</p></td></tr><tr><td colspan="1"><p>A</p></td><td colspan="1"><p>B</p></td><td colspan="1"><p>C</p></td></tr><tr><td colspan="1"><p>Diameter of wire  (mm)</p></td><td colspan="1"><p>Braiding angle</p></td><td colspan="1"><p>External diameter of stent  (mm)</p></td></tr></thead><tbody><tr><td colspan="1"><p>1</p></td><td colspan="1"><p>0.09</p></td><td colspan="1"><p>60</p></td><td colspan="1"><p>15</p></td></tr><tr><td colspan="1"><p>2</p></td><td colspan="1"><p>0.11</p></td><td colspan="1"><p>45</p></td><td colspan="1"><p>20</p></td></tr><tr><td colspan="1"><p>3</p></td><td colspan="1"><p>0.13</p></td><td colspan="1"><p>30</p></td><td colspan="1"><p>25</p></td></tr></tbody></table></tablegroup><tablegroup><tablecaption id="tbl3"><text>Results of the orthogonal test using weight grade method of the nasal stent.</text></tablecaption><table frame="topbot"><thead><tr><td colspan="1" rowspan="2"><p>Trial</p></td><td colspan="2"><p>Experiment index</p></td><td colspan="1" rowspan="2"><p><math><mrow/></math>
                                *</p></td></tr><tr><td colspan="1"><p><math><mrow><msup><mn>1</mn></msup></mrow></math></p></td><td colspan="1"><p><math><mrow><msup/></mrow></math></p></td></tr></thead><tbody><tr><td colspan="1"><p>0.00</p></td></tr><tr><td colspan="1"><p>10.97</p></td><td colspan="1"><p>19.14</p></td><td colspan="1"><p>13.42</p></td></tr><tr><td colspan="1"><p>18.14</p></td><td colspan="1"><p>14.88</p></td><td colspan="1"><p>17.16</p></td></tr><tr><td colspan="1"><p>4</p></td><td colspan="1"><p>9.70</p></td><td colspan="1"><p>17.43</p></td><td colspan="1"><p>12.02</p></td></tr><tr><td colspan="1"><p>5</p></td><td colspan="1"><p>30.59</p></td><td colspan="1"><p>36.16</p></td><td colspan="1"><p>32.26</p></td></tr><tr><td colspan="1"><p>6</p></td><td colspan="1"><p>43.25</p></td><td colspan="1"><p>37.49</p></td><td colspan="1"><p>41.52</p></td></tr><tr><td colspan="1"><p>7</p></td><td colspan="1"><p>41.77</p></td><td colspan="1"><p>43.56</p></td><td colspan="1"><p>42.31</p></td></tr><tr><td colspan="1"><p>8</p></td><td colspan="1"><p>63.08</p></td><td colspan="1"><p>52.60</p></td><td colspan="1"><p>59.94</p></td></tr><tr><td colspan="1"><p>9</p></td><td colspan="1"><p>100.00</p></td></tr></tbody></table></tablegroup><tablegroup><tablecaption id="tbl4"><label>TABLE 4</label><text>Results of the orthogonal test of the nasal stent.<query>Q18: Kindly check
                    Tables 4 and 5 Captions are identical.</query></text></tablecaption><table frame="topbot"><thead><tr><td colspan="3"><p>﻿Experiment index</p></td></tr><tr><td colspan="1"><p>Reaction force (N)</p></td><td colspan="1"><p>Elongation deformation (mm)</p></td><td colspan="1"><p>Bending stiffness (N・mm)</p></td></tr></thead><tbody><tr><td colspan="1"><p>0.67</p></td><td colspan="1"><p>28.65</p></td><td colspan="1"><p>3.13</p></td></tr><tr><td colspan="1"><p>1.19</p></td><td colspan="1"><p>72.21</p></td><td colspan="1"><p>8.75</p></td></tr><tr><td colspan="1"><p>1.53</p></td><td colspan="1"><p>32.83</p></td><td colspan="1"><p>7.50</p></td></tr><tr><td colspan="1"><p>1.13</p></td><td colspan="1"><p>64.86</p></td><td colspan="1"><p>8.25</p></td></tr><tr><td colspan="1"><p>2.12</p></td><td colspan="1"><p>32.70</p></td><td colspan="1"><p>13.75</p></td></tr><tr><td colspan="1"><p>2.72</p></td><td colspan="1"><p>28.05</p></td><td colspan="1"><p>14.14</p></td></tr><tr><td colspan="1"><p>2.65</p></td><td colspan="1"><p>31.00</p></td><td colspan="1"><p>15.63</p></td></tr><tr><td colspan="1"><p>3.66</p></td><td colspan="1"><p>27.29</p></td><td colspan="1"><p>18.75</p></td></tr><tr><td colspan="1"><p>5.41</p></td><td colspan="1"><p>62.22</p></td><td colspan="1"><p>32.50</p></td></tr></tbody></table></tablegroup><tablegroup><tablecaption id="tbl5"><label>TABLE 5</label><text>Results of the orthogonal test of the nasal stent.</text></tablecaption><table frame="topbot"><thead><tr><td colspan="2" rowspan="2"><p>Factor No</p></td></tr></thead><tbody><tr><td colspan="1" rowspan="3"><p>Ki</p></td><td colspan="1"><p>10.20</p></td><td colspan="1"><p>18.11</p></td><td colspan="1"><p>33.82</p></td></tr><tr><td colspan="1"><p>28.60</p></td><td colspan="1"><p>35.21</p></td><td colspan="1"><p>30.58</p></td></tr><tr><td colspan="1"><p>47.94</p></td><td colspan="1"><p>52.90</p></td><td colspan="1"><p>41.81</p></td></tr><tr><td colspan="1"><p>R</p></td><td colspan="1"><p>37.74</p></td><td colspan="1"><p>34.78</p></td><td colspan="1"><p>-8.00</p></td></tr><tr><td colspan="1"><p>Importance sequence</p></td></tr><tr><td colspan="1"><p>The optimum level</p></td><td colspan="1"><p>A3</p></td><td colspan="1"><p>B3</p></td><td colspan="1"><p>C3</p></td></tr></tbody></table></tablegroup></tail></article><article><meta><aid>fbioe-2023-1066391</aid><doi>10.3389/fbioe.2023.1066391</doi></meta><head><lrh><query>LRH: <ins>Maltz-Matyschsyk et al.</ins></query></lrh><rrh><query>RRH: <url url="https://doi.org/10.3389/fbioe.2023.1066391" title="https://doi.org/10.3389/fbioe.2023.1066391">10.3389/fbioe.2023.1066391</url></query></rrh><articletitle>Development of a <ins rule="ACEtool_articletitleShouldBeInSentenceCase">b</ins><del rule="ACEtool_articletitleShouldBeInSentenceCase">B</del>iomarker ignature using <ins rule="ACEtool_articletitleShouldBeInSentenceCase">g</ins><del rule="ACEtool_articletitleShouldBeInSentenceCase">G</del>rating coupled <ins rule="ACEtool_articletitleShouldBeInSentenceCase">f</ins><del rule="ACEtool_articletitleShouldBeInSentenceCase">F</del>luorescence <ins rule="ACEtool_articletitleShouldBeInSentenceCase">p</ins><del rule="ACEtool_articletitleShouldBeInSentenceCase">P</del>lasmonic <ins rule="ACEtool_articletitleShouldBeInSentenceCase">m</ins><del rule="ACEtool_articletitleShouldBeInSentenceCase">M</del>icroarray for diagnosis of
            MIS-C<query>Q1: Confirm whether the article title is correct. </query></articletitle><aug><authors><query>Q2: The citation and surnames of all of the authors have been highlighted.
                    Check that they are correct and consistent with your previous publications, and
                    correct them if needed. Please note that this may affect the indexing of your
                    article in repositories such as PubMed. If adding/removing authors, or changing
                    the order of this list, please provide us with a signed . </query><au id="au1"><fnm>Michele</fnm><snm>Maltz-Matyschsyk</snm><sup><xref rid="authorid:https://loop.frontiersin.org/people/124485/overview" title="authorid:https://loop.frontiersin.org/people/124485/overview">
                            AUTHORID</xref></sup></au><au id="au2"><fnm>Clare K.</fnm><snm>Melchiorre</snm></au><au id="au3"><fnm>Katherine W.</fnm><snm>Herbst</snm></au><au id="au4"><fnm>Alexander H.</fnm><snm>Hogan</snm></au><au id="au5"><fnm>Kristina</fnm><snm>Dibble</snm></au><au id="au6"><fnm>Brandon</fnm><snm>O’Sullivan</snm></au><au id="au7"><fnm>Joerg</fnm><snm>Graf</snm></au><au id="au8"><fnm>Aishwarya</fnm><snm>Jadhav</snm></au><au id="au9"><fnm>David A.</fnm><snm>Lawrence</snm><sup><xref id="aff5" title="aff5">5</xref></sup></au><au id="au10"><fnm>William T.</fnm></au><au id="au11"><fnm>Kyle J.</fnm></au><au id="au12"><fnm>Justin D.</fnm><snm>Radolf</snm></au><au id="au13"><fnm>Juan C.</fnm><snm>Salazar</snm></au><au id="au14"><fnm>Michael A.</fnm><snm>Lynes</snm></au><collab>Connecticut Children’s COVID</collab><query>Q3: If the following authors would like their LOOP profile to be linked to
                    the final published version, ensure that they with Frontiers at the provided
                    link, and provide us with the URLs to their profile(s). Non-registered authors
                    and authors with profiles set to "Private" will have the default profile image
                    displayed. Note that we will not be able to add profile links after
                    publication. Alexander H. Hogan Kristina Dibble Aishwarya
                    Jadhav Kyle J. Carson </query><query>Q4: There is a discrepancy between the styling of the author names in the
                    submission system and the manuscript. We have used [Clare K. Melchiorre, David
                    A. Lawrence, William T. Lee, Justin D. Radolf, Juan C. Salazar] instead of [C
                    lare Melchiorre, David Lawrence, William Lee, Justin David Radolf, Juan Carlos
                    Salazar ]. Please confirm that it is correct. </query></authors><aff id="aff1"><text><affnorg>Department of Molecular and Cell Biology</affnorg><affnorg>University of Connecticut</affnorg><affncity>Storrs</affncity><affnstate>CT</affnstate><affncountry>United States</affncountry><query>Q5: Confirm that all author affiliations are correctly listed. Per our
                        style guidelines, affiliations are listed sequentially and follow author
                        order. Requests for non-sequential affiliation listing will not be
                        fulfilled. Note that affiliations should reflect those at the time during
                        which the work was undertaken. If adding new affiliations, specify if these
                        should be listed as a present address instead of a regular affiliation. </query></text></aff><aff id="aff2"><text><affnorg>Connecticut Children’s Medical Center</affnorg><affncity>Hartford</affncity></text></aff><aff id="aff3"><label/><text><affnorg>University of Connecticut Health Center</affnorg><affncity>Farmington</affncity></text></aff><aff id="aff4"><label/><text><affnorg>Wadsworth Center</affnorg><affnorg>New York State Department of Health</affnorg><affncity>Albany</affncity><affnstate>NY</affnstate></text></aff><aff id="aff5"><label/><text><affnorg>University at Albany School of Public Health</affnorg><affncity>Rensselaer</affncity></text></aff><cor id="corlowast"><text>Correspondence: Michael A. Lynes, <e-address type="email">
                    Michael.Lynes@uconn.edu</e-address><query>Q6: Confirm that the email address in
                    your correspondence section is accurate. Any changes to corresponding authors
                    requires individual confirmation from all original and added/removed
                    corresponding authors. </query></text></cor><fneditedby><url url="https://loop.frontiersin.org/people/1449777/overview" title="https://loop.frontiersin.org/people/1449777/overview">Zhiyang Li</url>,
                Nanjing Drum Tower Hospital, China</fneditedby><fneditedby><url url="https://loop.frontiersin.org/people/1270657/overview" title="https://loop.frontiersin.org/people/1270657/overview">Lei Li</url>, St.
                Jude Children<ins rule="ACEtool_rule_change_apostrophes_to_straight_quotes-1_except_secionaAppsectiona">
                ’</ins><del rule="ACEtool_rule_change_apostrophes_to_straight_quotes-1_except_secionaAppsectiona">
                '</del>s Research Hospital, United States<xref id="https://loop.frontiersin.org/people/415292/overview" title="https://loop.frontiersin.org/people/415292/overview">Robert H.</xref><url url="https://loop.frontiersin.org/people/415292/overview" title="https://loop.frontiersin.org/people/415292/overview"> Austin</url>,
                Princeton University, United States</fneditedby><fnother><p xmlns:m="http://www.w3.org/1998/Math/MathML/">This article was submitted to
                    Biosensors and Biomolecular Electronics, a section of the journal Frontiers in
                    Bioengineering and Biotechnology</p></fnother></aug><abs><abstract-sec><simple-para>Multisystem inflammatory syndrome in children (MIS-C) is a rare but
                    serious condition that can develop 4<ins rule="ACEtool_rule-ndash-numbers-3_ignoreRangewithFold">–</ins><del rule="ACEtool_rule-ndash-numbers-3_ignoreRangewithFold">-</del>6<ins> </ins>weeks after a school age child becomes infected by SARS-CoV-2. To date,
                    in the United States more than 8,862 cases of MIS-C have been identified and 72
                    deaths have occurred. This syndrome typically affects children between the ages
                    of 5<ins rule="ACEtool_rule_ndash_numRangePreceededbyKeyterms_ignoreRangewithFold">
                    –</ins>13;
                    57% are Hispanic/Latino/Black/non-Hispanic, 61% of patients are males and 100%
                    have either tested positive for SARS-CoV-2 or had direct contact with someone
                    with COVID-19. Unfortunately, diagnosis of MIS-C is difficult, and delayed
                    diagnosis can lead to cardiogenic shock, intensive care admission, and prolonged
                    hospitalization. There is no validated biomarker for the rapid diagnosis of
                    MIS-C. In this study, we used Grating Coupled Fluorescence Plasmonic (GCFP)
                    microarray technology to develop biomarker signatures in pediatric salvia and
                    serum samples from patients with MIS-C in the United States and Colombia. GCFP
                    measures antibody-antigen interactions at individual regions of interest (ROIs)
                    on a gold-coated diffraction grating sensor chip in a sandwich immunoassay to
                    generate a fluorescent signal based on analyte presence within a sample. Using a
                    microarray printer, we designed a first-generation biosensor chip with the
                    capability of capturing 33 different analytes from 80<math/>
                    of sample (saliva or serum). Here, we show potential biomarker signatures in
                    both saliva and serum samples in six patient cohorts. In saliva samples, we
                    noted occasional analyte outliers on the chip within individual samples and were
                    able to compare those samples to 16S RNA microbiome data. These comparisons
                    indicate differences in relative abundance of oral pathogens within those
                    patients. Microsphere Immunoassay (MIA) of immunoglobulin isotypes was also
                    performed on serum samples and revealed MIS-C patients had several COVID
                    antigen-specific immunoglobulins that were significantly higher than other
                    cohorts, thus identifying potential new targets for the second-generation
                    biosensor chip. MIA also identified additional biomarkers for our
                    second-generation chip, verified biomarker signatures generated on the
                    first-generation chip, and aided in second-generation chip optimization.
                    Interestingly, MIS-C samples from the United States had a more diverse and
                    robust signature than the Colombian samples, which was also illustrated in the
                    MIA cytokine data. These observations identify new MIS-C biomarkers and
                    biomarker signatures for each of the cohorts. Ultimately, these tools may
                    represent a potential diagnostic tool for use in the rapid identification of
                    MIS-C.<query>Q7: The abstract should ideally be structured according to the
                    IMRaD format (Introduction, Methods, Results and Discussion). Provide a
                    structured abstract if possible. </query></simple-para></abstract-sec></abs><keywordsdefault><kwd>COVID<ins rule="ACEtool_UCA_rule_usage_of_term_COVID-19" blackbox="true">-</ins>19</kwd><kwd>MIS-C</kwd><kwd>diagnostic</kwd><kwd>biomarkers</kwd><kwd>icroarray</kwd><query>Q8: Confirm that the keywords are correct, and keep them to a maximum of eight
                and a minimum of five. (Note: a keyword can be made up of one or more words.). </query></keywordsdefault><funding-group><award-group><awardrecipient>10.13039/100000002</awardrecipient><fundsource>National Institutes of Health</fundsource></award-group></funding-group></head><body><seca id="sec1"><sectitle>Introduction<query>Q9: Check if the section headers (i.e., section leveling)
                have been correctly captured. </query></sectitle><paragraph>Acute pediatric SARS-CoV-2 infections, although usually mild, have
                hospitalized over 150,000 children since the coronavirus disease-2019 (COVID-19)
                pandemic began (<url url="https://covid.cdc.gov/covid-data-tracker/" title="https://covid.cdc.gov/covid-data-tracker/">
                https://covid.cdc.gov/covid-data-tracker/#new-hospital-admissions</url>). In rare
                instances, two to <ins rule="ACEtool_rule-spelloutToNumeral_CalendarUnits">6 </ins><del rule="ACEtool_rule-spelloutToNumeral_CalendarUnits">six </del>weeks after an
                acute infection, children can develop a severe inflammatory disorder known as
                multisystem inflammatory syndrome in children (MIS-C) (<xref id="bib_guimarães_et_al_2021" title="bib_guimarães_et_al_2021">Guimarães
                et al., 2021</xref>; <xref id="bib_radia_et_al_2021" title="bib_radia_et_al_2021">Radia
                et al., 2021</xref>). The syndrome is non-specific and is associated with, but not
                limited to, the following symptoms: abdominal pain, diarrhea, vomiting, rashes, red
                eyes, red or swollen hands/feet, red cracked lips, cough, sore throat, fever,
                cardiovascular dysfunction, and respiratory dysfunction (<xref id="bib_feldstein_et_al_2020" title="bib_feldstein_et_al_2020">Feldstein et al.,
                2020</xref>; <xref id="bib_ramaswamy_et_al_2020" title="bib_ramaswamy_et_al_2020">Ramaswamy
                et al., 2020</xref>; <xref id="bib_guimarães_et_al_2021" title="bib_guimarães_et_al_2021">Guimarães et al., 2021</xref>; <xref id="bib_radia_et_al_2021" title="bib_radia_et_al_2021">Radia et al., 2021</xref>
                ; <xref id="bib_algarni_and_alghamdi_2022" title="bib_algarni_and_alghamdi_2022">Algarni
                and Alghamdi. 2022</xref>). According to the CDC as of <ins rule="ACEtool_UKVersionForDatePattern_1">30 January</ins><del rule="ACEtool_UKVersionForDatePattern_1">January 30,</del> 2023 in the US there
                have been 9,344 MIS-C patients (“CDC COVID Data Tracker: Multisystem
                Inflammatory Syndrome in Children (MIS-C)” n.d.). Half of children with MIS-C
                are admitted to the intensive care unit (ICU) and 76 children have died from MIS-C.
                Unfortunately, MIS-C symptoms and the associated immune response mimics other
                inflammatory diseases. For example, Kawasaki disease (an acute and self-limited
                vasculitis of unknown etiology) shares many clinical and laboratory markers with
                MIS-C (e.g,
                fever, rash, red eyes, inflammatory markers) leading to misdiagnosis and delaying
                definitive management (<xref id="bib_newburger_et_al_2016" title="bib_newburger_et_al_2016">Newburger et al., 2016</xref>; <xref id="bib_phamduy_et_al_2021" title="bib_phamduy_et_al_2021">Phamduy et al., 2021</xref>
                ).</paragraph><paragraph>Diagnosing MIS-C and Kawasaki (and atypical Kawasaski Disaease) often depends
                on blood laboratory markers; however, venipunctures can be invasive and traumatic,
                and it can be difficult to collect substantial blood volumes in pediatric patients (<xref id="bib_bagnasco_et_al_2012" title="bib_bagnasco_et_al_2012">Bagnasco et al.,
                2012</xref>). The development of a simple and fast diagnostic tool that requires
                small volumes of serum or saliva to distinguish between these inflammatory diseases
                would help decrease diagnostic time and allow for optimized treatment options.<ins/>
                (<xref id="bib_li_et_al_2020b" title="bib_li_et_al_2020b">Li et al., 2020</xref>; <xref id="bib_mahmoud_et_al_2021" title="bib_mahmoud_et_al_2021">Mahmoud et al., 2021</xref>
                )<ins rule="ACEtool_LE_rule_remove_punctuations_before_opening_bracket_Insert_after_closing_bracket_withoutListA">
                .</ins> Current approaches to the analysis of biofluids using bead-based multiplex
                ELISA immunoassays, multi-parameter flow cytometry, reverse phase arrays, 2-D gel
                electrophoresis, 2-D differential in-gel electrophoresis (2-D DIGE), and antibody
                (Ab) microarrays can be time consuming, demanding of larger sample sizes, and labor
                intensive. (<xref id="bib_amanullah_et_al_2002" title="bib_amanullah_et_al_2002">Amanullah
                et al., 2002</xref>; <xref id="bib_noordin_and_nurulhasanah_2013" title="bib_noordin_and_nurulhasanah_2013">Noordin and Nurulhasanah, 2013</xref>).
                In this study, we created a novel grating-coupled fluorescent plasmonics (GCFP)
                microarray assay using 33 analytes to define the biosignatures of children effected
                by SARS-CoV-2 infection. In previous studies, GCFP has been demonstrated to be a
                highly sensitive tool for exploring proteomic profiles in both serum and saliva (<xref id="bib_molony_et_al_2012" title="bib_molony_et_al_2012">Molony et al., 2012</xref>
                ; <xref id="bib_rice_et_al_2012" title="bib_rice_et_al_2012">Rice et al., 2012</xref>
                ; <xref id="bib_chou_et_al_2020" title="bib_chou_et_al_2020">Chou et al., 2020</xref>
                ; <xref id="bib_cady_et_al_2021" title="bib_cady_et_al_2021">Cady et al., 2021</xref>).
                In brief, this technology is on based surface plasmon resonance (SPR): the physical
                phenomenon of energy transfer at a metal-dielectric interface (<xref id="fig1" title="fig1">Figures 1A,B</xref>) (<xref id="bib_unfricht_et_al_2005" title="bib_unfricht_et_al_2005">Unfricht et al.,
                2005</xref>; <xref id="bib_jin_et_al_2006" title="bib_jin_et_al_2006">Jin et al.,
                2006</xref>; <xref id="bib_marusov_et_al_2012" title="bib_marusov_et_al_2012">Marusov
                et al., 2012</xref>; <xref id="bib_molony_et_al_2012" title="bib_molony_et_al_2012">Molony
                et al., 2012</xref>; <xref id="bib_chou_et_al_2020" title="bib_chou_et_al_2020">Chou
                et al., 2020</xref>). Under specific optical conditions, the energy of the light
                excites electron density oscillation (the plasmon) within the metal coating on the
                sensor chip, reducing the intensity of the reflected light. Using the diffraction
                grating on the chip, the wave vector of the illuminating beam of light can be
                matched with the plasmon wave vector. The gold grating plus the use of a fluorophore
                increases the collected light, thereby enhancing the signal (<xref id="fig1" title="fig1">Figure 1B</xref>) (<xref id="bib_reilly_et_al_2006" title="bib_reilly_et_al_2006">Reilly et al., 2006</xref>). Here we describe a
                new approach to MIS-C diagnostics that can be applied to both serum and saliva
                analysis. We demonstrate that the modification of a gold-coated nanoscale grating
                surface chip with capture antibodies targeting different analytes in a biofluid
                sample, combined with the use of surface plasmon resonance-enhanced fluorescence,
                assesses biomarkers simultaneously creating a biomarker signature (including both
                positive and negative detection), which can potentially distinguish MIS-C from other
                diseases. This assay combines the detection of several biomarkers into a biomarker
                signature, and we hypothesize that testing numerous biomarkers increases the
                likelihood of developing a robust biosignature for MIS-C. We also identify potential
                new markers of MIS-C and optimize sensitivity of current analytes within the
                microarray, which along with ongoing studies will inform the design of a
                second-generation chip that is more specific to MIS-C.</paragraph></seca><seca id="sec2"><sectitle>Material and 
                ethods</sectitle><secb id="sec2_1"><sectitle>Biological samples</sectitle><paragraph>Our prospective observational study included 260 subjects, birth to
                    ≤21 years of age, enrolled <ins rule="ACEtool_UKVersionForDatePattern_1">1
                    April</ins><del rule="ACEtool_UKVersionForDatePattern_1">April 1,</del> 2020,
                    through <ins rule="ACEtool_UKVersionForDatePattern_1">1 May</ins><del rule="ACEtool_UKVersionForDatePattern_1">May 1,</del> 2022, at sites in
                    Connecticut, United States and Cali, Colombia. After obtaining IRB approval
                    (#21-004), subjects were enrolled in two cohorts: an experimental cohort (Cohort
                    A) and a reference cohort (Cohort B). The experimental cohort was comprised of
                    subjects who were positive for SARS-CoV-2 infection per antigen or PCR testing
                    and hospitalized for COVID-19 symptoms (subgroup A1); hospitalized and meeting
                    the Center for Disease Control’s criteria for MIS-C (subgroup A2); and
                    non-hospitalized subjects testing positive for SARS-CoV-2 by antigen or PCR,
                    (subgroup A3). The reference cohort was comprised of SARS-CoV-2 negative
                    subjects who were: hospitalized with a diagnosis of Kawasaki disease (subgroup
                    B1); hospitalized because of an acute viral infection (subgroup B2); or healthy
                    controls undergoing routine ambulatory surgery (subgroup B3). To ensure correct
                    subgroup assignment, cases were independently reviewed and adjudicated by three
                    pediatric specialists. Demographic data, health history, current symptoms, and
                    in-patient treatments and diagnostic testing results were collected at baseline.
                    Subjects will be followed for up to <ins rule="ACEtool_rule-spelloutToNumeral_CalendarUnits">4 </ins><del rule="ACEtool_rule-spelloutToNumeral_CalendarUnits">four </del>years <del rule="ACEtool_rule_toItalicise_latinTermsExceptbibitem">via</del> survey for
                    health and SARS-CoV-2 vaccine status.</paragraph></secb><secb id="sec2_2"><sectitle>Patient <ins rule="ACEtool_sectionbTitleShouldBeInSentenceCaseUppercaseAfterColonDashes">
                    s</ins><del rule="ACEtool_sectionbTitleShouldBeInSentenceCaseUppercaseAfterColonDashes">
                    S</del>aliva processing</sectitle><paragraph>Patient saliva samples were stored at <ins rule="ACEtool_rule_minus_spacedHyphenBeforeNumber" blackbox="true">−</ins>80<ins rule="ACEtool_rule-degreeC-remove-space-1" blackbox="true">°</ins><del rule="ACEtool_rule-degreeC-remove-space-1" blackbox="true">º</del>C for
                    at least 24<ins rule="ACEtool_rule-expandedwkdymoyr-unitspace" blackbox="true">
                     h</ins><del rule="ACEtool_rule-expandedwkdymoyr-unitspace" blackbox="true">
                    hours</del> prior to processing. The samples were placed in the biosafety
                    cabinet and allowed to thaw at room temperature for approximately 20<ins rule="ACEtool_rule-expandedwkdymoyr-unitspace" blackbox="true"> min</ins><del rule="ACEtool_rule-expandedwkdymoyr-unitspace" blackbox="true"> minutes</del>.
                    Once thawed, the tubes were cleaned with alcohol wipes and centrifuged at 200 <i><ins rule="ACEtool_rule_toDeleteMultiplicationSymbolAndItalicise_Centrifugation_g">
                    g</ins></i><del rule="ACEtool_rule_toDeleteMultiplicationSymbolAndItalicise_Centrifugation_g">x
                    g</del> for 15<ins rule="ACEtool_rule-wkdymoyrabbre-unitspace-1-without-ranges">
                     min</ins><del rule="ACEtool_rule-wkdymoyrabbre-unitspace-1-without-ranges">
                    mins</del> at 4<ins rule="ACEtool_rule-degreeC-remove-space-1" blackbox="true">
                    °</ins><del rule="ACEtool_rule-degreeC-remove-space-1" blackbox="true">
                    º</del>C. For samples to be analyzed with the grating-coupled fluorescent
                    plasmonic biosensor chip, 500μL
                    of supernatant was aliquoted and 35μL
                    of protease inhibitor dissolved in 1mL PBS
                    was added (Pierce™ protease inhibitor tablet, Thermo Fisher Scientific,
                    MA, USA) was added. For samples intended to be used in 16S RNA PacBio
                    sequencing, 250<ins rule="ACEtool_rule-singleunit-unitspace-6-without-ranges">
                     </ins>μL of supernatant was aliquoted and heat-inactivated for 30<del rule="ACEtool_rule-wkdymoyrabbre-unitspace-1-without-ranges"> mins</del> at
                    56<del rule="ACEtool_rule-degreeC-remove-space-1" blackbox="true"> º</del>C.
                    Once processed, samples were stored at 80C
                    until use.</paragraph></secb><secb id="sec2_3"><sectitle>Patient erum <ins rule="ACEtool_sectionbTitleShouldBeInSentenceCaseUppercaseAfterColonDashes">
                    p</ins><del rule="ACEtool_sectionbTitleShouldBeInSentenceCaseUppercaseAfterColonDashes">
                    P</del>rocessing</sectitle><paragraph>Sera were isolated from patient blood samples by resting the blood for
                    approximately 30
                    after collection to allow for coagulation. The non-coagulated fraction was
                    transferred into a 15mL
                    tube and centrifuged at 1000  for 15.
                    Supernatant was then transferred to a new tube and centrifuged at 1000  for 5. Supernatants were aliquoted into 200μL
                    cryovials and stored at 80<del rule="ACEtool_rule-degreeC-remove-space-1" blackbox="true">°</del>C
                    until transferred to participating laboratories.</paragraph></secb><secb id="sec2_4"><sectitle>Printing of grating-coupled fluorescent plasmonic (GCFP<query>Q10: The
                    abbreviation "GCFP" has been defined as "Grating Coupled Fluorescence Plasmonic"
                    as well as "grating-coupled fluorescent plasmonic". Please check if the
                    representation should be made consistent in the article.</query>) biosensor chip</sectitle><paragraph>Biosensor chips were fabricated and processed as described previously
                    with the following modifications (; 
                    ; 
                    ; ).
                    Capture antibodies were diluted to 250μg/mL with
                    PBS () and
                    printed on the GCFP chips using a 0.35mm
                    diameter microarray pin and a SpotBot II microarray printer (ArrayIt, CA, U<ins>
                    nited </ins>S<ins>tates</ins><del>A</del>) or an XactII microarray printer
                    (LabNEXT, NJ, <ins>United States</ins><del>USA</del>). Each capture antibody was
                    spotted to create five individual regions of interest (ROI) per analyte on each
                    biosensor chip. During printing, microarrays were kept at a relative humidity of
                    70% and at ambient temperature (AT) (<del>~</del>25<del rule="ACEtool_rule-degreeC-remove-space-1" blackbox="true"> ◦</del>C).
                    After printing, chips were allowed to dry at a relative humidity of 70% and AT (<ins>
                    −</ins>25C) for 1<ins rule="ACEtool_rule-wkdymoyrabbre-unitspace-1-without-ranges"> h</ins><del rule="ACEtool_rule-wkdymoyrabbre-unitspace-1-without-ranges"> hr</del>.
                    Chips were then transferred to a 50mL
                    polypropylene tube containing desiccant and stored at AT for up to 4weeks, with no significant signal loss (data not shown).</paragraph></secb><secb id="sec2_5"><sectitle><ins>Grating coupled fluorescence plasmonic</ins><del>GCFP</del> detection
                    assay</sectitle><paragraph>Biosensor chips were processed as previously described with the following
                    modifications (<xref id="bib_molony_et_al_2012" title="bib_molony_et_al_2012">Molony
                    et al., 2012</xref>; <xref id="bib_rice_et_al_2012" title="bib_rice_et_al_2012">Rice
                    et al., 2012</xref>; <xref id="bib_chou_et_al_2020" title="bib_chou_et_al_2020">Chou
                    et al., 2020</xref>) (). Chips were
                    fitted with plexiglass windows and gaskets to allow fluid to pass over the
                    surface of the chip. The chip was then blocked with 80 μL of
                    Superblock<ins rule="ACEtool_rule_superscript_letters_TM_shouldbe_changedto_trademark_symbol">
                    ™</ins><sup><del rule="ACEtool_rule_superscript_letters_TM_shouldbe_changedto_trademark_symbol">
                    TM</del></sup> T20 (PBS) blocking buffer (Thermo Fisher
                    Scientific, MA, U<ins>nited </ins>S) in a static
                    incubation for 1<del rule="ACEtool_rule-expandedwkdymoyr-unitspace" blackbox="true"> hour</del>.
                    Each chip was then washed with PBS-T at a flow rate of 0.5mL/min for 3
                    using a peristaltic pump. PBS doped with recombinant protein (20ng/mL) or patient
                    samples (80μL
                    of serum or saliva samples diluted with PBS to 1.5mL)
                    were then recirculated over the chip for 90
                    at 0.5mL/min for
                    3.
                    Each chip was then washed with PBS-T at 0.5mL/min for 3.
                    Biotinylated secondary antibody mixtures were created with all detection
                    antibodies at a concentration of 200 ng/mL and then recirculated over the
                    chip for 90. The chip was then washed with PBS-T at 0.5mL/min for 3
                    and then PBS containing 500ng/mL of streptavidin-AlexaFluor 647 (Thermo Fisher) was
                    recirculated over the chip for 1.
                    The chip was then washed for a final time with PBS-T at 0.5mL/min for 3
                    and 70μL
                    of PBS was injected into the flow cell. ROIs were then identified using Ciencia
                    software, Enhanced fluorescence Reader V2.3, and fluorescence intensity for each
                    ROI was collected using a GCFP reader (Ciencia, Inc.). A GCFP detection ratio
                    was used to normalize each ROI value as previously described (
                    )</paragraph></secb><secb id="sec2_6"><sectitle>16S-23S rRNA <ins rule="ACEtool_sectiondTitleShouldBeInSentenceCaseUppercaseAfterColonDashes">
                    m</ins><del rule="ACEtool_sectiondTitleShouldBeInSentenceCaseUppercaseAfterColonDashes">
                    M</del>icrobiome equencing</sectitle><paragraph>DNA was extracted using the Complete Lyse &amp; Purify kit (Shoreline
                    Biome, Farmington, CT, US). Saliva
                    samples were thawed on ice, and between 50<ins rule="ACEtool_rule-singleunit-unitspace-4-lc"> μ</ins><del rule="ACEtool_rule-singleunit-unitspace-4-lc"> µ</del>L and
                    200 µL of saliva was pelleted by centrifuged at <ins>5,</ins><del>5</del>500 rpm
                    for 10. Pellets were resuspended in nuclease-free
                    water, then purified according to the manufacturer’s protocol. Extracted
                    DNA was amplified with the StrainID Amplify kit according to manufacturer
                    protocol and as previously described (<xref id="bib_graf_et_al_2021" title="bib_graf_et_al_2021">Graf et al., 2021</xref>). Briefly,
                    10 µL of DNA and 10 µL of PCR mix (Shoreline Biome, <ins>United
                    States</ins>) were added to each well with barcoded primers. The
                    PCR reaction was carried out on a thermocycler (BioRad, Hercules, CA, ) according to manufacturer protocol. Amplicons were
                    screened on a QIAxcel (Qiagen, Germantown, MD, )
                    Advanced system using the Fast Analysis protocol. Samples were then pooled
                    together based on band intensity. Samples were cleaned using the GeneRead Size
                    Selection Kit (Qiagen, ) according to
                    manufacturer protocol and resuspended in 50 µL of elution buffer.
                    After verifying that both pools were pure, amplicons were pooled and sequenced
                    on a PacBio Sequel IIe. Sequences were demultiplexed with SBAnalyzer, then split
                    into groups of approximately 35 samples. DADA2 software (<url url="https://benjjneb.github.io/dada2/" title="https://benjjneb.github.io/dada2/">https://benjjneb.github.io/dada2/</url>)
                    was used to call ASVs, and taxonomy was assigned using the Athena database (
                    ; <xref id="bib_callahan_et_al_2016" title="bib_callahan_et_al_2016">Callahan et
                    al., 2016</xref>). Data analysis was performed in QIIME2 and R (<xref id="bib_mcmurdie_and_holmes_2013" title="bib_mcmurdie_and_holmes_2013">McMurdie
                    and Holmes, 2013</xref>; <xref id="bib_bolyen_et_al_2019" title="bib_bolyen_et_al_2019">Bolyen et al., 2019</xref>). Visualizations
                    were made with GraphPad Prism and microViz (<xref id="bib_barnett_et_al_2021" title="bib_barnett_et_al_2021">Barnett et al., 2021</xref>). The code used
                    is available at <url url="https://github.com/brandon-osullivan/Code-for-Maltz-Matyschsyk-et-al-2022" title="https://github.com/brandon-osullivan/Code-for-Maltz-Matyschsyk-et-al-2022">
                    https://github.com/brandon-osullivan/Code-for-Maltz-Matyschsyk-et-al-2022</url>.</paragraph></secb><secb id="sec2_7"><sectitle>Microsphere immunoassay<del> (MIA)</del> for <ins rule="ACEtool_sectiondTitleShouldBeInSentenceCaseUppercaseAfterColonDashes">
                    c</ins><del rule="ACEtool_sectiondTitleShouldBeInSentenceCaseUppercaseAfterColonDashes">
                    C</del>ytokines identification</sectitle><paragraph>Cytokines/Chemokine levels in the serum samples were measured in
                    duplicate using the Luminex<sup>®</sup> 200<sup>™</sup> instrument
                    and MilliplexMAP kits from EMD Millipore (Cat #HSTCMAG-28SK,
                    HCYTA-60K, HCYP2MAG-62K and HCYP4MAG-64K) according to manufacturer’s
                    protocol. A 96 well plate provided with the kit was first washed with
                    200 µl per well of wash buffer. The wash buffer was then discarded,
                    and 25 µl of serum sample was added to the plate in duplicate along
                    with 50 µl of standards and controls as provided with each kit. Assay
                    buffer (25 µl) was then added to the sample wells followed by
                    25 µl of premixed magnetic beads (provided with the kit) to each well.
                    The plate was covered with a dark lid and placed on a plate shaker (200 rpm
                    on a Barnstead 4625 Titer plate shaker) overnight at 4C in
                    a dark room. On the following day, the plate was washed 3X with 200 µl
                    of wash buffer using BioTek ELx405 microplate washer with
                    magnetic capture: after washing, detection antibodies (50 µl) were
                    added to each well and the plate was incubated for 1
                    on a plate shaker covered with a foil. Streptavidin-Phycoerythrin
                    (50 µl) was added to each well and the plate was incubated for
                    30 min on a plate shaker covered with foil. Finally, the plate was washed 3<ins>
                    ×</ins><del>X</del> with 200 µl of wash buffer using BioTek
                    ELx405 microplate washer and analyzed using the Luminex<sup>
                    ®</sup> 200 instrument (Calibrated each week with
                    Luminex 200 Calibration and Performance Verification kits: Cat # LX2R-CAL-K25,
                    LX2R-PVER-K25) with 150 µl of Sheath Fluid present in each well.
                    Standard curves were generated using the Luminex xPONENT
                    software and the concentrations of cytokines/chemokines in the serum samples
                    were calculated using these standard curves in pg/mL.</paragraph></secb><secb id="sec2_8"><sectitle><ins>Microsphere immunoassay</ins><del>MIA</del> for Ig response to
                    Sars-CoV-2 <ins rule="ACEtool_sectionbTitleShouldBeInSentenceCaseUppercaseAfterColonDashes">
                    e</ins><del rule="ACEtool_sectionbTitleShouldBeInSentenceCaseUppercaseAfterColonDashes">
                    E</del>pitopes</sectitle><paragraph>Specimens were assessed for the presence of antibodies reactive with
                    SARS-CoV-2 using an MIA as previously described (<xref id="bib_yates_et_al_2020" title="bib_yates_et_al_2020">Yates et al., 2020</xref>). Briefly,
                    recombinant SARS-CoV-2 N protein antigen (Native Antigen Company, <ins>United
                    Kingdom</ins><del>UK</del>) and the receptor binding domain (RBD) of the
                    SAR-CoV-2 spike protein (MassBiologics, MA, USA) were covalently linked to the
                    surface of fluorescent microspheres (Luminex Corporation, TX, USA). Additional
                    target antigens (S1 or S2 domain (Native Antigen, <ins>United Kingdom</ins><del>
                    UK</del>) of SARS-CoV-2 were included in the multiplexed microsphere assay.
                    Serum samples (25 μl) and antigen-conjugated microspheres (25μl)
                    were mixed and incubated before washing and further incubation with
                    phycoerythrin-conjugated antisera. The antisera used were chosen to specifically
                    recognize, as indicated, total antibodies (pan-Ig), or, individually IgM, IgA,
                    IgG, IgG1, IgG2, IgG3, IgG4. After washing, the microsphere fluorescence
                    intensity (MFI) was quantified with a FlexMap 3D Luminex analyzer (Luminex
                    Corporation, TX, US). Results were
                    either direct MFI values with reactivity based upon a defined cutoff MFI, or,
                    were normalized by comparison to the MFI of the negative controls and expressed
                    as the ratio between the two (P/N). Positive reactivity is determined by a
                    result that is ≥6
                    SD above the cutoff; results that fall between 3 SD and 6 SD are considered
                    “Indeterminate”.</paragraph></secb><secb id="sec2_9"><sectitle>Optimization of biosensor chip</sectitle><paragraph>We set out to optimize the initial biosensor chip configuration by
                    comparison to an established Luminex assay. First, we performed a dose response
                    curve examining the limit of detection for the 11 analytes that were evaluated
                    in both the GCFP assay and the Luminex data using parameters that had been
                    employed with the first-generation GCFP chip. Chips were spotted as described
                    above with the capture antibodies for the following analytes: TNF-α, IL-7,
                    IL-6, IL-4, IL-21, IL-2, IL-1β, IL-17A, IFN-δ, CCL-3, CCL20.
                    Recombinant proteins (R&amp;D Systems, MN, USA; Shenandoah Biotechnology, Inc,
                    PA, US) were then diluted to 5ng/mL, 1ng/mL, 200pg/mL, and 1pg/mL and
                    recirculated over the chip as described above. Detection ratios were calculated,
                    and the limit of detection was determined for each matched pair set by GCFP. We
                    then optimized the capture and secondary antibodies to reach values detectable
                    with the Luminex MIA assay.</paragraph></secb></seca><seca id="sec3"><secb id="sec3_1"><sectitle>Identification and validation of <ins rule="ACEtool_sectionbTitleShouldBeInSentenceCaseUppercaseAfterColonDashes">
                    r</ins><del rule="ACEtool_sectionbTitleShouldBeInSentenceCaseUppercaseAfterColonDashes">
                    R</del>egions of <ins rule="ACEtool_sectionbTitleShouldBeInSentenceCaseUppercaseAfterColonDashes">
                    i</ins><del rule="ACEtool_sectionbTitleShouldBeInSentenceCaseUppercaseAfterColonDashes">
                    I</del>nterest</sectitle><paragraph>Since MIS-C and COVID-19 are relativity new disease states, we set out to
                    develop our first generation GCFP biosensor chip based on literature available
                    early in the pandemic (<xref id="bib_cabrero_hernandez_2020" title="bib_cabrero_hernandez_2020">Cabrero-Hernandez, 2020</xref>; <xref id="bib_barmeir_et_al_2021" title="bib_barmeir_et_al_2021">Bar-Meir et al.,
                    2021</xref>; <xref id="bib_consiglio_et_al_2020" title="bib_consiglio_et_al_2020">Consiglio et al., 2020</xref>; <xref id="bib_ramaswamy_et_al_2020" title="bib_ramaswamy_et_al_2020">Ramaswamy et
                    al., 2020</xref>; <xref id="bib_whittaker_et_al_2020" title="bib_whittaker_et_al_2020">Whittaker et al., 2020</xref>; <xref id="bib_buszko_et_al_2021" title="bib_buszko_et_al_2021">Buszko et al., 2021</xref>
                    ; <xref id="bib_filbin_et_al_2021" title="bib_filbin_et_al_2021">Filbin et al.,
                    2021</xref>). These studies showed an array of cytokines, chemokines, tissue
                    damage markers, and inflammatory indicators that differed significantly in
                    children with MIS-C, COVID-19, and Kawasaki (). Our goals with the first-generation chip were to: 1) identify
                    commercially available matched pair antibodies for our ROIs to differentiate
                    MIS-C from COVID-19, Kawasaki, and healthy controls and 2) develop a GCFP assay
                    to simultaneously evaluate if these markers could be used as a disease-specific
                    biosignature. We validated 42 commercially available matched pair antibodies by
                    ELISA using recombinant proteins (<xref id="sec12" title="sec12">Supplementary
                    Figure S1</xref><del rule="ACEtool_rule_toChangeSupplementVarientstospecificOne_S_AfterTerm">FIG
                    S1</del>). Nine commercially available kits that did not meet our ELISA
                    standards when performed following manufacture protocols, and were omitted from
                    further analysis ().</paragraph></secb><secb id="sec3_2"><sectitle>Development of the grating-coupled fluorescent plasmonic biosensor chip
                    assay</sectitle><paragraph>Once matched-pair kits were validated using ELISA, we then tested their
                    ability to perform a sandwich-based immunoassay on the gold-coated nanoscale
                    grating surface chip using IL-6, IL-8 and both positive (Alexafluor-647 and
                    biotin-BSA) and negative (PBS) controls (<xref id="fig1" title="fig1">Figures 1</xref><ins rule="ACEtool_correctFigureCitation_JournalSpec">, </ins><xref id="fig2" title="fig2">2A</xref><del rule="ACEtool_correctFigureCitation_JournalSpec">Figure
                    1 and 2A</del>). When compared to PBS (negative
                    control), the fluorescent intensity within the ROIs for IL-6, IL-8 and positive
                    controls was significantly higher, indicating 20ng/mL of IL-6 and
                    IL-8 recombinant proteins could be detected with GCFP technology. Next, we
                    examined the specificity of the ROIs by spotting all the capture antibodies in  onto the chip and recirculating
                    20 ng/mL of recombinant CCL5, galactin-3 and CCL7 diluted in PBS over the
                    biosensor chip (). When compared to
                    PBS (negative control ROIs), the fluorescent intensity within the ROIs for CCL5,
                    galactin-3 and CCL7 were significantly higher, indicating that the GCFP assay
                    was able to capture and detect these recombinant proteins at cognate ROIs and
                    that there was no significant cross-reactivity between these recombinant
                    proteins and unrelated ROIs. To evaluate the use of human salvia as the sample
                    matrix, CCL5 and CLL7 (20 ng/mL) were spiked into commercially available
                    pooled human saliva (Innovative Research, MI, US<del>
                    A</del>) (<xref id="fig2" title="fig2">Figure 2C</xref>). Spiked samples in
                    pooled saliva matrix produced higher values than when the same analytes were
                    diluted in PBS owing to the presence of endogenous CCL5 and CCL7 in the saliva
                    pool. A heat map was created using the detection ratio for each set of 5 ROIs (). The heat map shows the detection
                    ratio and indicates positive detection of all recombinant proteins when
                    normalizing to the negative control ROIs on the same chip.</paragraph></secb><secb id="sec3_3"><sectitle>Analysis of patient samples by <ins>grating coupled fluorescence plasmonic</ins><del>
                    GCFP</del></sectitle><paragraph>The first-generation GCFP chip was then evaluated to identify a candidate
                    biomarker signature of disease using data from each of our 6 cohorts. Patient
                    saliva and serum were analyzed with the biosensor chips and the fluorescent
                    intensities were captured using GCFP reader (Ciencia, Inc., CT, U
                    S) ().
                    For each patient sample, an image was produced from the reader; Ciencia software
                    was used to identify ROIs, and then the fluorescent intensities for each ROI
                    were measured and the corresponding detection ratios calculated. <xref id="fig3" title="fig3">Figure 3</xref> shows representative
                    saliva data generated from a randomly selected patient from cohort B2. The image
                    generated from patient ID 210041005 shows that five capture antibodies and the
                    two positive controls (Biotin-BSA and alexafluor-647 labeled BSA) have a
                    positive signal (). Cystatin C,
                    Marapsin, CRP, Galectin-3, and IL-8 ROIs were each significantly different from
                    the negative control, indicating that these analytes are present at high levels
                    in this patient’s saliva ().
                    The fluorescent intensities were then normalized to the negative control and a
                    heat map was generated to visualize the biomarker signature (). Cystatin C, Marapsin, CRP, Galectin-3, and
                    IL-8 all had high detection ratios. Saliva from the six cohorts (A1<ins rule="ACEtool_rule_Equalto_wordspace"> = </ins><del rule="ACEtool_rule_Equalto_wordspace">=</del>15, A29, A36, B14, B213, B37) were similarly analyzed, and
                    results are displayed as heatmaps (<xref id="fig4" title="fig4">Figures 4A,B</xref>).  shows the mean
                    for each analyte from all the patient samples in each of the 6 cohorts. From
                    this initial small data set we can begin to identify potential biomarkers for A2
                    (CXCL10), A3 (sDC25) and B1(IL-1  and IL-2). Interestingly, when
                    comparing individual patients from each cohort we can see variation in these
                    biomarker signatures, suggesting variation in disease state presentation (). From the serum cohorts, 56 samples
                    (A113, A212, B112, B212, B37) were analyzed with the
                    first-generation biosensor chip configuration and heat maps were generated for
                    each group and for each individual patient (<xref id="fig5" title="fig5">Figure
                    5A</xref>) shows the mean for each analyte from all the
                    patient samples run in each of the 5 cohorts and indicates potential biomarker
                    signatures for each cohort. In A2 (MIS-C group) biomarker sCD25 was found to be
                    a potential unique biomarker for this group, while IL-21 was a unique biomarker
                    for B1 (Kawasaki). Again, variation between individuals’ biomarker
                    signatures within the different cohorts indicates heterogeneous disease
                    presentation ().</paragraph></secb><secb id="sec3_4"><sectitle>Interrogation of  saliva outliers using 16S-23S rRNA gene amplicon sequence analysis</sectitle><paragraph>We noted some analyte outliers within individual saliva samples (). To further analyze the saliva from
                    these samples, we performed 16S-23S’ rRNA PacBio sequencing. For this
                    study, we singled out sequencing data for the samples that were run over the
                    first-generation biosensor chip and compared the relative abundances of
                    different bacterial species. To identify bacterial species that were more
                    abundant in the samples that were analyte outliers, we applied a 99% confidence
                    interval, and confirmed outliers with the ROUT method. These data revealed a
                    difference in relative abundance of several bacterial species, some of which
                    could be linked to immunocompromised status, oral hygiene or other diseases (<xref id="fig6" title="fig6">Figure 6</xref>). For
                    example, sample 2100410014 from cohort A3 had an inflammatory profile that more
                    closely resembled a sample from the MIS-C or Kawasaki cohorts. This sample also
                    had highly elevated levels of <i>P<ins rule="ACEtool_abbreviateOrHighlightForAbbreviatingGenusWithDotInBinomialAfterFirstOccurrence_DoNotAbbreSentenceBegin_ExcludingListedParastyles">
                    .</ins><del rule="ACEtool_abbreviateOrHighlightForAbbreviatingGenusWithDotInBinomialAfterFirstOccurrence_DoNotAbbreSentenceBegin_ExcludingListedParastyles">
                    orphorymonas</del> endodontalis</i>, a known oral pathogen, with a relative
                    abundance of 19.26% of the overall community (median = 0.0%) (). In sample 2100410113, another saliva sample
                    that was an outlier in the biomarker analysis, we found that the community was
                    composed primarily of <i>Streptococcus</i> sp. A12 (63.45%, median = 0.74%) (<xref id="fig6" title="fig6">Figure 6C</xref>). Sample 2100430008 had high levels
                    of <i>Gemella sanguinis</i> (17.61%, median = 0.59%) and 
                    sp. A12 (8.00%, median = 0.74%) (<xref id="fig6" title="fig6">Figures 6C,D</xref>).
                    Sample 2100440031 had raised levels of <i>P<ins rule="ACEtool_highlightOrExpandGenusInBinomialAtItsFirstOccurrenceAndAbbreviateWithDotSubsequentlyExcludingListedParastyles">
                    orphorymonas </ins><del rule="ACEtool_highlightOrExpandGenusInBinomialAtItsFirstOccurrenceAndAbbreviateWithDotSubsequentlyExcludingListedParastyles">
                    . </del>endodontalis</i> (0.64%, median = 0.0%) and <i>G<del rule="ACEtool_abbreviateOrHighlightForAbbreviatingGenusWithDotInBinomialAfterFirstOccurrence_DoNotAbbreSentenceBegin_ExcludingListedParastyles">
                    emella</del> haemolysans</i> (4.65%, median = 0.84%) (<xref id="fig6" title="fig6">Figures 6B,E</xref>). In sample 2100410044, the majority of the
                    community was <i>Streptococcus salivarius</i> (61.67%, median = 2.05%) (<xref id="fig6" title="fig6">Figure 6F</xref>). Sample 2100410011 had elevated
                    levels of <i>Streptococcus pneumoniae</i> (6.77%, median = 0.0%) (<xref id="fig6" title="fig6">Figure 6G</xref>). 2100410072 also had elevated
                    levels of <i>S. pneumoniae</i> (2.20%, median 0.0%), as well as above average
                    levels of <i>G<ins rule="ACEtool_highlightOrExpandGenusInBinomialAtItsFirstOccurrenceAndAbbreviateWithDotSubsequentlyExcludingListedParastyles">
                    emella </ins>haemolysans</i> (7.26%, median = 0.84%) (<xref id="fig6" title="fig6">Figures 6E,G</xref>).
                    In sample 2100410018, we observed elevated levels of  sp.
                    ChDC B345 (28.39%, median = 1.34%) (<xref id="fig6" title="fig6">Figure 6H</xref>).
                    Our last GCFP analyte outlier, sample 2100410034, had elevated levels of <i>S.
                    salivarius</i> (18.09%, median = 2.05%) and <i>Schaalia odontolytica</i>
                    (17.07%, median = 3.36%) (<xref id="fig6" title="fig6">Figures 6F,I</xref>).</paragraph></secb><secb id="sec3_5"><sectitle>Refining the composition of a second-generation chip using <ins>Microsphere
                    Immunoassay</ins></sectitle><paragraph>Concurrent with these microarray studies, candidates for inclusion on a
                    second generation GCFP sensor chip were evaluated. We examined 249 serum samples
                    (180 from the US and 69 from
                    Colombia) from five different cohorts (A1, A2, B1, B2 and B3).
                    Patient samples were analyzed for levels of 26 cytokines/chemokines using the
                    Luminex xMAP multiplex assay. IL-4, IL-6, IL-10, and IL-13,
                    known to be involved in Th type immune response and promoting B cell
                    differentiation to plasma cells, were significantly elevated in the A2 (MIS-C
                    cohort) when compared to most other cohorts (<xref id="fig7" title="fig7">Figure
                    7A</xref><citation>fig7</citation>). Furthermore, chemokines IL-8 and CXCL11
                    were also found to be expressed at higher levels in the A2 cohort. By
                    comparison, the first-generation GCFP chip detected higher IL-8 for cohorts A1,
                    A2, B1 and IL-4 in cohorts A1 and A2 (),
                    while it did not detect IL-6 for any of the cohorts. It is important to note
                    that MIA may use different proprietary antibodies or conditions or recognize
                    different epitopes on these targets. The results from the Luminex studies were
                    representative of a higher sample size than the GCFP analysis, which may also
                    contribute to differences in the results. MIA data did confirm IL-10, IL-13 and
                    CXCL11 as possible new targets for the second-generation chip.</paragraph><paragraph>The antibody response to the SARS-CoV-2 nucleocapsid and spike components
                    (full spike, RBD, S1, S2) were measured using a MIA to separately detect
                    anti-viral IgM, IgA, and all four IgG subclasses. <xref id="fig7" title="fig7">Figures
                    7B–G</xref> shows that responses in the MIS-C cohort were substantially
                    different from standard COVID-19 infections and from healthy controls. Note that
                    some sera in the control cohort had antibodies to either the spike proteins or
                    nucleocapsid, indicating previously undetected SARS-CoV-2 infection or an
                    unreported vaccination. The predominant IgG subclasses produced in response to
                    COVID-19 infection are IgG (<ins rule="ACEtool_correctSeparatorAndChangedToSemicolonInDirectCitationText">;</ins><del rule="ACEtool_correctSeparatorAndChangedToSemicolonInDirectCitationText">,</del><xref id="bib_yates_et_al_2021" title="bib_yates_et_al_2021">2021</xref>); both
                    the COVID-19 and MIS-C cohorts had prominent IgG response centered
                    around the RBD/S1 components of SARS-CoV-2 spike protein. The MIS-C cohort
                    generally made a stronger IgG response as compared to the COVID-19
                    cohort. Notably, the MIS-C cohort made a significantly higher IgA response to
                    SARS-COV-2 spike domains as compared to the COVID-19 cohort (<xref id="fig7" title="fig7">Figure 7G</xref>), indicating SARS-COV-2 spike antigen as a
                    possible target for the second generation GCFP chip.</paragraph></secb><secb id="sec3_6"><sectitle>Comparison of 
                    biosensor chip biomarker signature to Cytokine <ins>Microsphere Immunoassay</ins><del>
                    MIA</del> results</sectitle><paragraph>We compared US serum samples with Colombia serum samples using both GCFP
                    biomarker signature data and cytokine microbead assay (<xref id="fig8" title="fig8">Figure 8A</xref><del rule="ACEtool_correctSeparatorAndChangedToSemicolonInDirectCitationText">
                    and</del>).
                    In cohort A2 (MIS-C), the biomarkers detected by the GCFP chip in US serum
                    samples produced a more complex and robust signature when compared to the
                    Colombia serum samples (). We also
                    compared US patient saliva samples with Colombia saliva samples: biomarker
                    signatures produced by GCFP microarray had a trend similar to that observed with
                    serum samples (<xref id="fig8" title="fig8">Figure 8B</xref>). Correspondingly,
                    MIA performed on serum samples showed lower levels of cytokine in Cohort A2
                    Colombia samples compared to US samples ().
                    Taken together these data indicate a difference in immune response between these
                    two populations.</paragraph><paragraph>To compare MIA data directly with the biomarker signature generated on
                    the first-generation chip, 11 analytes that had been included in both assays and
                    detection ratios were log transformed to visualize the data by cohort and as
                    individual patients (<xref id="fig9" title="fig9">Figure 9</xref>).
                    The heat map reveals that most of the analytes were detected within both
                    biomarker signatures generated from MIA and GCFP for the cohorts with the
                    exception of IL-4, IL-6, CCL20 and IL-21. When we compare individual samples,
                    similar signature patterns were found in the following samples for both MIA and
                    GCFP; 2100410146, 2100410150, 2100410042, 2100410049, 2100410131, 2100410168,
                    2100410184, 2100440014, 2100410153, 2100410114, 2100410208, 2100440008,
                    21004400062, 2100410094, 2100410139, and 2100410165. When noting the quantified
                    analyte levels (pg/mL) in the microbead assay dataset () it also becomes clear that some
                    of the analytes (IL-4, IL-6 and CCL20) were not detected on the GCFP chip while
                    others, like IL-1  were detected on the chip but not within the
                    microbead assay. To address this, we performed a dose response curve on the
                    first-generation chip for analytes that were measured both by MIA and GCFP using
                    PBS that was doped with different amounts of recombinant proteins (10ng, 5ng,
                    1ng, 200pg, 1pg/mL)
                    (<xref id="fig10" title="fig10">Figure 10A</xref><citation>fig10</citation>).
                    These data indicate that for many of the analytes analyzed by both MIA and GCFP,
                    the first-generation chip has a detection limit of 1ng/mL while MIA
                    could detect levels as low as 1pg/mL, which
                    could explain the analytes that were undetected by GCFP. We further optimized
                    the GCFP chip to improve the assay’s limit of detection (<xref id="fig10" title="fig10">Figure 10B</xref>). We first increased the amount of secondary
                    antibody to 10-fold the amount recommended by the manufacturers for ELISA. We
                    did not see an improvement with this change (<xref id="fig10" title="fig10">Figure
                    10B</xref>). We then increased the amount of capture antibody immobilized on the
                    GCFP chip by twofold (500μg/mL) and we were able to see an improvement in limit of
                    detection for most analytes, indicating that manipulating capture reagents can
                    further improve detection limits. Future studies for the nextgeneration chip will not only be focused on adding
                    other reported analytes now known to be important for MIS-C, but also optimizing
                    each analyte reagent set to allow for detection in the pg/mL range.</paragraph></secb></seca><seca id="sec4"><paragraph>Clinicians need a rapid, accurate test for MIS-C to guide treatment
                decisions. Here we show that using GCFP technology we can characterize two biomarker
                signatures within two different biofluids (serum and saliva), one for a group/cohort
                and one for an individual patient. In saliva, the GCFP biomarker analytes found in
                all disease state cohorts were Cystatin C, Marapsin, Galactin-3, and IL-8. When
                designing the chip we included Cystatin C for its potential as being predicative of
                renal injury and due to its observed elevated levels in COVID-19 patients (). We
                were able to detect Cystatin C in all our cohorts; only one patient did not produce
                detectable Cystatin C. The normal range of Cystatin C is 10<del>
                – </del>12mg/mL
                in saliva and, 0.63–8.0 mg/mL in serum; and has been shown to be
                upregulated in people with poor oral hygiene (<xref id="bib_lie_et_al_2001" title="bib_lie_et_al_2001">Lie et al., 2001</xref>; <xref id="bib_dickinson_2002" title="bib_dickinson_2002">Dickinson, 2002</xref>; <xref id="bib_ziegelasch_et_al_2019" title="bib_ziegelasch_et_al_2019">Ziegelasch et
                al., 2019</xref>). This suggested that Cystatin C may present at levels exceeding
                the upper limit of GCFP detection under the conditions tested. Marapsin/pancreasin
                is a trypsin-like serine protease that has been described in pancreatic tissue;
                little is known about its role in other systems although it can be expressed in
                stratified squamous epithelium tissues (esophagus, cervix and larynx) (<xref id="bib_bhagwandin_et_al_2003" title="bib_bhagwandin_et_al_2003">Bhagwandin et
                al., 2003</xref>; <xref id="bib_li_et_al_2009" title="bib_li_et_al_2009">Li et al.,
                2009</xref>). We included this analyte to potentially predict pancreatic health
                since reduced pancreatic function increases risk of developing severe COVID-19 (<xref id="bib_abramczyk_et_al_2022" title="bib_abramczyk_et_al_2022">Abramczyk et al.,
                2022</xref>). Our biosensor chip was able to detect marapsin in all of the infected
                cohorts (A1-3 &amp; B1-2), but not in the healthy cohort (B3). Interestingly,
                marapsin has been found to be upregulated in the epidermis of patients with
                psoriasis and/or regenerating wound infections, suggesting a possible role in
                infection (<xref id="bib_li_et_al_2009" title="bib_li_et_al_2009">Li et al., 2009</xref>).
                Galectin-3 is a ß-galactoside binding lectin that can drive neutrophil
                chemotaxis, bind TLR4, and increase production of pro-inflammatory cytokines during
                viral infections (<xref id="bib_joo_et_al_2001" title="bib_joo_et_al_2001">Joo et
                al., 2001</xref>; <xref id="bib_filer_et_al_2009" title="bib_filer_et_al_2009">Filer
                et al., 2009</xref>; <xref id="bib_henderson_and_sethi_2009" title="bib_henderson_and_sethi_2009">Henderson and Sethi, 2009</xref>; <xref id="bib_burguillos_et_al_2015" title="bib_burguillos_et_al_2015">Burguillos et
                al., 2015</xref>). Increased serum levels of galectin-3 (&gt;30ng/mL) have been
                correlated with severe COVID-19 outcomes (<xref id="bib_eduardo_et_al_2022" title="bib_eduardo_et_al_2022">Eduardo et al., 2022</xref>). Our biomarker
                signature showed galectin-3 was present in all cohorts, while lower in healthy
                controls, indicating a role in infection. Galectin-3 may be upregulated in COVID-19
                cohorts (A1,2,3) but the amount found in saliva were near saturation for the GCFP
                assay as configured. Finally, IL-8 cytokines are produced by a wide range of cells
                including oral keratinocytes and are a potential biomarker for predicting oral
                disease (<xref id="bib_finoti_et_al_2017" title="bib_finoti_et_al_2017">Finoti et
                al., 2017</xref>; <xref id="bib_lopez_labady_et_al_2021" title="bib_lopez_labady_et_al_2021">Lopez-Labady et al., 2021</xref>). IL-8 was
                also reported early in the pandemic to be a sensitive serum biomarker in both mild
                and severe COVID-19 patients (<xref id="bib_li_et_al_2020" title="bib_li_et_al_2020">Li
                et al., 2020</xref>). Interestingly, GCFP detected salivary IL-8 in all cohorts,
                while in serum it was detected only in the A1, A2 and B1 cohorts.</paragraph><paragraph>There were some cohort-unique saliva biomarkers contributing to the biomarker
                signature from each of the different cohorts. GCFP detection of CXCL10 was only seen
                in Cohort A2 (MIS-C). CXCL10 is a chemokine that is produced by many different cell
                lines and tissues (Jong-Ho <xref id="bib_lee_et_al_2020" title="bib_lee_et_al_2020">Lee
                et al., 2020</xref>). This chemokine has been identified in several studies as a
                contributing factor to the modulation and intensity of inflammation caused by
                SARS-CoV2 and recently was shown to be at higher levels in MIS-C patients (<xref id="bib_callahan_et_al_2021" title="bib_callahan_et_al_2021">Callahan et al.,
                2021</xref>; <xref id="bib_caldarale_et_al_2021" title="bib_caldarale_et_al_2021">Caldarale
                et al., 2021</xref>). sCD25 was solely detected on the GFCP chip in sera from cohort
                A3 (mild COVID). sCD25 is the soluble form of IL-2R alpha chain, has been linked to
                T-cell proliferation and inflammatory disease, and is a driver of disease
                pathogenesis (<xref id="bib_russell_et_al_2012" title="bib_russell_et_al_2012">Russell
                et al., 2012</xref>). sCD25 was reported to be upregulated in the serum of pediatric
                patients with SARs-CoV2 infections and MIS-C (<xref id="bib_mostafa_et_al_2022" title="bib_mostafa_et_al_2022">Mostafa et al., 2022</xref>). It is interesting
                to note that sCD25 is present in the saliva from the A3 cohort and present in the
                serum biomarker signature from A1, A2, and B1 cohorts. In Kawasaki patient serum,
                sCD25 has been found to be 3-100x higher than in healthy controls, which is
                consistent with our observations (<xref id="bib_teraura_et_al_2016" title="bib_teraura_et_al_2016">Teraura et al., 2016</xref>). In cohort B1, we
                observe the most diverse saliva biomarker signature when compared to the other
                cohorts, with ferritin, IL-1β and IL-2 being uniquely found at elevated levels
                in this cohort. Studies have indicated that high serum levels of ferritin are
                present in Kawasaki patients and ferritin is a predictor of non-responsiveness to
                intravenous immunoglobulin (IVIG) therapy (<xref id="bib_yamamoto_et_al_2015" title="bib_yamamoto_et_al_2015">Yamamoto et al., 2015</xref>; <xref id="bib_kim_et_al_2021" title="bib_kim_et_al_2021">Kim et al., 2021</xref>; <xref id="bib_qiu_et_al_2022" title="bib_qiu_et_al_2022">Qiu et al., 2022</xref>).
                IL-1β has previously been reported to play a key role in the inflammatory
                profile of Kawasaki disease, and IL-2 is significantly higher in children with
                Kawasaki than in healthy controls (<xref id="bib_okada_et_al_2003" title="bib_okada_et_al_2003">Okada et al., 2003</xref>; <xref id="bib_hoang_et_al_2014" title="bib_hoang_et_al_2014">Hoang et al., 2014</xref>
                ; <xref id="bib_alphonse_et_al_2016" title="bib_alphonse_et_al_2016">Alphonse et
                al., 2016</xref>). These findings indicate that data obtained by GCFP in saliva
                samples are consistent with recent scientific studies and show potential for this
                assay as a diagnostic tool. We showed that there was variation between individual
                saliva samples in patients within the same cohort, indicating differences in immune
                responsiveness.</paragraph><paragraph>The microbiome 16S RNA data helped to decipher potential reasons for some of
                the observed differences within cohorts by demonstrating imbalances in the microbial
                community or the presence of oral pathogens. In future studies, we plan on designing
                an approach to detect these imbalances and/or pathogens by using an oligonucleotide
                based GCFP biosensor chip to characterize the oral microbiome. Ultimately, it will
                be interesting to explore the possibility of doing both protein capture, antibody
                capture, and oligonucleotide analyte capture on the same sensor chip to further
                improve the efficiency and versatility of the assay.</paragraph><paragraph>Serum samples demonstrated a more complex biomarker signature than saliva
                samples, on both individual and inter-cohort levels (<xref id="fig4" title="fig4 fig5">Figures 4, 5</xref>), which could be due to increased analyte
                presence in serum compared to saliva, better preservation of analyte in serum, or
                the choices of analytes included on the first-generation chip. The salivary proteome
                has 3,074 unique human proteins and only shares 1,234 proteins with blood plasma (<url url="https://www.salivaryproteome.org" title="https://www.salivaryproteome.org">
                https://www.salivaryproteome.org</url>). GCFP biomarker analytes found in all
                disease state cohorts were cystatin C, ferritin, galectin 3, and perforin. As noted
                above, cystatin C, galectin-3 and ferritin are all found in serum at levels &gt;250ng/mL which could be
                at the limit of saturation for these assays. As expected, perforin, a glycoprotein
                responsible for pore formation in cell membranes of target cells, which plays an
                important role in cytotoxic activity, was not a marker within our healthy control
                group, thus showing selectivity of disease states on our chip (<xref id="bib_osińska_et_al_2014" title="bib_osińska_et_al_2014">Osińska
                et al., 2014</xref>). A2 and B1 serum cohorts shared 3 analytes not found in other
                cohorts: HSP70, IL-1β, and IL-2. HSP70, a stress protein known to induce
                inflammation and has been linked to pathogenesis of Kawasaki disease (<xref id="bib_lu_et_al_1998" title="bib_lu_et_al_1998">Lu et al., 1998</xref>; <xref id="bib_hulina_et_al_2018" title="bib_hulina_et_al_2018">Hulina et al., 2018</xref>)
                was not present in A2 saliva but was present in B1 saliva samples. ACE2 (angiotensin
                converting enzyme-2) is a monocarboxypeptidase found within cell membranes or as a
                soluble protein throughout the body (<xref id="bib_jiang_et_al_2014" title="bib_jiang_et_al_2014">Jiang et al., 2014</xref>). It is a member of the
                renin-angiotensin system (RAS) and has been implicated in diabatic cardiovascular
                complications and chronic heart failure; elevated expression has been linked to
                severe COVID-19, and it is a receptor for SARS-CoV2 entry into the cell (<xref id="bib_patel_et_al_2013" title="bib_patel_et_al_2013">Patel et al., 2013</xref>
                ; 
                ; <xref id="bib_beyerstedt_et_al_2021" title="bib_beyerstedt_et_al_2021">Beyerstedt
                et al., 2021</xref>).We detected ACE2 in the serum biomarker signatures for A1, A2,
                and B1. While ACE2 levels in cohorts A1 and A2 are consistent with recent scientific
                literature, it is not a known biomarker in Kawasaki disease, despite the fact that
                cardiac disease (coronary artery aneurysms, myocarditis, pericarditis, congestive
                heart failure, pericardial effusion, and arrhythmias) is a complication in these
                patients (<xref id="bib_tizard_2005" title="bib_tizard_2005">Tizard, 2005</xref>).
                The detection of ACE2 within cohort B1 could suggest the presence of cardiac disease
                within individuals of this group.</paragraph><paragraph>We have demonstrated the versatility of the GCFP microarray, the option to
                manipulate the composition of the microarray features, and the potential to detect
                over 1000 analytes in one assay (<xref id="bib_guignon_and_lynes_2014" title="bib_guignon_and_lynes_2014">Guignon, and Lynes, 2014</xref>; <xref id="bib_yuk_et_al_2013" title="bib_yuk_et_al_2013">Yuk et al., 2013</xref>; 
                ; <xref id="bib_unfricht_et_al_2005" title="bib_unfricht_et_al_2005">Unfricht et
                al., 2005</xref>; ; <xref id="bib_reilly_et_al_2006" title="bib_reilly_et_al_2006">Reilly
                et al., 2006</xref>). In the current study, using a small sample volume (7080µL)
                of either saliva or serum, we were able to begin to identify an initial biomarker
                signature for the different cohorts studied, showing that GCFP microarrays can be a
                potential novel approach for MIS-C disease diagnosis. ELISA or microbead immunoassay
                (MIA<query>Q11: The abbreviation "MIA" has been defined as "Microsphere Immunoassay"
                as well as "microbead immunoassay". Please check if the representation should be
                made consistent in the article.</query>), the gold standards for analyte
                measurement, use larger sample volume than GCFP, an especially important
                consideration with pediatric patients. We were also able to modify the protocol to
                increase assay sensitivity. MIA data in this study revealed four potential new GCFP
                targets, IL-10, IL-13, CXCL11 and SARS-COV-2 spike antigen, that can be added to the
                second-generation GCFP chip. By including more biomarkers on the chip, we can
                establish a more specific signature for each disease state tested, including
                indicators of individual organ function as well as systemic health. We are also able
                to detect disease state variation between patients within a disease group, which
                could potentially help with individualized diagnostics and treatment and provide
                faster treatment options per patient. It is important to note that negative markers
                (ones that do not appear as signals in these cohorts) are also informative and may
                be useful in excluding patients as belonging to one of these cohorts who present
                with those markers. We started building the first-generation GCFP chip at the
                beginning of the COVID pandemic. In future studies, ongoing research will be
                utilized to design a microarray in the second-generation chip that will produce
                biosignature that is even more specific and sensitive to MIS-C. Our data demonstrate
                GCFP microarrays as a novel, professional point of care diagnostic tool.</paragraph></seca><seca id="sec5"><sectitle>The Connecticut Children’s COVID Collaborative</sectitle><p>The collaborative should be included at the end of the authorship byline for all
                publications. Please refer to journal guidelines for specific instructions. Example:
                Smith B, Doe J and The Connecticut Children’s COVID Collaborative. <b>Salazar,
                Juan C</b>, Connecticut Children’s Medical Center, Hartford, Connecticut
                06106, United States, and University of Connecticut Health Center, Farmington,
                Connecticut 06030, United States; <b>Lynes, Michael A</b>, University of
                Connecticut, Storrs, Connecticut 06269, United States; <b>Lawrence David A,</b>
                Wadsworth Center, New York State Department of Health, Albany, New York 12208,
                United States, and University at Albany School of Public Health, Rensselaer, New
                York 12144, United States; <b>Brimacombe, Michael</b>, Connecticut Children’s
                Medical Center, Hartford, Connecticut 06106, United States, and University of
                Connecticut Health Center, Farmington, Connecticut 06030, United States; <b>Carroll,
                Christopher L,</b> onnecticut Children’s Medical Center, Hartford,
                Connecticut 06106, United States, and University of Connecticut Health Center,
                Farmington, Connecticut 06030, United States; <b>Carson, Kyle J</b>, Wadsworth
                Center, New York State Department of Health, Albany, New York 12208, United States; <b>Dagenais,
                Taylor RT</b>, Big Rose Web Design LLC, Middleton, Wisconsin 53562, United States; <b>De
                La Cruz Macías, Catalina</b>, Centro de Estudios en Infectología
                Pediátrica, Cali, Colombia; <b>El Chebib, Hassan</b>, Connecticut
                Children’s Medical Center, Hartford, Connecticut 06106, United States, and
                University of Connecticut Health Center, Farmington, Connecticut 06030, United
                States; <b>George, Joshy</b>, The Jackson Laboratory for Genomic Medicine,
                Farmington, Connecticut 06032, United States; <b>Ghassabian, Akhgar</b>, New York
                University Grossman School of Medicine, New York, New York 10016, United States; <b>Giles,
                Steven S</b>, Big Rose Web Design LLC, Middleton, Wisconsin 53562, United States; <b>Graf
                Jeorg</b>, University of Connecticut, Storrs, Connecticut 06269, United States; <b>Gunter,
                Courtney</b>, The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut
                06032, United States; <b>Herbst, Katherine W</b>, Connecticut Children’s
                Medical Center, Hartford, Connecticut 06106, United States; <b>Hawley, Kelly L</b>,
                Connecticut Children’s Medical Center, Hartford, Connecticut 06106, United
                States, and University of Connecticut Health Center, Farmington, Connecticut 06030,
                United States; <b>Hogan, Alexander H</b>, Connecticut Children’s Medical
                Center, Hartford, Connecticut 06106, United States, and University of Connecticut
                Health Center, Farmington, Connecticut 06030, United States; <b>Jadhav, Aishwarya</b>,
                Wadsworth Center, New York State Department of Health, Albany, New York 12208,
                United States; <b>Kozhaya, Lina</b>, The Jackson Laboratory for Genomic Medicine,
                Farmington, Connecticut 06032, United States; <b>Lee, William T</b>, Wadsworth
                Center, New York State Department of Health, Albany, New York 12208, United States,
                and University at Albany School of Public Health, Rensselaer, New York 12144, United
                States; <b>López, Eduardo L</b>, Centro de Estudios en Infectología
                Pediátrica, Cali, Colombia; <b>Maltz-Matyschsyk</b>, Michele, University of
                Connecticut, Storrs, Connecticut 06269, United States; <b>Melchiorre, Clare K</b>,
                Michele, University of Connecticut, Storrs, Connecticut 06269, United States; <b>O’Sullivan,
                Brandan</b>, University of Connecticut, Storrs, Connecticut 06269, United States; <b>Radolf,
                Justin D</b>, University of Connecticut Health Center, Farmington, Connecticut
                06030, United States; <b>Unutmaz, Derya</b>, The Jackson Laboratory for Genomic
                Medicine, Farmington, Connecticut 06032, United States.</p></seca><seca id="sec6"><paragraph>The original contributions presented in the study are included in the
                article/, further
                inquiries can be directed to the corresponding author<del>/s</del>.<query>Q12:
                Confirm that the Data Availability statement is accurate. Note that this statement
                may have been amended to adhere to our Publication Ethics guidelines. </query></paragraph></seca><seca id="sec7"><sectitle>Ethics tatement<role>ethics</role></sectitle><paragraph>The studies involving human participants were reviewed and approved by the
                IRB. Written informed consent to participate in this study was provided by the
                participants’ legal guardian/next of kin.<query>Q13: If your article requires
                an Ethics statement, please confirm that the statement in this proof is correct. If
                this is not the latest version, please provide a revised Ethics statement. If your
                article contains identifiable human images, please check our Policies and
                Publication Ethics . </query></paragraph></seca><seca id="sec8"><sectitle>Author <ins rule="ACEtool_sectionaTitleShouldBeInSentenceCaseUppercaseAfterColonDashes">c</ins><del rule="ACEtool_sectionaTitleShouldBeInSentenceCaseUppercaseAfterColonDashes">C</del>
                ontributions</sectitle><paragraph>MMM Planned experiments, developed GCFP assay, ran GCFP patient
                samples, analysed GCFP data, and wrote the manuscript. C<del>K</del>M Planned
                experiments, developed GCFP assay, organized and supervised reagent validation,
                discussed experiments, and helped writing of the manuscript. K<del>W</del>H planned,
                organized, supervised sample collection, discussed experiments, helped with writing
                of the manuscript. A<del>H</del>H planned, organized, and supervised sample
                diagnostics, discussed experiments, and helped with writing of the manuscript. BO<ins rule="ACEtool_deleteAuthorDegAndRoleAbbreviateAuthorsNameInAckWithAlertForSameInitial">
                ’S</ins> ran, analysed 16S-23S rRNA microbiome sequencing and helped with
                writing of the manuscript. JG Planned, discussed experiments, and helped writing of
                the manuscript. AJ ran and analysed MIA for cytokine identification and helped with
                writing of the manuscript. DL Planned, discussed experiments, and helped
                writing of the manuscript. K<del>J</del>C performed MIS for Ig response to
                Sars-CoV-2 epitopes. WTL Planned, discussed experiments, and helped writing of the
                manuscript. JR Planned, discussed experiments, and helped writing of the
                manuscript. JS Planned, discussed experiments, and helped writing of the manuscript.
                ML Supervised, planned, discussed experiments, and helped writing of the
                manuscript. All authors contributed to the article and approved the submitted
                version</paragraph></seca><seca id="sec9"><sectitle>Funding</sectitle><paragraph>Research reported in this publication was supported by the Eunice Kennedy
                Shriver National Institute of Child and Human Development of the National Institutes
                of Health under award number 1R61HD105613-01 We would also like to acknowledge
                Robert and Francine Shanfield for their generous donation in support of this
                research, without which this article would not be possible.<query>Q14: Confirm if
                the edit made in the “Author Contributions” section is correct. </query></paragraph></seca><seca id="sec10"><sectitle><ins rule="ACEtool_rule_insert_sectiona">Conflict of Interest</ins></sectitle><paragraph>ML has intellectual property (U.S. Patent #7,655,421) related to
                functional phenotyping of leukocytes by SPR microarray. ML, MMM,
                DL, and JG have ongoing, NIH-funded, collaborations with Ciencia, Inc.</paragraph><paragraph>The remaining authors declare that the research was conducted in the absence
                of any commercial or financial relationships that could be construed as a potential
                conflict of interest.<query>Q15: Confirm if the text included in the Conflict of
                Interest statement is correct. Please do not suggest edits to the wording of the
                final sentence, as this is standard for Frontiers' journal style. </query></paragraph></seca><seca id="sec11"><sectitle>Publisher’s Note</sectitle></seca><seca id="sec12"><sectitle>Supplementary 
                aterial</sectitle><paragraph>The Supplementary Material for this article can be found online at: <url url="https://www.frontiersin.org/articles/10.3389/fbioe.2023.1066391/full \l supplementary-material" title="https://www.frontiersin.org/articles/10.3389/fbioe.2023.1066391/full#supplementary-material">
                https://www.frontiersin.org/articles/10.3389/fbioe.2023.1066391/full#supplementary-material</url><query>Q16:
                Ensure that any supplementary material is correctly published at this link: . If the
                link does not work, you can check the file(s) directly in the production forum; the
                published supplementary files appear in green. Please make sure all Supplementary
                files are cited. Please also provide captions for these files, if relevant. If you
                have any corrections, please provide new files and republish them in the forum.
                Frontiers will deposit ALL supplementary files to FigShare and they will receive a
                DOI. Notify us of any previously deposited material. If the Supplementary Material
                files contain identifiable or copyright images, please keep in mind that it is your
                responsibility, as the author, to ensure you have permission to use the images in
                the article. Please check this for information on author responsibilities and the
                publication images. </query></paragraph></seca></body><tail><ack><acknowledgements>We would like to thank Christina Aglieco and Berivan Hamoto for
                collecting and processing saliva samples. We would also like to thank our colleagues
                Adriana Camacho, Carlie DeFelice, Kristina Dibble, Hilda Giraldo, Stephanie Lesmes,
                Isabel Orbe, Celina Porcaro, Jessika Rodrígueza, Noah Schulman, and Beatriz
                Vanegas for their vital contribution to the project, including participant
                recruitment and biospecimen collection and processing.</acknowledgements></ack><bibreference><bibliography-sec><bib-reference id="bib_abramczyk_et_al_2022"><label>Abramczyk et al., 2022</label><journal><aus><au><snm>Abramczyk</snm></au><au><snm>Nowaczyński</snm></au><au><snm>Adam</snm></au><au><snm>Wojnicz</snm></au><au><snm>Zatyka</snm></au><au><snm>Kuzan</snm></au></aus><atl>Consequences of COVID-19 for the pancreas</atl><stl>Int. J. Mol. Sci.</stl><first-page>864</first-page><doi>10.3390/ijms23020864</doi></journal></bib-reference><bib-reference id="bib_algarni_and_alghamdi_2022"><label>Algarni and Alghamdi, 2022</label><journal><aus><au><snm>Algarni</snm><fnm>A. S.</fnm></au><au><snm>NjoudAlamri</snm><fnm>M. N Z. K, R A.</fnm></au><au><snm>Alghamdi</snm></au><au><snm>Alsubhi</snm><fnm>R. S.</fnm></au></aus><atl>Clinical practice guidelines in multisystem inflammatory syndrome
                            (MIS-C) related to COVID-19: A critical review and recommendations</atl><stl>World J. Pediatr.</stl><first-page>83</first-page><doi>10.1007/s12519-021-00499-w</doi></journal></bib-reference><bib-reference id="bib_alphonse_et_al_2016"><label>Alphonse et al., 2016</label><journal><aus><au><snm>Alphonse</snm></au><au><snm>Prince</snm></au><au><snm>Trang</snm><fnm>T. D.</fnm></au><au><snm>Shumitzu</snm></au><au><snm>Hoang</snm><fnm>T L.</fnm></au><au><snm>McCrindle</snm><fnm>B W.</fnm></au></aus><atl>Inositol-triphosphate 3-kinase C mediates inflammasome activation and
                            treatment response in Kawasaki disease</atl><stl>J. Immunol.</stl><first-page>3481</first-page><last-page>3489</last-page><msc3>LP – 3489</msc3><doi>10.4049/jimmunol.1600388</doi></journal></bib-reference><bib-reference id="bib_amanullah_et_al_2002"><label>Amanullah et al., 2002</label><journal><aus><au><snm>Amanullah</snm></au><au><snm>Hewitt</snm></au><au><snm>Nienow</snm><fnm>A. W.</fnm></au><au/><au><snm>Chartrain</snm></au><au><snm>Buckland</snm><fnm>B. C.</fnm></au><au><et-al>et al</et-al></au></aus><adate>2002</adate><atl>Application of multi-parameter flow cytometry using fluorescent probes
                            to study substrate toxicity in the indene bioconversion</atl><stl>Biotechnol. Bioeng.</stl><first-page>239</first-page><last-page>249</last-page><doi>10.1002/BIT.10477</doi></journal></bib-reference><bib-reference id="bib_bagnasco_et_al_2012"><label>Bagnasco et al., 2012</label><journal><aus><au><snm>Bagnasco</snm></au><au><snm>Pezzi</snm></au><au><snm>Rosa</snm></au><au><snm>Fornonil</snm></au><au><snm>Sasso</snm></au></aus><atl>Distraction techniques in children during venipuncture: An Italian
                            experience</atl><stl>J. Prev. Med. Hyg.</stl><first-page>44</first-page><last-page>48</last-page><doi>10.15167/2421-4248/JPMH2012.53.1.314</doi></journal></bib-reference><bib-reference id="bib_barmeir_et_al_2021"><label>Bar-Meir et al., 2021</label><journal><aus><au><snm>Bar-Meir</snm><fnm>M.t</fnm></au><au><snm>Godfrey</snm></au><au><fnm>A. R.</fnm><snm>Shack</snm></au><au><snm>Hashkes</snm></au><au><fnm>O</fnm><snm>Goldzweig</snm></au><au><snm>Megged</snm></au></aus><atl>Characterizing the differences between multisystem inflammatory
                            syndrome in children and Kawasaki disease</atl><stl>Sci. Rep.</stl><first-page>13840</first-page><last-page>13845</last-page><doi>10.1038/s41598-021-93389-0</doi><query>Q17: Cite the reference “Lee et al., 2017” inside the
                            text. https://www.frontiersin.org.cn/authors-proof-support/#QA28</query></journal></bib-reference><bib-reference id="bib_barnett_et_al_2021"><label>Barnett et al., 2021</label><journal><aus><au><snm>Barnett</snm></au><au><snm>Ilja</snm></au><au><snm>Penders</snm></au></aus><atl>MicroViz: An R package for microbiome data visualization and statistics</atl><stl>J. Open Source Softw.</stl><iss>63</iss><first-page>3201</first-page><doi>10.21105/joss.03201</doi></journal></bib-reference><bib-reference id="bib_beyerstedt_et_al_2021"><label>Beyerstedt et al., 2021</label><journal><aus><au><snm>Beyerstedt</snm></au><au><snm>Barbosa Casaro</snm></au><au><snm>Érika</snm><fnm>B. R.</fnm></au></aus><atl>COVID-19: Angiotensin-converting enzyme 2 (ACE2) expression and tissue
                            susceptibility to SARS-CoV-2 infection</atl><stl>Eur. J. Clin. Microbiol. Infect. Dis. Official Publ. Eur. Soc. Clin.
                            Microbiol.</stl><first-page>905</first-page><last-page>919</last-page><doi>10.1007/s10096-020-04138-6</doi></journal></bib-reference><bib-reference id="bib_bhagwandin_et_al_2003"><label>Bhagwandin et al., 2003</label><journal><aus><au><snm>Bhagwandin</snm></au><au><snm>Hau</snm></au><au><snm>Clair</snm><fnm>J M-S.</fnm></au><au><snm>Paul</snm></au><au><snm>George</snm></au></aus><adate>2003</adate><atl>Structure and activity of human pancreasin, a novel tryptic serine
                            peptidase expressed primarily by the pancreas</atl><stl>J. Biol. Chem.</stl><first-page>3363</first-page><last-page>3371</last-page><doi>10.1074/jbc.M209353200</doi></journal></bib-reference><bib-reference id="bib_bolyen_et_al_2019"><label>Bolyen et al., 2019</label><journal><aus><au><snm>Bolyen</snm><fnm>E</fnm></au><au><snm>Rideout</snm><fnm>J R.</fnm></au><au><snm>Dillon</snm></au><au><snm>Bokulich</snm><fnm>N. A.</fnm></au><au><snm>Abnet</snm><fnm>C C.</fnm></au><au><snm>Al-Ghalith</snm><fnm>G. A.</fnm></au></aus><atl>Reproducible, interactive, scalable and extensible microbiome data
                            science using QIIME 2</atl><first-page>852</first-page><last-page>857</last-page><doi>10.1038/s41587-019-0209-9</doi></journal></bib-reference><bib-reference id="bib_burguillos_et_al_2015"><label>Burguillos et al., 2015</label><journal><aus><au><snm>Burguillos</snm><fnm>M A.</fnm></au><au><snm>Svensson</snm></au><au><snm>Tim</snm></au><au><snm>Boza-Serrano</snm></au><au><snm>Garcia-Quintanilla</snm><fnm>A</fnm></au><au><snm>Kavanagh</snm></au></aus><atl>Microglia-secreted galectin-3 acts as a toll-like receptor 4 ligand and
                            contributes to microglial activation</atl><stl>Cell Rep.</stl><first-page>1626</first-page><last-page>1638</last-page><doi>10.1016/j.celrep.2015.02.012</doi></journal></bib-reference><bib-reference id="bib_buszko_et_al_2021"><label>Buszko et al., 2021</label><journal><aus><au><snm>Buszko</snm></au><au><snm>Nita-Lazar</snm></au><au><fnm>J-H.</fnm></au><au><fnm>P. L.</fnm><snm>Schwartzberg</snm></au><au><fnm>Da</fnm><snm>Verthelyi</snm></au><au><fnm>H A.</fnm><snm>Young</snm></au></aus><atl>Lessons learned: New insights on the role of cytokines in COVID-19</atl><stl>Nat. Immunol.</stl><first-page>404</first-page><doi>10.1038/s41590-021-00901-9</doi></journal></bib-reference><bib-reference id="bib_cabrero_hernandez_2020"><label>Cabrero-Hernandez, 2020</label><journal><aus><au><snm>Cabrero-Hernandez</snm></au><au><snm>Garcia-Salido</snm></au><au><snm>Leoz-Gordillo</snm></au><au><snm>Alonso-Cadenas</snm></au><au><snm>Gochi-Valdovinos</snm></au><au><snm>Gonzalez Brabin</snm></au></aus><atl>Severe SARS-CoV-2 infection in children with suspected acute abdomen: A
                            case series from a tertiary hospital in Spain</atl><stl>Pediatr. Infect. Dis. J.</stl><first-page>e195</first-page><last-page>e198</last-page><doi>10.1097/inf.0000000000002777</doi></journal></bib-reference><bib-reference id="bib_cady_et_al_2021"><label>Cady et al., 2021</label><journal><aus><au><snm>Cady</snm></au><au><fnm>N</fnm><snm>Tokranova</snm></au><au><snm>Minor</snm></au><au><snm>Nikvand</snm></au><au><snm>Klemen</snm></au><au><fnm>W T.</fnm></au></aus><atl>Multiplexed detection and quantification of human antibody response to
                            COVID-19 infection using a plasmon enhanced biosensor platform</atl><stl>Biosens. Bioelectron.</stl><vol>171</vol><first-page>112679</first-page><doi>10.1016/J.BIOS.2020.112679</doi></journal></bib-reference><bib-reference id="bib_caldarale_et_al_2021"><label>Caldarale et al., 2021</label><e-host><aus><au><snm>Caldarale</snm></au><au><snm>Giacomelli</snm></au><au><snm>Garrafa</snm></au><au><snm>Tamassia</snm></au><au><snm>Morreale</snm></au><au><snm>Poli</snm></au></aus><atl>Plasmacytoid dendritic cells depletion and elevation of IFN-γ
                            dependent chemokines CXCL9 and CXCL10 in children with multisystem
                            inflammatory syndrome</atl><msc3>Available at:</msc3><url url="https://www.frontiersin.org/articles/10.3389/fimmu.2021.654587" title="https://www.frontiersin.org/articles/10.3389/fimmu.2021.654587">
                            https://www.frontiersin.org/articles/10.3389/fimmu.2021.654587</url></e-host></bib-reference><bib-reference id="bib_callahan_et_al_2016"><label>Callahan et al., 2016</label><journal><aus><au><snm>Callahan</snm><fnm>B. J.</fnm></au><au><snm>McMurdie</snm></au><au><snm>Rosen</snm><fnm>M.l J.</fnm></au><au/><au><snm>Johnson</snm></au><au><snm>Holmes</snm><fnm>S. P.</fnm></au></aus><atl>DADA2: High-Resolution sample inference from illumina amplicon data</atl><first-page>581</first-page><last-page>583</last-page><doi>10.1038/nmeth.3869</doi></journal></bib-reference><bib-reference id="bib_callahan_et_al_2021"><label>Callahan et al., 2021</label><journal><aus><au/><au><snm>Seth</snm></au><au><snm>Crawford</snm></au><au><snm>Lehman</snm><fnm>C. W.</fnm></au><au><snm>Morrison</snm><fnm>H. A.</fnm></au><au><snm>Ivester</snm><fnm>H. M.</fnm></au></aus><atl>The pro-inflammatory chemokines CXCL9, CXCL10 and CXCL11 are
                            upregulated following SARS-CoV-2 infection in an AKT-dependent manner</atl><stl>Viruses</stl><first-page>1062</first-page><doi>10.3390/v13061062</doi></journal></bib-reference><bib-reference id="bib_chou_et_al_2020"><label>Chou et al., 2020</label><journal><aus><au><snm>Chou</snm></au><au><snm>Lasek-Nesselquist</snm></au><au><snm>Taubner</snm></au><au><snm>Pilar</snm></au><au><snm>Guignon</snm></au><au><snm>Page</snm></au></aus><atl>A fluorescent plasmonic biochip assay for multiplex screening of
                            diagnostic serum antibody targets in human lyme disease</atl><stl>PLOS ONE</stl><first-page>e0228772</first-page><doi>10.1371/JOURNAL.PONE.0228772</doi></journal></bib-reference><bib-reference id="bib_consiglio_et_al_2020"><label>Consiglio et al., 2020</label><journal><aus><au><snm>Consiglio</snm><fnm>C. R.</fnm></au><au><snm>Cotugno</snm></au><au><snm>Sardh</snm></au><au><snm>Pou</snm></au><au><snm>Amodio</snm></au><au><snm>Rodriguez</snm></au></aus><atl>The immunology of multisystem inflammatory syndrome in children with
                            COVID-19</atl><stl>Cell</stl><vol>183</vol><first-page>968</first-page><last-page>981.e7</last-page><doi>10.1016/J.CELL.2020.09.016</doi></journal></bib-reference><bib-reference id="bib_dickinson_2002"><label>Dickinson, 2002</label><journal><aus><au><snm>Dickinson</snm><fnm>D. P.</fnm></au></aus><atl>Salivary (SD-Type) cystatins: Over one billion years in the
                            making—but to what purpose?</atl><stl>Crit. Rev. Oral Biol. Med.</stl><first-page>485</first-page><last-page>508</last-page><doi>10.1177/154411130201300606</doi></journal></bib-reference><bib-reference id="bib_eduardo_et_al_2022"><label>Eduardo et al., 2022</label><journal><aus><au><snm>Eduardo</snm><fnm>C-A.</fnm></au><au><snm>Limon-de la Rosa</snm></au><au><snm>Salgado-de la Mora</snm></au><au><snm>Valdez-Sandoval</snm></au><au><snm>Palacios-Jimenez</snm></au><au><snm>Rodriguez-Alvarez</snm></au></aus><atl>Galectin-3 as a potential prognostic biomarker of severe COVID-19 in
                            SARS-CoV-2 infected patients</atl><first-page>1856</first-page><doi>10.1038/s41598-022-05968-4</doi></journal></bib-reference><bib-reference id="bib_feldstein_et_al_2020"><label>Feldstein et al., 2020</label><journal><aus><au><snm>Feldstein</snm><fnm>L. R.</fnm></au><au><snm>EricaRoseNewhams</snm><fnm>B. S M. H P. C, M M.</fnm></au><au><fnm>M B F.</fnm></au><au><snm>Newburger</snm><fnm>J W.</fnm></au><au><fnm>M. B. F.</fnm></au></aus><atl>Multisystem inflammatory syndrome in U.S. Children and adolescents</atl><stl>N. Engl. J. Med.</stl><vol>383</vol><first-page>334</first-page><last-page>346</last-page><doi>10.1056/NEJMOA2021680</doi></journal></bib-reference><bib-reference id="bib_filbin_et_al_2021"><label>Filbin et al., 2021</label><journal><aus><au><snm>Filbin</snm><fnm>M R.</fnm></au><au><snm>Mehta</snm></au><au><snm>Schneider</snm></au><au><snm>Kyle</snm></au><au><snm>Kays</snm><fnm>J R. G.</fnm></au><au><snm>Gentili</snm></au></aus><atl>Longitudinal proteomic analysis of severe COVID-19 reveals
                            survival-associated signatures, tissue-specific cell death, and
                            cell-cell interactions</atl><stl>Cell Rep. Med.</stl><first-page>100287</first-page><doi>10.1016/J.XCRM.2021.100287</doi></journal></bib-reference><bib-reference id="bib_filer_et_al_2009"><label>Filer et al., 2009</label><journal><aus><au><snm>Filer</snm></au><au><snm>Bik</snm></au><au><fnm>G N.</fnm><snm>Parsonage</snm></au><au><fnm>J</fnm><snm>Fitton</snm></au><au><snm>Trebilcock</snm></au><au><fnm>K</fnm><snm>Howlett</snm></au></aus><atl>Galectin 3 induces a distinctive pattern of cytokine and chemokine
                            production in rheumatoid synovial fibroblasts via selective signaling
                            pathways</atl><stl>Arthritis &amp; Rheumatism</stl><vol>60</vol><first-page>1604</first-page><last-page>1614</last-page><doi>10.1002/art.24574</doi></journal></bib-reference><bib-reference id="bib_finoti_et_al_2017"><label>Finoti et al., 2017</label><journal><aus><au><snm>Finoti</snm><fnm>L. S.</fnm></au><au><snm>Nepomuceno</snm></au><au><snm>Pigossi</snm><fnm>S C.</fnm></au><au><snm>Corbi</snm><fnm>S C. T.</fnm></au><au><snm>Rodrigo</snm></au><au><snm>Scarel-Caminaga</snm></au></aus><atl>Association between interleukin-8 levels and chronic periodontal
                            disease: A PRISMA-compliant systematic review and meta-analysis</atl><stl>Medicine</stl><vol>96</vol><iss>22</iss><first-page>e6932</first-page><url url="https://journals.lww.com/md-journal/Fulltext/2017/06020/Association_between_interleukin_8_levels_and.18.aspx" title="https://journals.lww.com/md-journal/Fulltext/2017/06020/Association_between_interleukin_8_levels_and.18.aspx">
                            https://journals.lww.com/md-journal/Fulltext/2017/06020/Association_between_interleukin_8_levels_and.18.aspx</url></journal></bib-reference><bib-reference id="bib_graf_et_al_2021"><label>Graf et al., 2021</label><journal><aus><au><fnm>L. N.</fnm></au><au><snm>Caimano</snm></au><au/><au><snm>Gratalo</snm></au><au><snm>Fasulo</snm></au><au><snm>Driscoll</snm></au></aus><atl>High-resolution differentiation of enteric bacteria in premature infant
                            fecal microbiomes using a novel RRNA amplicon</atl><stl>MBio</stl><first-page>036566</first-page><last-page>e3720</last-page><doi>10.1128/mBio.03656-20</doi></journal></bib-reference><bib-reference id="bib_guignon_and_lynes_2014"><label>Guignon and Lynes, 2014</label><journal><aus><au><fnm>E. F.</fnm></au><au/></aus><atl>Sensitivity enhancement of a grating-based surface plasmon-coupled
                            emission (SPCE) biosensor chip using gold thickness</atl><stl>Chem. Phys. Lett.</stl><vol>591</vol><first-page>5</first-page><last-page>9</last-page><doi>10.1016/j.cplett.2013.10.081</doi></journal></bib-reference><bib-reference id="bib_guimarães_et_al_2021"><label>Guimarães et al., 2021</label><journal><aus><au><snm>Guimarães</snm></au><au><snm>Pissarra</snm></au><au><snm>Reis-Melo</snm></au><au/></aus><atl>Multisystem inflammatory syndrome in children (misc): A systematic
                            review</atl><stl>Int. J. Clin. Pract.</stl><vol>75</vol><first-page>e14450</first-page><doi>10.1111/IJCP.14450</doi></journal></bib-reference><bib-reference id="bib_henderson_and_sethi_2009"><label>Henderson and Sethi, 2009</label><journal><aus><au><snm>Henderson</snm><fnm>N C.</fnm></au><au><snm>Sethi</snm></au></aus><atl>The regulation of inflammation by galectin-3</atl><stl>Immunol. Rev.</stl><vol>230</vol><first-page>160</first-page><last-page>171</last-page><doi>10.1111/j.1600-065X.2009.00794.x</doi></journal></bib-reference><bib-reference id="bib_hoang_et_al_2014"><label>Hoang et al., 2014</label><journal><aus><au/><au><snm>Shimizu</snm></au><au><snm>Ling</snm></au><au><snm>Adriana</snm><fnm>H. T W</fnm></au><au><snm>Levin</snm></au><au><snm>Hibberd</snm><fnm>M L.</fnm></au></aus><atl>Global gene expression profiling identifies new therapeutic targets in
                            acute Kawasaki disease</atl><stl>Genome Med.</stl><first-page>541</first-page><doi>10.1186/s13073-014-0102-6</doi></journal></bib-reference><bib-reference id="bib_hulina_et_al_2018"><label>Hulina et al., 2018</label><journal><aus><au><snm>Hulina</snm></au><au><snm>Rajković</snm><fnm>M G.</fnm></au><au><snm>Daniela</snm><fnm>J. D.</fnm></au><au><snm>Jelić</snm></au><au><snm>Dojder</snm></au><au><snm>Čepelak</snm></au><au><snm>Rumora</snm></au></aus><atl>Extracellular Hsp70 induces inflammation and modulates
                            LPS/LTA-Stimulated inflammatory response in THP-1 cells</atl><stl>Cell Stress &amp; Chaperones</stl><first-page>373</first-page><last-page>384</last-page><doi>10.1007/s12192-017-0847-0</doi></journal></bib-reference><bib-reference id="bib_jiang_et_al_2014"><label>Jiang et al., 2014</label><journal><aus><au/><au/><au><snm>Dong</snm></au><au/><au/></aus><atl>Angiotensin-converting enzyme 2 and angiotensin 1–7: Novel
                            therapeutic targets</atl><stl>Nat. Rev. Cardiol.</stl><first-page>413</first-page><last-page>426</last-page><doi>10.1038/nrcardio.2014.59</doi></journal></bib-reference><bib-reference id="bib_jin_et_al_2006"><label>Jin et al., 2006</label><journal><aus><au><fnm>G b.</fnm></au><au><snm>Unfricht</snm></au><au><snm>Fernandez</snm><fnm>S. M.</fnm></au></aus><atl>Cytometry on a chip: Cellular phenotypic and functional analysis using
                            grating-coupled surface plasmon resonance</atl><first-page>200</first-page><last-page>206</last-page><doi>10.1016/J.BIOS.2005.12.021</doi></journal></bib-reference><bib-reference id="bib_joo_et_al_2001"><label>Joo et al., 2001</label><journal><aus><au><snm>Joo</snm><fnm>H-G.</fnm></au><au><fnm>P S.</fnm><snm>Goedegebuure</snm></au><au><snm>Sadanaga</snm></au><au><snm>Nagoshi</snm></au><au><fnm>W</fnm><snm>von Bernstorff</snm></au><au><fnm>T J.</fnm><snm>Eberlein</snm></au></aus><atl>Expression and function of galectin-3, a β-galactoside-binding
                            protein in activated T lymphocytes</atl><stl>J. Leukoc. Biol.</stl><first-page>555</first-page><last-page>564</last-page><doi>10.1189/jlb.69.4.555</doi></journal></bib-reference><bib-reference id="bib_kim_et_al_2021"><label>Kim et al., 2021</label><journal><aus><au><fnm>S H.</fnm></au><au><snm>Song</snm><fnm>E S.</fnm></au><au/><au><snm>Eom</snm><fnm>G. H.</fnm></au><au/><au><snm>YoungCho</snm></au></aus><atl>Serum ferritin as a diagnostic biomarker for Kawasaki disease</atl><stl>Alm</stl><first-page>318</first-page><last-page>322</last-page><doi>10.3343/alm.2021.41.3.318</doi></journal></bib-reference><bib-reference id="bib_lee_et_al_2020"><label>Lee et al., 2020</label><journal><aus><au/><au><fnm>H-S.</fnm></au><au><snm>Joon</snm><fnm>K. L.</fnm></au></aus><atl>The importance of early recognition, timely management, and the role of
                            healthcare providers in multisystem inflammatory syndrome in children</atl><stl>Jkms</stl><vol>36</vol><first-page>177</first-page><last-page>e20</last-page><doi>10.3346/jkms.2021.36.e17</doi></journal></bib-reference><bib-reference id="bib_lee_et_al_2017"><label>Lee et al., 2017</label><journal><aus><au/><au><snm>Won</snm></au><au><fnm>H-H.</fnm></au><au><snm>Ha</snm></au><au><snm>ZangLee</snm></au></aus><atl>Pathogenic roles of CXCL10 signaling through CXCR3 and TLR4 in
                            macrophages and T cells: Relevance for arthritis</atl><stl>Arthritis Res. Ther.</stl><first-page>163</first-page><doi>10.1186/s13075-017-1353-6</doi></journal></bib-reference><bib-reference id="bib_li_et_al_2020"><label>Li et al., 2020</label><journal><aus><au/><au/><au/><au/><au/></aus><atl>Interleukin-8 as a biomarker for disease prognosis of coronavirus
                            disease-2019 patients</atl><stl>Front. Immunol.</stl><first-page>602395</first-page><doi>10.3389/fimmu.2020.602395</doi></journal></bib-reference><bib-reference id="bib_li_et_al_2009"><label>Li et al., 2009</label><journal><aus><au><snm>Dimitry</snm></au><au><snm>Stuart</snm></au><au><fnm>R</fnm><snm>Ganesan</snm></au><au><fnm>S</fnm><snm>Sa</snm></au><au><snm>Ferrando</snm></au></aus><atl>The serine protease marapsin is expressed in stratified squamous
                            epithelia and is up-regulated in the hyperproliferative epidermis of
                            psoriasis and regenerating wounds</atl><vol>284</vol><first-page>218</first-page><last-page>228</last-page><doi>10.1074/jbc.M806267200</doi></journal></bib-reference><bib-reference id="bib_li_et_al_2020b"><journal><aus><au/><au/><au><snm>Ding</snm></au><au><fnm>H.-M.</fnm></au><au><fnm>B-Y.</fnm></au><au/></aus><atl>Predictive value of serum cystatin C for risk of mortality in severe
                            and critically ill patients with COVID-19</atl><stl>World J. Clin. Cases</stl><iss>20</iss><first-page>4726</first-page><last-page>4734</last-page><doi>10.12998/wjcc.v8.i20.4726</doi></journal></bib-reference><bib-reference id="bib_lie_et_al_2001"><label>Lie et al., 2001</label><journal><aus><au><snm>Lie</snm></au><au><snm>Loos</snm><fnm>B. G.</fnm></au><au><snm>Henskens</snm></au><au><snm>Timmerman</snm><fnm>M. F.</fnm></au><au><snm>Veerman</snm></au><au><snm>van der Velden</snm></au></aus><atl>Salivary cystatin activity and cystatin C in natural and experimental
                            gingivitis in smokers and non-smokers</atl><stl>J. Clin. Periodontology</stl><first-page>979</first-page><last-page>984</last-page><doi>10.1034/j.1600-051x.2001.028010979.x</doi></journal></bib-reference><bib-reference id="bib_lopez_labady_et_al_2021"><label>Lopez-Labady et al., 2021</label><journal><aus><au><snm>Lopez-Labady</snm><fnm>T</fnm></au><au><snm>JeanethBologna-Molina</snm></au><au><snm>Villarroel-Dorrego</snm></au></aus><atl>Expression of interleukin-1ß and interleukin-8 in oral potentially
                            malignant disorders and carcinomas</atl><stl>Front. Oral Health</stl><first-page>649406</first-page><last-page>6</last-page><doi>10.3389/froh.2021.649406</doi></journal></bib-reference><bib-reference id="bib_lu_et_al_1998"><label>Lu et al., 1998</label><journal><aus><au/><au/><au/></aus><adate>1998</adate><atl>HSP60, HSP70 in the pathogenesis of Kawasaki disease: Implication and
                            action</atl><stl>J. Tongji Med. Univ. = Tong Ji Yi Ke Da Xue Xue Bao</stl><first-page>145</first-page><last-page>148</last-page><doi>10.1007/BF02888523</doi></journal></bib-reference><bib-reference id="bib_mahmoud_et_al_2021"><label>Mahmoud et al., 2021</label><journal><aus><au><snm>Mahmoud</snm></au><au><snm>EmanFouda</snm></au><au><snm>Kotby</snm></au><au><snm>Ibrahim</snm></au><au><snm>Gamal</snm></au><au><snm>el Gendy</snm><fnm>Y. G.</fnm></au></aus><atl>The ‘golden hours’ algorithm for the management of the
                            multisystem inflammatory syndrome in children (MIS-C)</atl><stl>Glob. Pediatr. Health</stl><first-page>2333794X2199033</first-page><doi>10.1177/2333794X21990339</doi></journal></bib-reference><bib-reference id="bib_marusov_et_al_2012"><label>Marusov et al., 2012</label><journal><aus><au><snm>Marusov</snm></au><au><snm>Sweatt</snm></au><au><snm>Pietrosimone</snm></au><au><snm>Benson</snm></au><au><snm>Geary</snm><fnm>S. J.</fnm></au><au><snm>Silbart</snm><fnm>L. K.</fnm></au></aus><atl>A microarray biosensor for multiplexed detection of microbes using
                            grating-coupled surface plasmon resonance imaging</atl><stl>Environ. Sci. Technol.</stl><last-page>359</last-page><doi>10.1021/ES201239F</doi></journal></bib-reference><bib-reference id="bib_mcmurdie_and_holmes_2013"><label>McMurdie and Holmes, 2013</label><journal><aus><au/></aus><atl>Phyloseq: An R package for reproducible interactive analysis and
                            graphics of microbiome census data</atl><first-page>e61217</first-page><doi>10.1371/journal.pone.0061217</doi></journal></bib-reference><bib-reference id="bib_molony_et_al_2012"><label>Molony et al., 2012</label><journal><aus><au><snm>Molony</snm><fnm>R. D.</fnm></au><au><snm>Rice</snm></au><au><snm>Shetty</snm></au><au><snm>Dey</snm></au><au/></aus><atl>Mining the salivary proteome with grating-coupled surface plasmon
                            resonance imaging and surface plasmon coupled emission microarrays <i>current
                            Protocols in toxicology</i> chapter</atl><stl>Curr. Protoc. Toxicol.</stl><iss>53</iss><msc3>Unit 18.16.1-19</msc3><doi>10.1002/0471140856.TX1816S53</doi></journal></bib-reference><bib-reference id="bib_mostafa_et_al_2022"><label>Mostafa et al., 2022</label><journal><aus><au><snm>Mostafa</snm><fnm>G A.</fnm></au><au><snm>Mohamed Ibrahim</snm></au><au><snm>Abeer Al</snm><fnm>S S.</fnm></au></aus><x>, (</x><atl>Up-regulated serum levels of soluble CD25 and soluble CD163 in
                            pediatric patients with SARS-CoV-2</atl><stl>Eur. J. Pediatr.</stl><vol>181</vol><first-page>2299</first-page><last-page>2309</last-page><doi>10.1007/s00431-022-04398-8</doi></journal></bib-reference><bib-reference id="bib_newburger_et_al_2016"><label>Newburger et al., 2016</label><journal><aus><au/><au><snm>Takahashi</snm></au><au><snm>Burns</snm></au></aus><atl>Kawasaki disease</atl><stl>J. Am. Coll. Cardiol.</stl><vol>67</vol><first-page>1738</first-page><last-page>1749</last-page><doi>10.1016/J.JACC.2015.12.073</doi></journal></bib-reference><bib-reference id="bib_noordin_and_nurulhasanah_2013"><label>Noordin and Nurulhasanah, 2013</label><journal><aus><au><snm>Noordin</snm></au><au><snm>Nurulhasanah</snm></au></aus><atl>Proteomics technology – a powerful tool for the biomedical
                            scientists</atl><stl>Malays. J. Med. Sci. MJMS</stl><last-page>2</last-page><query>Q18: Provide the doi for “Noordin and Nurulhasanah,
                            2013”. https://www.frontiersin.org.cn/authors-proof-support/#QA53</query></journal></bib-reference><bib-reference id="bib_okada_et_al_2003"><label>Okada et al., 2003</label><journal><aus><au><snm>Okada</snm></au><au><snm>Shinohara</snm></au><au><snm>Kobayashi</snm></au><au><snm>Inoue</snm></au><au><snm>Tomomasa</snm></au><au/></aus><atl>Effect of corticosteroids in addition to intravenous gamma globulin
                            therapy on serum cytokine levels in the acute phase of Kawasaki disease
                            in children</atl><stl>J. Pediatr.</stl><vol>143</vol><first-page>363</first-page><last-page>367</last-page><doi>10.1067/S0022-3476(03)00387-1</doi></journal></bib-reference><bib-reference id="bib_osińska_et_al_2014"><label>Osińska et al., 2014</label><journal><aus><au><snm>Osińska</snm><fnm>Iw.</fnm></au><au><snm>Popko</snm></au><au><snm>Demkow</snm></au></aus><atl>Perforin: An important player in immune response</atl><stl>Central-European J. Immunol.</stl><first-page>109</first-page><last-page>115</last-page><doi>10.5114/ceji.2014.42135</doi></journal></bib-reference><bib-reference id="bib_patel_et_al_2013"><label>Patel et al., 2013</label><journal><aus><au><snm>Patel</snm><fnm>V. B.</fnm></au><au><snm>Parajuli</snm></au><au><snm>Oudit</snm><fnm>G. Y.</fnm></au></aus><atl>Role of angiotensin-converting enzyme 2 (ACE2) in diabetic
                            cardiovascular complications</atl><stl>Clin. Sci.</stl><vol>126</vol><first-page>471</first-page><last-page>482</last-page><doi>10.1042/CS20130344</doi></journal></bib-reference><bib-reference id="bib_phamduy_et_al_2021"><label>Phamduy et al., 2021</label><journal><aus><au><snm>Phamduy</snm><fnm>T. T.</fnm></au><au><snm>Smith</snm></au><au/><au><fnm>P. T.</fnm></au><au><fnm>M</fnm><snm>Brimacombe</snm></au><au><snm>Alexander</snm></au></aus><atl>Kawasaki disease hospitalizations in the United States
                            2016–2020: A comparison of before and during the coronavirus
                            disease 2019 era.Pediatr</atl><stl>Infect. Dis. J.</stl><first-page>e407</first-page><last-page>e412</last-page><doi>10.1097/INF.0000000000003289</doi></journal></bib-reference><bib-reference id="bib_qiu_et_al_2022"><label>Qiu et al., 2022</label><journal><aus><au/><au/><au><snm>GuoFan</snm></au><au><fnm>W. X.</fnm></au><au/></aus><atl>The clinical implications of serum ferritin in Kawasaki disease: A
                            helpful biomarker for evaluating therapeutic responsiveness, coronary
                            artery involvement and the tendency of macrophage activation syndrome</atl><stl>Archives Med. Sci. AMS</stl><first-page>267</first-page><last-page>274</last-page><doi>10.5114/aoms/144293</doi></journal></bib-reference><bib-reference id="bib_radia_et_al_2021"><label>Radia et al., 2021</label><journal><aus><au><snm>Radia</snm></au><au><snm>Williams</snm></au><au><snm>Agrawal</snm></au><au><snm>Harman</snm></au><au><snm>Jonathan</snm></au><au><snm>Cook</snm></au></aus><atl>Multi-system inflammatory syndrome in children &amp; adolescents
                            (MIS-C): A systematic review of clinical features and presentation</atl><stl>Paediatr. Respir. Rev.</stl><last-page>57</last-page><doi>10.1016/J.PRRV.2020.08.001</doi></journal></bib-reference><bib-reference id="bib_ramaswamy_et_al_2020"><label>Ramaswamy et al., 2020</label><journal><aus><au><snm>Ramaswamy</snm><fnm>A.i</fnm></au><au><snm>Brodsky</snm><fnm>N. N.</fnm></au><au><snm>Tomokazu</snm></au><au><snm>Comi</snm></au><au><snm>Asashima</snm></au><au><snm>Hoehn</snm><fnm>K. B.</fnm></au></aus><atl>Post-infectious inflammatory disease in MIS-C features elevated
                            cytotoxicity signatures and autoreactivity that correlates with severity</atl><stl>MedRxiv Prepr. Serv. Health Sci.</stl><vol>2020</vol><first-page>20241364</first-page><doi>10.1101/2020.12.01.20241364</doi></journal></bib-reference><bib-reference id="bib_reilly_et_al_2006"><label>Reilly et al., 2006</label><journal><aus><au><snm>Reilly</snm></au><au><snm>Nessing</snm><fnm>P. A.</fnm></au><au/></aus><atl>SPR surface enhanced fluorescence with a gold-coated corrugated sensor
                            chip</atl><stl>Proc. SPIE</stl><vol>6099</vol><first-page>60990E</first-page><doi>10.1117/12.646165</doi></journal></bib-reference><bib-reference id="bib_rice_et_al_2012"><label>Rice et al., 2012</label><journal><aus><au/><au><snm>Stern</snm><fnm>E. F. G., D A. L.</fnm></au></aus><atl>Antigen-specific T cell phenotyping microarrays using grating coupled
                            surface plasmon resonance imaging and surface plasmon coupled emission</atl><first-page>264</first-page><last-page>269</last-page><doi>10.1016/J.BIOS.2011.10.029</doi></journal></bib-reference><bib-reference id="bib_russell_et_al_2012"><label>Russell et al., 2012</label><journal><aus><au><snm>Russell</snm><fnm>S. E.</fnm></au><au><snm>Anne C Moore</snm><fnm>P. G. F</fnm></au><au><snm>Walsh</snm></au></aus><atl>Soluble IL-2rα (SCD25) exacerbates autoimmunity and enhances the
                            development of Th17 responses in mice</atl><first-page>e47748</first-page><doi>10.1371/journal.pone.0047748</doi></journal></bib-reference><bib-reference id="bib_teraura_et_al_2016"><label>Teraura et al., 2016</label><journal><aus><au><snm>Teraura</snm></au><au><snm>Kotani</snm></au><au><snm>Minami</snm></au><au><snm>Takeshima</snm></au><au><snm>Shimooki</snm></au><au><snm>Kajii</snm></au></aus><atl>The serum concentration of soluble interleukin-2 receptor in patients
                            with Kawasaki disease</atl><stl>Ann. Clin. Biochem.</stl><vol>54</vol><first-page>209</first-page><last-page>213</last-page><doi>10.1177/0004563216677583</doi></journal></bib-reference><bib-reference id="bib_tizard_2005"><label>Tizard, 2005</label><journal><aus><au><snm>Tizard</snm><fnm>E. J.</fnm></au></aus><atl>Complications of Kawasaki disease</atl><stl>Curr. Paediatr.</stl><first-page>62</first-page><last-page>68</last-page><doi>10.1016/j.cupe.2004.09.002</doi></journal></bib-reference><bib-reference id="bib_unfricht_et_al_2005"><label>Unfricht et al., 2005</label><journal><aus><au><snm>Colpitts</snm><fnm>S. L.</fnm></au><au><fnm>S.M.</fnm></au></aus><atl>Grating-coupled surface plasmon resonance: A cell and protein
                            microarray platform</atl><stl>Proteomics</stl><iss>17</iss><first-page>4432</first-page><last-page>4442</last-page><doi>10.1002/PMIC.200401314</doi></journal></bib-reference><bib-reference id="bib_whittaker_et_al_2020"><label>Whittaker et al., 2020</label><journal><aus><au><snm>Whittaker</snm></au><au><snm>Bamford</snm></au><au><snm>Kenny</snm></au><au><snm>Kaforou</snm></au><au><snm>Jones</snm><fnm>C. E.</fnm></au><au><snm>Shah</snm></au></aus><atl>Clinical characteristics of 58 children with a pediatric inflammatory
                            multisystem syndrome temporally associated with SARS-CoV-2</atl><stl>JAMA</stl><vol>324</vol><first-page>259</first-page><doi>10.1001/JAMA.2020.10369</doi></journal></bib-reference><bib-reference id="bib_yamamoto_et_al_2015"><label>Yamamoto et al., 2015</label><journal><aus><au><snm>Yamamoto</snm></au><au><snm>Sato</snm></au><au><snm>Hoshina</snm></au><au><snm>Kojiro</snm></au><au><snm>Kusuhara</snm></au></aus><atl>Utility of ferritin as a predictor of the patients with Kawasaki
                            disease refractory to intravenous immunoglobulin therapy</atl><stl>Mod. Rheumatol.</stl><first-page>898</first-page><last-page>902</last-page><doi>10.3109/14397595.2015.1038430</doi></journal></bib-reference><bib-reference id="bib_yates_et_al_2020"><label>Yates et al., 2020</label><book><aus><au><snm>Yates</snm><fnm>J L.</fnm></au><au><snm>Dylan</snm><fnm>J. E</fnm></au><au><fnm>D T.</fnm><snm>Hunt</snm></au><au><fnm>R C.</fnm><snm>Girardin</snm></au><au><snm>Dupuis</snm></au><au><fnm>A F.</fnm><snm>Payne</snm></au></aus><btl>Serological analysis reveals an imbalanced IgG subclass composition
                            associated with COVID-19 disease severity</btl><pub>MedRxiv</pub><doi>10.1101/2020.10.07.20208603</doi><query>Q19: Ref. Yates et al., 2020: Please provide the city name of the
                            publisher. https://www.frontiersin.org.cn/authors-proof-support/#QA52</query></book></bib-reference><bib-reference id="bib_yates_et_al_2021"><label>Yates et al., 2021</label><journal><aus><au><fnm>J. L.</fnm></au><au><snm>DylanEhrbar</snm></au><au><fnm>D. T.</fnm></au><au><fnm>R. C.</fnm></au><au><snm>AlanDupuis</snm></au><au/></aus><atl>Serological analysis reveals an imbalanced IgG subclass composition
                            associated with COVID-19 disease severity</atl><first-page>100329</first-page><doi>10.1016/j.xcrm.2021.100329</doi></journal></bib-reference><bib-reference id="bib_yuk_et_al_2013"><label>Yuk et al., 2013</label><journal><aus><au><snm>Yuk</snm><fnm>J S.</fnm></au></aus><atl>Highly sensitive grating coupler-based surface plasmon-coupled emission
                            (SPCE) biosensor for immunoassay</atl><stl>Analyst</stl><vol>138</vol><first-page>2576</first-page><last-page>2582</last-page><doi>10.1039/C3AN00135K</doi></journal></bib-reference><bib-reference id="bib_ziegelasch_et_al_2019"><label>Ziegelasch et al., 2019</label><journal><aus><au><snm>Ziegelasch</snm></au><au><snm>Vogel</snm></au><au><snm>Müller</snm></au><au><snm>Tremel</snm></au><au><snm>Jurkutat</snm></au><au/></aus><atl>Cystatin C serum levels in healthy children are related to age, gender,
                            and pubertal stage</atl><stl>Pediatr. Nephrol. Berl. Ger.</stl><first-page>449</first-page><last-page>457</last-page><doi>10.1007/s00467-018-4087-z</doi></journal></bib-reference></bibliography-sec></bibreference><figuregroup id="fig1"><figcaption id="fig1"><text><del rule="ACEtool_UCA_rule_insert_pipe_symbol_in_floating_elements" blackbox="true">. </del>GCFP assay and wavelength pathway. <ins rule="ACEtool_MultipartFigureLabelsShouldbeBoldStyle_fullContent_withCommaSepartor" blackbox="true">(<b>A)</b></ins><del rule="ACEtool_MultipartFigureLabelsShouldbeBoldStyle_fullContent_withCommaSepartor" blackbox="true">(A)</del> Capture antibodies are immobilized onto a
                    gold-coated nanoscale grating surface chip by pin spotting. Chips were then
                    fitted with plexiglass windows and gaskets to create a flow cell for fluid to
                    pass over the surface of the printed chip. Fluid containing potential analytes
                    can then be run over the assembled chip, followed by biotinylated secondary
                    antibodies and then streptavidin-Alexafluor647, with washes in between steps
                    with PSB-T. The chip can then be placed in a GCFP reader where a laser
                    illuminates the chip and the fluorescence intensity is collected with a camera
                    and each ROI is analyzed using Enhanced Fluorescence Reader software, V2.3. <del rule="ACEtool_MultipartFigureLabelsShouldbeBoldStyle_fullContent_withCommaSepartor" blackbox="true">(B)</del>. Under normal SPR optical conditions, the energy
                    of the light excites electron density oscillation (the plasmon) within the metal
                    coating on the sensor chip, reducing the intensity of the reflected light (Black
                    lines). Using the diffraction grating on the chip, the wave vector of the
                    illuminating beam of light can be matched with the plasmon wave vector (red
                    lines). The gold grating plus the use of a fluorophore increases the collected
                    light, thereby enhancing the signal (red lines).<query>Q20: Ensure that all the
                    figures, tables, and captions are correct, and that all figures are of the
                    highest quality/resolution. If necessary, you may upload improved figures to the
                    Production Forum. Please note that figures and tables must be cited
                    sequentially, per the . </query></text></figcaption></figuregroup><figuregroup id="fig2"><figcaption id="fig2"><text>Development of sandwich-based ELISA assay on a
                    gold-coated nanoscale grating surface chip.  Capture antibodies for IL-6 and IL-8 were
                    immobilized onto the chip, along with the negative control (PBS) and two
                    positive controls; biotin-BSA (BLC-BSA, to show streptavidin binding) and
                    Alexafluor 647-BSA (to show stabilization during washing), 20ng/mL of
                    recombinant IL-6 and IL-8 were flowed over the chip. The fluorescence intensity
                    was collected as previously described. Fluorescent intensity within the ROIs for
                    IL-6, IL-8 and positive controls was significantly higher than the negative
                    control.  Forty-two capture antibodies were immobilized onto
                    the chip, 20 ng/mL each of recombinant CCL5, galactin-3 and CCL7 diluted in
                    PBS was run over the chip and the fluorescence intensity was collecting for each
                    ROI as previously described. The fluorescent intensity within the ROIs for CCL5,
                    galactin-3 and CCL7 were significantly higher than the negative control. <del rule="ACEtool_MultipartFigureLabelsShouldbeBoldStyle_fullContent_withCommaSepartor" blackbox="true">(C)</del> Forty-two capture antibodies were immobilized onto
                    the chip, 20 ng/mL of recombinant protein CCL5 and CCL7 diluted in human
                    saliva was run over the chip and the fluorescence intensity was collected for
                    each ROI as previously described. The fluorescent intensity within the ROIs for
                    CCL5 and CCL7 were significantly higher than the negative control. <del rule="ACEtool_MultipartFigureLabelsShouldbeBoldStyle_fullContent_withCommaSepartor" blackbox="true">(D)</del> A heat map was generated using the detection
                    ratio, which was normalized to the negative control to compare data in B and . One-way ANOVA analysis was performed (*<i><del rule="ICEtool_Ital_LatinSingleLtrVariableAfterMathOper">p</del></i>
                    &lt;0.05, **
                    &lt;0.01, ***
                    &lt;0.001, ****
                    &lt;0.0001. The data are presented as the average of five ROIs for each
                    analyte (<ins rule="ACEtool_rule_use_correct_operators_in_online">
                     ± </ins><del rule="ACEtool_rule_use_correct_operators_in_online">
                    +/- </del>standard error of the mean).</text></figcaption></figuregroup><figuregroup id="fig3"><figcaption id="fig3"><text>Example of patient (210041005) data generated from
                    GCFP assay.  Forty-two unique capture antibodies were
                    immobilized on regions of interest in sets of 5 ROIs on the chip and patient
                    sample number 210041005 was run over the chip and an image of the GCFP sensor
                    chip output was captured.  Fluorescent intensity within the ROIs were
                    collected as previously described, detecting cystatin C, Marapsin, D-dimer,
                    galaectin-3, and IL-8.  A heat map of the detection ratio was generated
                    and shows detection of the same analytes as in . One-way ANOVA analysis was performed (*
                    &lt;0.05, **
                    &lt;0.01, ***
                    &lt;0.001, ****
                    &lt;0.0001. The data are presented as the average of five ROIs for each
                    analyte (standard error of the mean).</text></figcaption></figuregroup><figuregroup id="fig4"><figcaption id="fig4"><text>GCFP detection ratio for patient saliva samples.
                    Saliva samples obtained from each of the patient cohorts; 54 samples (A1= 15, A29, A36, B14, B213, B37) were run over the
                    first-generation biosensor chip.  Heat maps generated for each cohort using the mean
                    detection ratio for each analyte, showing candidate biomarkers for the A2
                    (CXCL10), A3 (sDC25) and B1(IL-1β and IL-2) cohorts.  Heat maps generated for each individual patient
                    demonstrate individual variation in disease state.</text></figcaption></figuregroup><figuregroup id="fig5"><figcaption id="fig5"><text>GCFP detection ratio for serum samples from patient
                    cohorts. Serum samples from each of the cohorts were tested on the first
                    generation GCFP biosensor chip. 56 samples (A113, A212, B112, B212, B37) were tested.  Heat maps generated for each cohort using the mean
                    detection ratio for each analyte, showing a more robust signature per cohort
                    then within saliva.  Heat maps generated for each patient, showing
                    individual variation in disease state.</text></figcaption></figuregroup><figuregroup id="fig6"><figcaption id="fig6"><text>Salivary microbiome of samples analyzed using GCFP.
                    From saliva samples analyzed by GCFP using the first generation GCFP biosensor
                    chip, 34 samples were also analyzed by 16S RNA high throughput sequencing.
                    Relative abundance at species level was calculated.  Relative abundance of the top 20 most abundant
                    taxa across all samples. <b><ins rule="ACEtool_MultipartFigureLabelsShouldbeBoldStyle_fullContent_withCommaSepartor" blackbox="true">(B–I)</ins></b><del rule="ACEtool_MultipartFigureLabelsShouldbeBoldStyle_fullContent_withCommaSepartor" blackbox="true">(B-I)</del> Plots of the relative abundance for 8 bacterial
                    species that were elevated in one or more outlier samples from analyte data.
                    Error bars represent a 95% confidence interval of the median. Points in red were
                    identified as outliers by the ROUT method. Samples that were analyte outliers
                    and had an increase in that species are labeled with their cohort.</text></figcaption></figuregroup><figuregroup id="fig7"><figcaption id="fig7"><text>Potential analytes found by MIA can inform the
                    evolving composition of a second generation GCFP biosensor chip.  A
                    heat map was generated from microbead immunoassay from serum samples for each
                    cohort. * Indicates a significant difference in that cytokine for the A2 cohort
                    for CXCL11, IL-8, IL-6, IL-4, IL-13, &amp; IL-10 analytes. <b><ins rule="ACEtool_MultipartFigureLabelsShouldbeBoldStyle_fullContent_withCommaSepartor" blackbox="true">(B–G)</ins></b><del rule="ACEtool_MultipartFigureLabelsShouldbeBoldStyle_fullContent_withCommaSepartor" blackbox="true">(B-G)</del> The antibody response to the SARS-CoV-2
                    nucleocapsid and spike components (full spike, RBD, S1, S2), the MIS-C cohort
                    had a significantly higher IgA response to SARS-COV-2 spike domains as compared
                    to the COVID-19 cohort. One-way ANOVA analysis was performed (*
                    &lt;0.05, **
                    &lt;0.01, ***
                    &lt;0.001, ****
                    &lt;0.0001.</text></figcaption></figuregroup><figuregroup id="fig8"><figcaption id="fig8"><text>Comparison of USA vs
                    Colombia MIS-C patient samples by GCFP microarray.  Heat map of A2 serum samples comparing USA to
                    Colombia samples. The USA patient population has a more robust signature.  Heat of A2 saliva samples comparing USA to
                    Colombia samples, USA has a more robust signature.</text></figcaption></figuregroup><figuregroup id="fig9"><figcaption id="fig9"><text><ins rule="ACEtool_UCA_rule_insert_pipe_symbol_in_floating_elements" blackbox="true"><x> |</x></ins>Serum from Cohorts and individual patient comparison
                    of GCFP microarray assay to MIA. To compare a traditional MIA with the GCFP
                    microarray, 11 analytes were included in both assays.  A heat map was generated by log transforming GCFP
                    detection ratios and using the mean of each analyte detection ratio for each
                    cohort. Of the 11 analytes, 5 were below the detection limit of the GCFP first
                    generation biosensor chip.  A heat map generated by log transforming GCFP
                    detection ratios from individual serum samples from cohort A1.  A heat map generated by log transforming GCFP
                    detection ratios from individual serum samples from cohort A2.  A heat map generated by log transforming GCFP
                    detection ratios from individual serum samples from cohort B1. <del rule="ACEtool_MultipartFigureLabelsShouldbeBoldStyle_fullContent_withCommaSepartor" blackbox="true">(E)</del> A heat map generated by log transforming GCFP
                    detection ratios from individual serum samples from cohort B2. <del rule="ACEtool_MultipartFigureLabelsShouldbeBoldStyle_fullContent_withCommaSepartor" blackbox="true">(F)</del> A heat map generated by log transforming GCFP
                    detection ratios from individual serum samples from cohort B3. 16 of the 44
                    shared serum samples had similar biomarker signatures, while IL-4, IL-6 and
                    CCL20 were not consistently detected on the GCFP chip.</text></figcaption></figuregroup><figuregroup id="fig10"><figcaption id="fig10"><label>FIGURE 10</label><x/><text>Optimization of First Generation GCFP Chip.  Measurements of the limit of detection for 11
                    analytes from the first-generation biosensor chip. 1ng/mL is the
                    limit of detection for most analytes in this assay.  Optimizing reagents can increase the limit of
                    detection.</text></figcaption></figuregroup><tablegroup><tablecaption id="tbl1"><x/><text>Regions of interest used on first generation chip</text></tablecaption><table frame="topbot"><thead><tr><td colspan="1"><p>Marker class</p></td><td colspan="1"><p>Analytes</p></td></tr></thead><tbody><tr><td colspan="1"><p><b>Cytokines</b></p></td><td colspan="1"><p>IL-7, IL-21, IFNg, IL-15, IL-6, IL-10, IL-17, IL-2, IL-4, IL-1b,
                                TNFa, IL-33, IL-18 (total), IL-18BPa</p></td></tr><tr><td colspan="1"><p><b>Chemokines</b></p></td><td colspan="1"><p>CCL20, CXCL11, CCL24, CCL2, CCL3, CCL7, CXCL10, CXCL9, CCL5, CCL17,
                                CXCL8, CX3CL1</p></td></tr><tr><td colspan="1"><p><b>Interleukin receptor</b></p></td><td colspan="1"><p>sCD25</p></td></tr><tr><td colspan="1"><p><b>Kidney function</b></p></td><td colspan="1"><p>Cystatin C</p></td></tr><tr><td colspan="1"><p><b>Indicator of Inflammation</b></p></td><td colspan="1"><p>CRP</p></td></tr><tr><td colspan="1"><p><b>Range of biological processes</b></p></td><td colspan="1"><p>Galectin-3</p></td></tr><tr><td colspan="1"><p><b>Infection indicator</b></p></td><td colspan="1"><p>Procalcitonin</p></td></tr><tr><td colspan="1"><p><b>Type 1 membrane protein</b></p></td><td colspan="1"><p>B7-1/CD80</p></td></tr><tr><td colspan="1"><p><b>Protein found on antigen presenting cells</b></p></td><td colspan="1"><p>Perforin</p></td></tr><tr><td colspan="1"><p><b>Peptide involved in central and peripheral nervous systems</b></p></td><td colspan="1"><p>Neuropeptide Y</p></td></tr><tr><td colspan="1"><p><b>Serine protease that is expressed strongly in the pancreas</b></p></td><td colspan="1"><p>Marapsin/Pancreasin</p></td></tr><tr><td colspan="1"><p><b>Cell death</b></p></td><td colspan="1"><p>LDH(A)</p></td></tr><tr><td colspan="1"><p><b>Protein fragments produced when a blood clot</b></p></td><td colspan="1"><p>D-Dimer</p></td></tr><tr><td colspan="1"><p><b>Tissue damage</b></p></td><td colspan="1"><p>Cardiotrophin-1</p></td></tr><tr><td colspan="1"><p><b>Spike protein receptor</b></p></td><td colspan="1"><p>ACE-2</p></td></tr><tr><td colspan="1"><p><b>Heat shock protein</b></p></td><td colspan="1"><p>HSP70</p></td></tr><tr><td colspan="1"><p><b>Iron levels</b></p></td><td colspan="1"><p>Ferritin</p></td></tr></tbody></table></tablegroup><tablegroup><tablecaption id="tbl2"><text>MIA Cytokine levels US vs
                    Colombia</text></tablecaption><table frame="topbot"><thead><tr><td colspan="2" align="center"><p>A1</p></td><td colspan="2" align="center"><p>A2</p></td><td colspan="2" align="center"><p>B1</p></td><td colspan="2" align="center"><p>B2</p></td></tr></thead><tbody><tr><td colspan="1"><p><b>Cytokine (pg/mL)</b></p></td><td colspan="1" align="center"><p>US</p></td><td colspan="1" align="center"><p>Colombia</p></td></tr><tr><td colspan="1"><p><b>CXCL11</b></p></td><td colspan="1" align="center"><p>262.8</p></td><td colspan="1" align="center"><p>359.2</p></td><td colspan="1" align="center"><p>1123</p></td><td colspan="1" align="center"><p>520.2</p></td><td colspan="1" align="center"><p>379.3</p></td><td colspan="1" align="center"><p>466.5</p></td><td colspan="1" align="center"><p>181</p></td><td colspan="1" align="center"><p>195.6</p></td></tr><tr><td colspan="1"><p><b>GM-CSF</b></p></td><td colspan="1" align="center"><p>120.6</p></td><td colspan="1" align="center"><p>239.4</p></td><td colspan="1" align="center"><p>203.1</p></td><td colspan="1" align="center"><p>163.2</p></td><td colspan="1" align="center"><p>250.3</p></td><td colspan="1" align="center"><p>291.4</p></td><td colspan="1" align="center"><p>111.6</p></td><td colspan="1" align="center"><p>228.7</p></td></tr><tr><td colspan="1"><p><b>CX3CL1</b></p></td><td colspan="1" align="center"><p>236.1</p></td><td colspan="1" align="center"><p>246.3</p></td><td colspan="1" align="center"><p>272</p></td><td colspan="1" align="center"><p>254.2</p></td><td colspan="1" align="center"><p>246.9</p></td><td colspan="1" align="center"><p>268.3</p></td><td colspan="1" align="center"><p>213.6</p></td><td colspan="1" align="center"><p>244.9</p></td></tr><tr><td colspan="1"><p><b>IFN-γ</b></p></td><td colspan="1" align="center"><p>105</p></td><td colspan="1" align="center"><p>113.1</p></td><td colspan="1" align="center"><p>137.3</p></td><td colspan="1" align="center"><p>150.4</p></td><td colspan="1" align="center"><p>92.00</p></td><td colspan="1" align="center"><p>87.81</p></td><td colspan="1" align="center"><p>56.72</p></td><td colspan="1" align="center"><p>106.5</p></td></tr><tr><td colspan="1"><p><b>IL-10</b></p></td><td colspan="1" align="center"><p>46.3</p></td><td colspan="1" align="center"><p>174.6</p></td><td colspan="1" align="center"><p>187.4</p></td><td colspan="1" align="center"><p>157</p></td><td colspan="1" align="center"><p>71.07</p></td><td colspan="1" align="center"><p>79.41</p></td><td colspan="1" align="center"><p>26.82</p></td><td colspan="1" align="center"><p>75.5</p></td></tr><tr><td colspan="1"><p><b>CCL20</b></p></td><td colspan="1" align="center"><p>33.2</p></td><td colspan="1" align="center"><p>49.1</p></td><td colspan="1" align="center"><p>59.7</p></td><td colspan="1" align="center"><p>151.4</p></td><td colspan="1" align="center"><p>43.72</p></td><td colspan="1" align="center"><p>64.38</p></td><td colspan="1" align="center"><p>27.83</p></td><td colspan="1" align="center"><p>42.6</p></td></tr><tr><td colspan="1"><p><b>IL-12(p70)</b></p></td><td colspan="1" align="center"><p>5.3</p></td><td colspan="1" align="center"><p>7.6</p></td><td colspan="1" align="center"><p>5.2</p></td><td colspan="1" align="center"><p>5.9</p></td><td colspan="1" align="center"><p>6.6</p></td><td colspan="1" align="center"><p>6.052</p></td><td colspan="1" align="center"><p>6.3</p></td></tr><tr><td colspan="1"><p><b>IL-13</b></p></td><td colspan="1" align="center"><p>34.1</p></td><td colspan="1" align="center"><p>14.03</p></td><td colspan="1" align="center"><p>119.2</p></td><td colspan="1" align="center"><p>24.53</p></td><td colspan="1" align="center"><p>114.4</p></td><td colspan="1" align="center"><p>20.26</p></td><td colspan="1" align="center"><p>19.98</p></td><td colspan="1" align="center"><p>27.4</p></td></tr><tr><td colspan="1"><p><b>IL-17A</b></p></td><td colspan="1" align="center"><p>21.9</p></td><td colspan="1" align="center"><p>24.18</p></td><td colspan="1" align="center"><p>26.2</p></td><td colspan="1" align="center"><p>18.50</p></td><td colspan="1" align="center"><p>27.45</p></td><td colspan="1" align="center"><p>21.86</p></td><td colspan="1" align="center"><p>15.84</p></td><td colspan="1" align="center"><p>25.8</p></td></tr><tr><td colspan="1"><p><b>IL-1β</b></p></td><td colspan="1" align="center"><p>3.7</p></td><td colspan="1" align="center"><p>4.1</p></td><td colspan="1" align="center"><p>4.3</p></td><td colspan="1" align="center"><p>5.4</p></td><td colspan="1" align="center"><p>3.779</p></td></tr><tr><td colspan="1"><p><b>IL-2</b></p></td><td colspan="1" align="center"><p>7.4</p></td><td colspan="1" align="center"><p>6.8</p></td><td colspan="1" align="center"><p>6.4</p></td><td colspan="1" align="center"><p>6.9</p></td><td colspan="1" align="center"><p>7.1</p></td><td colspan="1" align="center"><p>4.4</p></td><td colspan="1" align="center"><p>7.3</p></td></tr><tr><td colspan="1"><p><b>IL-21</b></p></td><td colspan="1" align="center"><p>9.2</p></td><td colspan="1" align="center"><p>10.1</p></td><td colspan="1" align="center"><p>10.17</p></td><td colspan="1" align="center"><p>11.80</p></td><td colspan="1" align="center"><p>7.2</p></td><td colspan="1" align="center"><p>11</p></td></tr><tr><td colspan="1"><p><b>IL-4</b></p></td><td colspan="1" align="center"><p>71.05</p></td><td colspan="1" align="center"><p>689.4</p></td><td colspan="1" align="center"><p>125.6</p></td><td colspan="1" align="center"><p>532.0</p></td><td colspan="1" align="center"><p>106.6</p></td><td colspan="1" align="center"><p>146.0</p></td><td colspan="1" align="center"><p>129</p></td></tr><tr><td colspan="1"><p><b>IL-23</b></p></td><td colspan="1" align="center"><p>1103</p></td><td colspan="1" align="center"><p>792.4</p></td><td colspan="1" align="center"><p>1302</p></td><td colspan="1" align="center"><p>768.8</p></td><td colspan="1" align="center"><p>1530</p></td><td colspan="1" align="center"><p>43,016</p></td><td colspan="1" align="center"><p>532.5</p></td><td colspan="1" align="center"><p>1031</p></td></tr><tr><td colspan="1"><p><b>IL-5</b></p></td><td colspan="1" align="center"><p>8.4</p></td><td colspan="1" align="center"><p>6.068</p></td><td colspan="1" align="center"><p>19.4</p></td><td colspan="1" align="center"><p>7.8</p></td><td colspan="1" align="center"><p>20.49</p></td><td colspan="1" align="center"><p>24.93</p></td></tr><tr><td colspan="1"><p><b>IL-6</b></p></td><td colspan="1" align="center"><p>27.3</p></td><td colspan="1" align="center"><p>8.9</p></td><td colspan="1" align="center"><p>77.0</p></td><td colspan="1" align="center"><p>61.24</p></td><td colspan="1" align="center"><p>12.35</p></td><td colspan="1" align="center"><p>23.08</p></td><td colspan="1" align="center"><p>11.28</p></td></tr><tr><td colspan="1"><p><b>IL-7</b></p></td><td colspan="1" align="center"><p>18.5</p></td><td colspan="1" align="center"><p>15.5</p></td><td colspan="1" align="center"><p>18.59</p></td><td colspan="1" align="center"><p>30.50</p></td><td colspan="1" align="center"><p>13.68</p></td><td colspan="1" align="center"><p>14.66</p></td></tr><tr><td colspan="1"><p><b>IL-8</b></p></td><td colspan="1" align="center"><p>39.6</p></td><td colspan="1" align="center"><p>18.3</p></td><td colspan="1" align="center"><p>104</p></td><td colspan="1" align="center"><p>35.9</p></td><td colspan="1" align="center"><p>76.84</p></td><td colspan="1" align="center"><p>29.86</p></td><td colspan="1" align="center"><p>24.11</p></td><td colspan="1" align="center"><p>29.98</p></td></tr><tr><td colspan="1"><p><b>CCL3</b></p></td><td colspan="1" align="center"><p>32.7</p></td><td colspan="1" align="center"><p>43.86</p></td><td colspan="1" align="center"><p>48.5</p></td><td colspan="1" align="center"><p>26.4</p></td><td colspan="1" align="center"><p>37.11</p></td><td colspan="1" align="center"><p>28.67</p></td><td colspan="1" align="center"><p>73.93</p></td><td colspan="1" align="center"><p>32.95</p></td></tr><tr><td colspan="1"><p><b>CCL4</b></p></td><td colspan="1" align="center"><p>45.7</p></td><td colspan="1" align="center"><p>54.39</p></td><td colspan="1" align="center"><p>64.8</p></td><td colspan="1" align="center"><p>47.61</p></td><td colspan="1" align="center"><p>58.97</p></td><td colspan="1" align="center"><p>61.19</p></td><td colspan="1" align="center"><p>44.98</p></td><td colspan="1" align="center"><p>69.87</p></td></tr><tr><td colspan="1"><p><b>TNF-α</b></p></td><td colspan="1" align="center"><p>16.5</p></td><td colspan="1" align="center"><p>30.7</p></td><td colspan="1" align="center"><p>33.4</p></td><td colspan="1" align="center"><p>35.2</p></td><td colspan="1" align="center"><p>27.31</p></td><td colspan="1" align="center"><p>33.32</p></td><td colspan="1" align="center"><p>19.92</p></td><td colspan="1" align="center"><p>33.33</p></td></tr><tr><td colspan="1"><p><b>IFN-α2</b></p></td><td colspan="1" align="center"><p>124.7</p></td><td colspan="1" align="center"><p>227</p></td><td colspan="1" align="center"><p>214</p></td><td colspan="1" align="center"><p>153.6</p></td><td colspan="1" align="center"><p>267.7</p></td><td colspan="1" align="center"><p>183.5</p></td><td colspan="1" align="center"><p>465.2</p></td><td colspan="1" align="center"><p>234.5</p></td></tr><tr><td colspan="1"><p><b>IL-15</b></p></td><td colspan="1" align="center"><p>27.8</p></td><td colspan="1" align="center"><p>17.3</p></td><td colspan="1" align="center"><p>26.6</p></td><td colspan="1" align="center"><p>11.94</p></td><td colspan="1" align="center"><p>16.58</p></td><td colspan="1" align="center"><p>6.47</p></td><td colspan="1" align="center"><p>22.66</p></td><td colspan="1" align="center"><p>9.795</p></td></tr><tr><td colspan="1"><p><b>IL-18</b></p></td><td colspan="1" align="center"><p>270.7</p></td><td colspan="1" align="center"><p>362.7</p></td><td colspan="1" align="center"><p>835</p></td><td colspan="1" align="center"><p>1846</p></td><td colspan="1" align="center"><p>599.4</p></td><td colspan="1" align="center"><p>507.3</p></td><td colspan="1" align="center"><p>574.5</p></td><td colspan="1" align="center"><p>557.6</p></td></tr><tr><td colspan="1"><p><b>IL-33</b></p></td><td colspan="1" align="center"><p>422.8</p></td><td colspan="1" align="center"><p>85.4</p></td><td colspan="1" align="center"><p>831.4</p></td><td colspan="1" align="center"><p>930.3</p></td><td colspan="1" align="center"><p>712</p></td><td colspan="1" align="center"><p>355.5</p></td><td colspan="1" align="center"><p>250.4</p></td></tr><tr><td colspan="1"><p><b>IFN-β</b></p></td><td colspan="1" align="center"><p>1421</p></td><td colspan="1" align="center"><p>527</p></td><td colspan="1" align="center"><p>3446</p></td><td colspan="1" align="center"><p>468</p></td><td colspan="1" align="center"><p>3158</p></td><td colspan="1" align="center"><p>156.8</p></td><td colspan="1" align="center"><p>2750</p></td><td colspan="1" align="center"><p>647.4</p></td></tr></tbody></table></tablegroup></tail></article></root>